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The dynamics of cell signalling are critical to cell fate decisions. Human Epidermal 
growth factor Receptors (HERs)-mediated Ras/Raf/MEK/ERK and PI3K/Akt 
signalling cascades relay extracellular signals from the plasma membrane to targets 
in the nucleus and cytoplasm and play pivotal roles in cell fate determination 
including proliferation, differentiation and cell survival. Both pathways, once 
activated, are further regulated by complex feedback loops which may exert either 
positive or negative effects on cascade components and can result in signalling 
oscillation. In this study, heregulin (HRG) - and epidermal growth factor (EGF)-
stimulated oscillation of both p-ERK1/2 and p-Akt expression in breast cancer cell 
lines was demonstrated. The oscillation was cell line dependent and was observed in 
MCF-7 and MCF-7/HER2-18 cells but not in BT474 cells. The oscillation was 
augmented by cycloheximide implicating transcriptional involvement. Gene 
expression analysis identified 29 genes as possible candidates involved in the 
transcriptional feedback regulation. Apart from the feedback regulation, feed-
forward regulation was also observed.  To expedite the analyses In-cell Western and 
Reverse Phase Protein Array (RPPA) assays were developed. A scheme of 
transcriptional feedback loops regulating the oscillation in the ERK1/2 pathway is 
proposed, including negative feedback loops to ERK1/2 from DUSPs, early positive 
and late negative feedback loops to MEK1/2 and positive feedback loops to HER-3 
from AREG, HB-EGF, CYR61 and CTGF. Two HER-2-targeted inhibitory 
monoclonal antibodies were investigated – trastuzumab and pertuzumab. 
Trastuzumab not only inhibited the growth of HER-2 over-expressing MCF-7/HER2-
18 cells and BT474 cells but also that of EGF-driven MCF-7 cells which expressed 
low/moderate HER-2 levels. Pertuzumab blocked the growth of both MCF-7 and 
MCF-7/HER2-18 driven by either EGF or HRG. When used in combination with 
trastuzumab, pertuzumab had much more potent activity in inhibiting cell growth and 
signalling than either single drug. Trastuzumab and pertuzumab had opposing effects 
on immediate p-ERK1/2 signalling and trastuzumab’s effects on signalling could be 
mimicked by the PI3K inhibitor LY294002. PTPN13, a non-receptor type tyrosine 
protein phosphatase, is a proposed tumour suppressor in breast cancer. This was 
investigated as a candidate regulator of the signalling oscillation and although not 
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observed as a transcriptional modulator of the oscillation, its high expression level 
was observed to be associated with cell growth inhibition in MCF-7/HER2-18 cells 
by trastuzumab. Moreover, immunohistochemical analysis of 121 clinical tumours 
which had received trastuzumab treatment revealed the correlation between the 
expression level of PTPN13 and the mutation status of PIK3CA. In conclusion, the 
observed oscillation may contribute to the elucidation of the complex regulation of 
signalling pathways, which is vital to the different cell fate decision made through 
the same core pathway. The synergy between trastuzumab and pertuzumab supports 
the clinical use of the combination treatment and suggested PI3K/Akt pathway as the 
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Breast cancer is a malignant heterogeneous disease which originates in normal breast 
cells. It arises mostly in women, but men can get breast cancers too. Breast cancer is 
the most commonly diagnosed cancer among women in the UK.  Nearly 46,000 new 
cases arise each year and nearly 1,000 women die of breast cancer every month in 
the UK (from www.breakthrough.org.uk). To better understand breast cancers, it is 
necessary and helpful to have some basic knowledge about the anatomy and 
physiology of the normal breast. 
1.1 The anatomy and physiology of the normal breast  
 
The female breast, which is located over the pectoral muscles of the chest wall and 
attached to the chest wall by fibrous strands called Cooper’s ligaments, is basically 
composed of glandular tissues and stroma including fatty and fibrous tissues as well 
as blood and lymphatic vessels. A layer of fatty tissue surrounds the breast glands 
and extends throughout the breast providing a soft consistency for the breast. The 
anatomy is illustrated in Figure 1. The glandular tissues consist of lobules and 
lactiferous ducts. During lactation, milk is produced by the bulbs at the end of the 
lobules and transferred to the nipple through the lactiferous ducts.  The arteries 
transport oxygen-rich blood from the heart to the breast and the veins bring the 
oxygen-depleted blood back to the heart. The breast is also made up of lymphatic 
tissues which offer the breast immunity to foreign invaders. An understanding of the 
lymphatic system (shown in Figure 2) is important since it is the major route for 
breast cancer cells to spread. The lymph nodes which are small bean-shaped 
collections of immune cells are connected by the lymphatic vessels. In the lymphatic 
vessels is clear fluid called lymph. The breast tissue fluid and waste products are 
carried away from the breasts in the lymph through the lymphatic vessels. Sometimes 
breast cancer cells can spread to the lymph nodes (initially to the axillary lymph 
nodes). The more lymph nodes in which cancer cells are found, the higher is the 
possibility of metastases to other organs. However, not all women with breast cancer 
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cells in lymph nodes will have metastasis and women developing metastases may not 
have breast cancer cells in lymph nodes. 
 
Figure 1 The anatomy of normal breast. 1. Chest wall, 2. Pectoral muscles, 3. Lobules, 4. Nipple, 5. 
Areola, 6. Lactiferous duct, 7. Fat, 8. skin. The top left of the picture shows the enlargement of cross 
section of the duct: A normal duct cells, B basement membrane, C lumen (this picture is reproduced 
from Wikipedia). 
 
Figure 2 The lymphatic system of female breasts. Most of the lymph vessels in the breast are 
connected to the under-arm nodes which are called axillary lymph nodes while some are connected to 
the nodes inside the chest called internal mammary lymph nodes and to the nodes above the 
collarbone (supraclavicular lymph nodes) or below (infraclavicular lymph nodes).  
(Reproduced from the online resources of BC Cancer Agency, 
http://www.bccancer.bc.ca/HPI/Nursing/Education/breastcancer/breasthealthbasics.htm).                       
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1.2 Biology of breast cancer 
 
Cancer is a class of diseases characterized by uncontrolled cell growth, invasion and 
sometimes metastasis. These three malignant properties differentiate cancers from 
benign tumours which are abnormal tissue masses with limited growth, no invasion 
or metastasis. Among the three properties, metastasis accounts for more than 90% of 
cancer-related deaths (1). Cancers can be classified into the following five groups by 
the types of cells that form the tumours. 
1) Carcinoma: malignant tumours derived from epithelial cells. 
2) Sarcoma: malignant tumours derived from connective tissue, or 
mesenchymal cells. 
3) Lymphoma and leukemia: malignancies derived from hematopoietic cells. 
4) Germ cell tumour: tumours derived from totipotent cells. 
5) Blastic tumour or blastoma: A tumour (usually malignant) which 
resembles an immature or embryonic tissue. 
Breast cancer refers to cancers originating in breast tissues. The majority of breast 
cancers are carcinomas. The most common types of breast cancer develop initially 
from abnormalities in epithelial cells of the ducts. These cells are shown in the 
enlargement of Figure 1. 
1.3 Metastasis of breast cancer 
 
The process of breast cancer spreading to other parts of the body is called metastasis. 
The major sites of metastasis are the bone, lungs, liver and the brain (2). Among 
these sites bones are the most common sites of metastasis (3). Primary tumours need 
to undergo several steps before becoming metastatic. Tumour cells proliferate and 
then invade across basement membrane into local healthy tissues. The invading 
tumour cells then invade the circulatory system through spreading to lymph nodes. 
Some cells survive in the circulatory system and then spread to distant target sites 
where cancer cells proliferate and form a micrometastasis. Finally, the 
micrometastasis becomes a metastasis through progressive colonisation.  
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As mentioned at the beginning of Section 1.2, metastasis accounts for more than 90% 
cancer-related death. So it is critically important to understand metastasis 
mechanisms to propose efficacious therapy strategies. Several models of cancer 
metastasis have been primarily described by Talmadge (4). The most prevailing 
model is the clonal selection of metastasis. Primary tumours from the same cells 
undergo multiple biochemical and molecular changes and then lead to clonal 
evolutions with phenotypic and behavioural diversities including enhanced migration 
capability, invasiveness and metastasis. In this model, tumour metastasis is believed 
to be the outcome of a clonally selective process during tumour progression, which 
has been supported by experimental data (5-8).    
 
Based on the observations that genetic alteration of breast cancer cells disseminated 
in bone marrow was generally different from that of primary tumour cells (9), 
another model called parallel evolution was proposed. This model interprets that 
dissemination of cancer cells in bone marrow occurs at an early stage and then 
cancer cells in bone marrow become metastatic in a primary tumour-independent 
way, which means that metastasis occurs at the beginning of progression and then 
primary tumours and metastatic tumours undergo parallel evolutions (10).  
 
The third model is the dynamic heterogeneity model of metastasis. This model 
suggests that the metastatic efficiency is determined by the generation rate of 
metastatic variants within tumours (4). The metastatic variants may be unstable, 
leading to a dynamic equilibrium of generation and loss of metastatic variants (11). 
This model also incorporates epithelial-to-mesenchymal transition (EMT) (4). EMT 
is a complex molecular and cellular programme that allows the transition of 
basement membrane-attaching epithelial cells to a motile and unpolarised 
mesenchymal cell phenotype including enhanced motility, invasiveness, increased 
production of extracellular matrix components and elevated resistance to apoptosis 
(12). In EMT epithelial cells lose the well-differentiated features such as cell-cell 
adhesion, polarity and immotility (13).  EMT plays a critical role in embryonic 
development (14), however, its role in tumour metastasis has been increasingly 
recognised (15, 16). It was demonstrated that EMT could result in the generation of 
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breast cancer cells with stem cell-like characteristics (17, 18). The existence of EMT 
in human tumours provides the basis to explain the characteristics of cancer 
progression and metastasis. 
1.4 Grading and staging of breast cancer 
 
The grading and staging of breast cancers can help doctors to assess prognosis and 
make a decision around the most appropriate treatment options to obtain the best 
outcome. 
  
Within pathological assessment, grading is a measure of the differentiation of 
tumours. For grading breast cancer, the Bloom-Richardson system (19) is used and 
has a scoring scale of 1 to 3. This grading system determines how aggressive breast 
cancers are by examining breast cancer cells and tissue structure under the 
microscope. The following three features are taken into account in this system and 
each feature is scored from 1 to 3.  
1) Percentage of tubular structures in tumours.  If there is extensive tubule 
formation, score 1 is given. If there is a moderate attempt at tubule formation, 
score 2 is awarded. If there is a slight or no tubule formation and cells grow 
in sheets and strands, score 3 is assigned. 
2) Degree of hyperchromatic and mitotic activity which is indicated by the 
number of hyperchromatic or mitotic figures in a microscopic high power 
field (400x magnification level). If only occasional hyperchromatic or 
mitotic figures are present per field, score 1 is assigned. Score 2 is given if 
there are two or three such figures present in most fields. Score 3 is awarded 
if more than three such figures are present in most fields. 
3) Nuclear grade which is indicated by nucleus size and uniformity. Score 1 is 
given if nuclei are fairly uniform in size, shape and staining. Score 2 is given 
if variation in uniformity is moderate. If a marked nuclear irregularity is 
observed, score 3 is given. 
 
Scores for the three features are all summed to a total ranging from 3 to 9. In terms of 
the total, breast cancers can be categorized into three grades as shown by Table 1. 
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Table 1 Tumour grade of breast cancers 
Total feature 
score 














Grade 1 (low grade) tumours look very like normal breast tissues, grow slowly and 
are not aggressive. They have the best prognosis. Grade 3 (high grade) tumours look 
very abnormal, grow more quickly and are aggressive. They have the worst 
prognosis. Grade 2 (moderate grade) tumours fall between the above two grades and 
have medium prognosis. 
 
Staging of breast cancer can tell doctors whether cancer is limited to one area in the 
breast, or if it has spread to healthy tissues inside the breast or to other parts of the 
body. The most commonly used staging system for breast cancers is the American 
Joint Committee on Cancer (AJCC) TNM system. ‘T’ describes the size of a tumour 
and whether it has invaded local tissues. ‘N’ describes whether a cancer has spread to 
regional lymph nodes.  ‘M’ describes whether a cancer has spread to other parts of 
the body (distant metastasis). According to the fifth edition of ‘AJCC cancer staging 
manual’(20) , this system classifies breast cancers based on the following criteria. 
 
Primary tumour (T) categories: 
TX: Primary tumour cannot be assessed*. 
T0: No evidence of primary tumour. 
Tis: Carcinoma in situ or Paget disease of the nipple with no associated tumour mass. 
T1: Tumour is 2 cm or less across in diameter. 
T2: Tumour is more than 2 cm but not more than 5 cm across. 
T3: Tumour is more than 5 cm across. 
 8
T4: Tumour of any size extending into the chest wall or skin. This includes 
inflammatory breast cancer. 
*Use of an "X" rather than a number or other suffix means that the parameter can not 
be assessed. 
Regional lymph nodes (N) categories: 
NX: Regional lymph nodes cannot be assessed. 
N0: Cancer cells have not spread to regional lymph nodes. 
N1: Cancer cells have spread to movable ipsilateral axillary lymph node(s) 
N2: Cancer cells have spread to ipsilateral axillary lymph node(s) fixed to one 
another or to other structures 
N3: Cancer cells have spread to ipsilateral infraclavicular lymph node(s) or internal 
mammary lymph node(s) with axillary lymph nodes or supraclavicular lymph 
node(s). 
Distant Metastasis (M) categories: 
MX: Presence of distant metastasis cannot be assessed. 
M0: No distant metastasis is present. 
M1: Distant metastasis to other parts of the body is present. 
 
 Once the characteristics of T, N, and M are determined, information is combined to 
define a breast cancer stage.  
Stage 0: Tis, N0, M0 
Stage I: T1, N0, M0 
Stage IIA: T0 or T1, N1, M0; T2, N0, M0 
Stage IIB: T2, N1, M0; T3, N0, M0 
Stage IIIA: T0 to T2, N2, M0; T3, N1 or N2, M0 
Stage IIIB: T4, any N, M0; any T, N3, M0 
Stage IV: any T, any N, M1 
 
Based on the determined stages of breast cancer, mean survival rate for patients with 
the same stages can be statistically predicted (Table 2). A 5-year survival rate refers 
to the percentage of patients who are still alive 5 years after diagnosis with a specific 
stage of breast caner. Deaths from other causes are not taken into account. Survival 
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rate is calculated based on previous outcomes of large number of patients who are 
diagnosed with breast cancer, but for individual patients doctors can not predict with 
certainty what will happen to them 5 years after prognosis. 
 
Table 2 Breast cancer stages and 5-year survival rate (adapted from American Cancer Society) 








1.5 Histopathological classification of breast cancer 
 
Pathologists categorise breast cancers according to their microscopic anatomy and 
other criteria including pathological grade of tumours. For example, the most 
common pathological types of breast cancer are invasive ductal carcinoma and 
invasive lobular carcinoma. There are four common forms of breast cancer. 
 
Lobular carcinoma in situ (LCIS): LCIS describes primary tumours initially 
developing in lobules which spread no further. It accounted for approximately 12% 
of in situ breast cancer diagnosed from 2002-2006 in the USA (21). Traditionally 
many pathologists believe that LCIS is an indicator of increased risk for developing 
invasive breast cancer in the future rather than a real cancer. It is also called lobular 
neoplasia. Women who are diagnosed with LCIS have a 25% chance of developing 
invasive breast cancers within 25 years of the initial diagnosis. Nowadays the 
majority of women who are diagnosed with LCIS on biopsy don’t receive therapy. 
Instead, their disease will be closely monitored after diagnostic biopsy including 
regular screening mammograms, annual clinical breast examinations and monthly 
breast self-examinations. For the prevention of invasive breast cancer with high risks 
or reduction of the risks, some women who have major concerns about developing  
cancer choose prophylactic mastectomy (no requirement of the removal of axillary 
lymph nodes) generally followed by breast reconstruction. Many breast surgeons 
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regard this approach as too aggressive. The alternative option to reduce the risk of 
developing invasive breast cancer is via administration of tamoxifen. Tamoxifen can 
reduce the risk of developing invasive breast cancer by 49% according to the clinical 
trial results of the American National Surgical Adjuvant Breast and Bowel Project P-
1 Study (22). The application of tamoxifen for women at high risk of breast cancer 
for prevention has been approved by the U.S. Food and Drug Administration (FDA) 
in 1998. 
 
Ductal carcinoma in situ (DCIS): DCIS is the most common non-invasive breast 
cancer and accounts for 80% cases of in situ breast cancers diagnosed from 2002-
2006 in America (21). DCIS develops in ducts of the breast but doesn’t break the 
internal wall of the ducts and invade the surrounding tissues. DCIS is typically 
classified according to the architectural pattern (solid, cribriform, papillary and 
micropapillary), the tumour grade (low, intermediate and high) and the presence or 
absence of comedo necrosis (23). The presence of comedo necrosis suggests the 
likelihood of the DCIS becoming more aggressive. The incidence of DCIS has 
increased profoundly since the early 1970s which may be due to the widespread use 
of screening mammography (21). For example, the estimated incidence in 1975 was 
5.8 per 100,000 women while the estimated incidence was 32.5 per 100,000 women 
in 2004 (23). DCIS is often detected by mammogram and then confirmed by biopsy. 
Nearly all women who are diagnosed with DCIS can be cured. The treatment of 
DCIS includes simple mastectomy and lumpectomy usually followed by radiation 
treatment. Simple mastectomy is the surgical removal of the entire breast not 
including the axillary lymph nodes. Lumpectomy is the removal of the cancerous 
mass including the margin of normal breast tissues. Lumpectomy is a breast 
conserving surgery. However, not all women are suitable for lumpectomy. According 
to the American Cancer Society online resources (Treatment of stage 0 (non-invasive) 
breast cancers; http://www.cancer.org/Cancer/BreastCancer/DetailedGuide/breast-
cancer-treating-stage0) women who have the following conditions are not ideal 
candidates for lumpectomy.  
1) The area of DCIS is very large. 
2) More than one area of cancer was detected in the same breast. 
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3) Lumpectomy can not completely remove the cancer. 
4) Women are pregnant at the time of radiation. 
5) Women have connective diseases.  
If the DCIS is ER-positive, tamoxifen can be administered after surgery to reduce the 
risk of recurrence and of developing invasive breast cancer.  
 
Infiltrating lobular carcinoma (ILC): ILC is also known as invasive lobular 
carcinoma, which develops in the lobules initially and then breaks the wall of the 
lobules and invades to connective tissue of the breasts. It is the second most common 
type of breast cancer after IDC and accounts for 8%-14% of breast cancers (24-26), 
but for unknown reasons the incidence of ILC is increasing from 1977 among 
women  of age 50 and above according to an epidemiological study (27). ILC’s 
features include hyperchromatic small round cells forming single infiltrating files. 
Patients with ILC often show no palpable mass or vague thickening in the breasts 
without distinct border (28). 
 
Infiltrating ductal carcinoma (IDC): IDC is also known as invasive ductal 
carcinoma, which develops in the ducts initially and then penetrates the wall of the 
ducts and invade other tissues within the breast or other regions of the body. It is the 
most common type of breast cancers and accounts for 80% of breast cancer 
diagnoses (from Cancer Research UK online resources).  
 
Additionally, there are also some less common types of breast cancer. 
 
Medullary carcinoma: medullary carcinoma is a type of IDC and takes the name 
from its colour, close to the colour of medulla of the brain. Tumour cells have large 
vesicular nuclei and prominent nucleoli. This type of tumour tends to form clear 
boundary between the tumour and the normal tissues. Prominent lymphocytic 
infiltrate both at the periphery and within the tumour is present. A tumour with less 
lymphocytic infiltration or an infiltrating margin in parts of the tumour is regarded as 
an atypical medullary carcinoma (29). 
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Mucinous carcinoma: A wide range of breast cancers produce mucin which is the 
major component of mucus. Among them is mucinous carcinoma which is 
characterized by the proliferation of clusters of generally small and uniform cells. 
These cells float in large amount of the extracellular mucus. The mucus is often 
visible to the naked eye (29). In mucinous carcinoma, mucin is the major component 
and surrounds the breast cancer cells. 
 
Tubular carcinoma: Tubular carcinoma is a rare subtype of infiltrating ductal 
carcinoma, accounting for less than 2% of all breast cancer cases (29, 30). Compared 
with IDC Not Otherwise Specified (NOS IDC), it occurs often among older patients 
with small size and dramatically less nodal involvement.  It is characterized by well-
differentiated, tube-shaped breast cancer cells which grow slowly and metastasize 
infrequently. The size of tubular carcinoma is very small usually ranging from 0.2 to 
2 cm in diameter. The majority of the cases are 1cm or less (29). It is nearly always 
oestrogen and progesterone positive and mostly HER-2 negative (31, 32). 
 
Inflammatory breast cancer: Inflammatory breast cancer (IBC) is a rare type of 
highly aggressive breast cancers. It is so called because of the symptoms being 
similar to those found in inflammation. It is defined in the clinic by the rapid 
development of diffuse erythema and edema (peau d’orange) over more than 1/3 of 
the breast surface often without palpable mass (29, 33). Invasion of cancer cells to 
local dermal lymph vessels may form tumour emboli which may impair the drainage 
and inflame and cause breast swell. IBC is characterized by the early age at diagnosis, 
poor prognosis and negative oestrogen/progesterone status. Approximately 60% of 
IBC have HER-2 over-expression. The treatments of IBC involve multimodality 
therapy including chemotherapy, radiotherapy, surgery, endocrine therapy and 
trastuzumab therapy.  
 
Paget’s disease of the nipple: Paget’s disease of the nipple was described by Sir 
James Paget in 1874 as a syndrome in which the ulceration of the nipple was 
associated with underlying cancer (29). It is characterized in the clinic by nipple or 
areola erythema, eczema, ulceration, bleeding and itching. The diagnosis is often 
 13
delayed for months due to these clinical characteristics. The diagnosis is confirmed 
with the full thickness biopsy of the areola and nipple (34). There is an underlying 
cancer in 80% of the cases and the cancers are not necessarily adjacent to the nipple-
areola area (35). 
 
Phyllodes tumour: Phyllodes tumours of breast are unusual fibroepithelial tumours 
which are categorized as benign, borderline and malignant subtypes. The prognosis 
of Phyllodes tumours is usually favourable. Regardless of the histological subtype, 
wide local excision with tumour-free margins of 1 cm or above is the primary 
therapy (29, 36).  
1.6 Molecular classification of breast cancer 
 
Breast cancer is a heterogeneous disease. Individual cancers have different prognoses 
and different responses to therapies. According to the prognostic and predictive value 
of the receptor status of cancer cells, breast cancers can be primarily grouped into 
hormone receptor-positive (ER+/PR+), HER-2-positive (HER-2+) and triple receptor 
negative (ER-, PR- and HER-2- ) categories based on immunohistochemistry (IHC) 
and fluorescence in situ hybridization (FISH). Classification of breast cancers into 
the former two categories is particularly useful since the targeted therapies available 
are only effective in these subsets of patients. For example, determination of 
hormone receptor status is useful to determine whether patients are candidates for 
endocrine therapy. Patients with hormone receptor negative status don’t benefit from 
endocrine therapy. However, even within the same hormone receptor-positive group, 
breast cancers can have a large variation in response to tamoxifen and 25% of 
ER+/PR+ fail to respond (37). A similar situation applies to HER-2 positive tumours 
and response to trastuzumab (38). Investigations are underway to understand the 
causes of differences in response to the same therapeutic regime and to define further 
the molecular classification of breast cancer, in particular whether further sub-
grouping of the molecular signatures might help differentiate which breast cancers 
respond to a particular therapy. Moreover, the techniques used to test the receptor 
status (IHC and FISH) can produce intra- and inter-laboratory variations since the 
interpretation of staining is to some degree subjective to individual pathologists and 
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thereby can result in false positives or false negatives which interfere with the use of 
appropriate therapies.   
 
The advent of high throughput gene expression profiling provides us with an 
opportunity to answer the above questions and to classify breast cancers based on 
gene expression patterns. Gene expression profiling revealed four broad subsets of 
breast cancers with distinct differences in prognosis and responsiveness to therapy 
according to gene expression patterns: luminal-like, basal-like, normal-like and 
HER-2 positive (39). As shown in Figure 3, these four subtypes of breast cancers 
have their own distinct gene expression patterns and their distinct different prognoses 
are shown in Figure 4. These four subtypes are defined by the expression of 
particular clusters of genes which are characteristically expressed under specific 
circumstances such as in luminal epithelial cells, basal epithelial cells and normal 




Figure 3 Gene expression patterns of 85 experimental samples representing 78 carcinomas, 3 
benign tumours, and 4 normal tissues, analyzed by hierarchical clustering using the 476 cDNA 
intrinsic clone set. (A) The tumour specimens were divided into five (or six) subtypes based on 
differences in gene expression. The cluster dendrogram showing the five (six) subtypes of tumours are 
coloured as: luminal subtype A, dark blue; luminal subtype B, yellow; luminal subtype C, light blue; 
normal breast-like, green; basal-like, red; and ERBB2+, pink. (B) The full cluster diagram scaled 
down. The coloured bars on the right represent the inserts presented in C–G. (C) ERBB2 amplicon 
cluster. (D) Novel unknown cluster. (E) Basal epithelial cell-enriched cluster. (F) Normal breast-like 
cluster. (G) Luminal epithelial gene cluster containing ER. Reprinted from ref (40). 
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Figure 4 Disease outcomes in two patient cohorts. (A) Time to development of distant metastasis in 
the 97 sporadic cases. (B) Overall survival for 72 patients with locally advanced breast cancer in the 
Norway cohort. The normal-like tumour subgroups were omitted from both data sets in this analysis. 
Reprinted from ref (41). 
 
In the luminal cluster, cytokeratins 8 and 18, transcriptional factors including GATA-
binding protein 3, X-box binding protein 1 and hepatocyte nuclear factor 3, ER and 
ER-activating genes such as LIV1 and CCND1 are expressed (Figure 3G) (39, 42). 
All luminal-like subtypes are ER-positive, fewer than 20% of luminal-like breast 
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cancers have TP53 (tumour protein 53 whose mutation was suggested to be an early 
event in breast cancer development and associated with poor prognosis (43)) 
mutations (42) and 63% of these tumours are low or intermediate grade (44), 
therefore these subtypes are generally sensitive to endocrine therapy. Within the 
luminal-like cluster, at least two subtypes have been differentiated: luminal A and 
luminal B (40, 42). Although in the same cluster, luminal A and luminal B have 
distinct characteristics. In general, luminal A cancers have higher ER-related gene 
expression and lower expression of proliferation-related genes than luminal B 
tumours (40, 41). Generally, luminal-like breast cancers have a good prognosis. 
However, there is a clear difference in the outcome between luminal A and luminal B 
with luminal B cancers having a significantly worse prognosis in multiple data sets 
(41, 45).  
 
Brenton et al in a review paper (45) emphasized that the array designation of HER-2 
positive tumours should not be confused with the clinical HER-2 over-expression 
tumours identified by IHC or FISH since not all clinical HER-2 over-expression 
tumours have mRNA expression changes that define the cluster. The HER-2-array 
subtype refers to a large group of tumours which are hormone receptor negative (low 
ER or related genes expression in array) but have a HER-2 associated gene 
expression pattern in the array. Clinical HER-2 over-expression tumours refer to 
those tumours identified by IHC for protein expression or by FISH for the excess 
number of gene copies. Most clinical HER-2 over-expression tumours will however 
fall into the HER-2-array positive subtype. However, others will over-express 
hormone receptors and most of these tumours are grouped into the luminal-like 
subtype (40-42). HER-2-array positive tumours carry a poor prognosis and are more 
than two-fold more likely to involve axillary lymph nodes than luminal A subtype 
besides having poor differentiation and higher grade (46). HER-2 array positive 
tumours are characterized by over-expression of other genes in the HER-2 amplicon 
such as GRB7 (Figure 3C). In spite of their poor prognosis, HER-2 array positive 
tumours demonstrated sensitivity to anthracycline and taxane-based neoadjuvant 
therapy (47). They also respond to molecularly targeted therapies such as 
trastuzumab. 
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The expression pattern of the basal-like subtype mimics that of basal epithelial cells 
in other parts of the body and normal myoepithelial cells in breasts. In this subtype 
the expression of ER and ER-related genes as well as HER-2 and related genes are 
deficient, but basal cytokeratins 5, 6, 14 and 17, integrin-β4 and laminin genes are 
strongly expressed (Figure 3E) (39). Proliferation-related genes are also expressed 
(39, 42). Basal-like breast tumours are more likely to have aggressive features such 
as TP53 mutation and a higher likelihood of being grade 3 than luminal A tumours 
(40, 46). Multiple independent data sets have also shown a poorer prognosis for 
basal-like tumours (40-42). Given their triple-negative receptor status, basal-like 
tumours are refractory to conventional targeted therapies such as endocrine therapy 
and trastuzumab therapy, leaving only chemotherapy as a systemic therapy. Despite 
the poor prognosis, basal-like tumours are sensitive to chemotherapy (45). Rouzier et 
al (47) and Carey et al (46) observed the higher response of basal-like tumours to 
anthracycline-based or combination of anthracycline and taxane-based neoadjuvant 
chemotherapies than non-basal-like tumours. This sensitivity however may not apply 
to all chemotherapeutic agents. As demonstrated by Sorlie et al (41) and Turner et al 
(48), most women carrying BRCA1 mutations generally develop basal-like breast 
cancers. BRCA1 functions in DNA repair and cell cycle checkpoint and loss of its 
functions may result in sensitivity to DNA damaging agents and resistance to mitotic 
spindle poisons (49). 
 
 In the first study to examine the comprehensive gene expression pattern of breast 
cancers (39), several tumours samples were clustered with three normal breast 
specimens (Figure 3 A, light green branches). Gene expression pattern of normal-like 
breast tumours are typified by the high expression of genes characteristic of basal 
epithelial cells and adipose cells and low expression of genes characteristic of 
luminal epithelial cells (39). 
 
This molecular classification has its inherent limitations, since up to 30% of breast 
cancers do not fall into any of the four categories (50). Evolution of the molecular 
classification may require new technological platform, availability of larger datasets 
as well as more understanding of breast cancer biology. 
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1.7 Risk factors for breast cancer 
 
Every woman is at risk of developing breast cancer, but some are at higher 
probability of developing the disease. It is very important to understand the risk 
factors since they influence the medical decision making. Risk factors have been 
identified through epidemiologic studies and new ones continue to be identified. Joy 
et al in their book ‘Saving women's lives: strategies for improving breast cancer 
detection and diagnosis’ (51) listed a number of risk factors. Here I summarize and 
describe these factors briefly. 
 
Germ-line and somatic mutations  
Before a cell becomes malignant, molecular changes which alter the protein’s 
function must accumulate. For example, the loss of function of tumour suppressor 
genes or gain of function of oncogenic genes may cause the occurrence of breast 
cancers. Some changes (mutations) may be inherited. Approximately 5-10% of 
breast cancer cases result from these types of change (52). Among the genes 
involved in breast cancer susceptibility, BRCA1 (breast cancer gene 1) and BRCA2 
(breast cancer gene 2) are two human tumour suppressor genes which account for a 
60% risk of being diagnosed with breast cancer during a woman’s lifetime when they 
become abnormal according to the online resources of National Cancer Institute, 
USA (BRCA1 and BRCA2: Cancer Risk and Genetic Testing, 
http://www.cancer.gov/cancertopics/factsheet/Risk/BRCA#r4). They help to repair DNA damage 
and kill cells in which the DNA damage can’t be repaired. When these two genes are 
damaged, cells harbouring the DNA damage may duplicate without control and 
develop into cancers. Women inheriting the deleterious mutations of BRCA1 or 
BRCA2 have increasingly higher risks for breast cancer than those women whose 
BRCA1 or BRCA2 functions normally, although these mutations are present in far 
less than 1% of the general population (53). Despite the risk for breast cancer being 
very substantial for the individual women who carry the inherited mutations, less 
than 10% of breast cancer cases result from germ-line mutations. The majority of 
breast cancer cases are due to molecular changes in somatic cells that occur during 
women’s lifetimes rather than being present in the germ-line. These molecular 
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changes could arise from exposure to carcinogens in the environment, random 
mutations occurring in cell division during lifetime and too much exposure to stimuli 
within the body such as oestrogen. Inherited mutations can sometimes sensitize 
certain genes to mutation. For example, BRCA1 and BRCA2 can repair DNA 
damage and if they are mutated, the ability of cells to correct the genetic mistakes 
happening during cell division will be diminished. As a result, mutations accumulate 
faster than they would otherwise.  
 
Past history of breast cancer 
Women who have had breast cancer in one breast have an increased risk of 
developing cancers in the other breast. Women who were diagnosed with LCIS 
and/or DCIS have an increased risk of developing invasive breast cancers. 
 
Current age 
It is understandable that age is considered as a risk factor. The longer that women 
live, the greater the chance that harmful mutations will accumulate. In addition, 
generally speaking, younger women have more potent immune systems than the 
elderly, which means that the immune system in young women has stronger 
surveillance ability. The table below (table 3) adapted from a published report 
written by the American Cancer Society in 2003 ‘Breast cancer facts and Figures 
2003-2004’ demonstrates the age-specific probability of developing breast cancer. 
 
Table 3 Age-specific probability of developing breast cancer* 
If current age 
is 
Then the probability of 
developing breast cancer in 
the next 10 years is: 
or 1 in: 
20 0.05% 2,152 
30 0.40% 251 
40 1.45% 69 
50 2.78% 36 
60 3.81% 26 
70 4.31% 23 
*Among those free of cancer at the beginning of age interval. Based on the cases diagnosed between 
1988 and 2000. Percentages and ‘1 in’ may not be numerically equivalent due to rounding. 
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Radiation exposure 
It is understandable that excessive exposure to radiation will cause genetic mutations 
in essential genes some of which correlate with the development of breast cancer 
such as in the BRCA1 and BRCA2 genes mentioned above. 
 
Breast density 
Younger women have denser breasts than the elderly. With aging, gland tissues will 
be replaced by fat tissues and connective tissues.  Denser breasts have more dark 
areas which interfere with the interpretation of mammograms. Several studies have 
demonstrated that breast cancer risk increases with rising breast density (54, 55). 
 
Family history 
Women in families where the first-degree relatives have had breast cancer have an 
increased risk of developing the disease (56). The risk is even higher if the first-
degree relative developed breast cancer before age 40 or if they have had cancers in 
both breasts (57). The effect of family history on breast cancer risk may be due to 
both the inherited mutations mentioned above and the similar life styles including 
environmental factors (58).  
 
Age at first birth and breast feeding 
The breasts before giving birth to babies are not completely developed, which means 
that some cells (mammary gland cells) are not well differentiated before first 
pregnancy (59-61) and have a higher potential to proliferate. The breasts will develop 
completely during pregnancy and after years of breast feeding when mammary gland 
cells divide and differentiate to be able to produce milk. Under the stimulation of 
circulating oestrogen, non-differentiated cells have an increased risk of uncontrolled 
growth and may become malignant. Women of an older age at their first birth have a 
higher risk themselves. Women who have never been pregnant have an even higher 
risk for developing breast cancer. Studies demonstrate those women who have their 
first full-term pregnancies at age before 25 have a lower risk than those nulliparous 
women or women who have their first pregnancies at the age of 30 or above.  Extra 
pregnancies can also reduce the risk to an even lower level (62). It has also been 
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shown that long-term breastfeeding can decrease risk (63). The longer the period of 
the breastfeeding, the lower the risk of developing breast cancers. 
 
Early menarche and late menopause  
During menopause the circulating levels of hormones such as oestrogen and 
progesterone produced by the ovaries reduces dramatically. Late menopause (after 
age 55) as well as early menarche (before age 12) means a longer exposure of the 
breast tissues to hormones, which increases the risk of breast cancer.   
 
Hormone replacement therapy 
Hormone replacement therapy (HRT) is a type of medical treatment applied to 
surgically premenopausal, menopausal and postmenopausal women who feel 
uncomfortable when the circulating hormones such as oestrogen and progesterone 
diminish. It involves the administration of oestrogen alone or with progesterone to 
boost hormone levels. The longer HRT is taken, the higher the risk of developing 
breast cancer (64). 
 
Alcohol intake 
It has been reported in multiple studies that alcohol consumption is associated with 
an increased risk of developing breast cancer (65-69). Ellison and Zhang et al (67) in 
their meta-analysis of epidemiologic studies carried out through 1999 demonstrated a 
dose-dependent monotonic increase of the relative risk for breast cancer regardless of 
the menopausal status and beverage types. The study conducted by Singletary and 
Gapstur (70) investigated the potential mechanisms of the association of alcohol 
intake with the increased risks. They found that the increased levels of oestrogen and 
androgen in women who consume alcohol were likely to be one of the mechanisms 
underlying the association. The other plausible mechanism was that the alcohol 
consumption may increase the susceptibility of the breasts to carcinogens. 
Controversially, others showed an inverse relation between red wine consumption 
along with other types of beverage and risks (71-73) which may be due to the effects 
of resveratrol and other substances in red wine causing a reduction of breast cancer 
risk (74-76). 
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Other risk factors 
Apart from the risk factors mentioned above, other factors such as race/ethnic groups, 
unhealthy living habits, physical activity and obesity have been associated with the 
risk of developing breast cancer. In the USA, white women are diagnosed with breast 
cancer more often than African American/black, Hispanic/Latina, Asian Pacific 
Islander, or American Indian/Alaska Native women (77). Women with poor physical 
activity (unhealthy living habits often result in poor physical activity) or who are 
overweight have an increased risk of developing breast cancer. 
 
From the above description it is likely that each individual factor interacts with 
others. Although many risk factors have been identified, it is impossible to determine 
which women will develop breast cancer and who will not as well as when and how 
individual women will develop breast cancer. Many women never develop breast 
cancer even though they bear some of risks mentioned above.  
1.8 Treatments for breast cancer 
 
There are multiple treatments for breast cancer in clinical use, including local therapy 
and systemic therapy. The local therapies include surgery and radiotherapy. The 




This treatment refers to the medical removal of the cancer from the breast and the 
lymphatic nodes. Basically there are two types of surgery including partial and entire 
breast removal known as lumpectomy and mastectomy respectively. In lumpectomy, 
which is often followed by adjuvant radiation for a couple of weeks, only the 
cancerous tissues as well as a rim of normal tissues are removed to conserve the 
breasts. Women who choose lumpectomy with adjuvant radiation will have the same 
expected lifetime survival as those who undergo mastectomy (78). There are a 
variety of mastectomy techniques in clinical use including simple mastectomy, 
modified radical mastectomy, radical mastectomy, skin sparing mastectomy and 
nipple sparing mastectomy. Which mastectomy approach is used will depend on 
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many factors such as breast size, the location of the lesion, whether the surgery is for 
prophylaxis or treatment and whether the patient intends to undergo reconstruction 
surgery. In simple mastectomy, one or both breasts are completely removed but the 
lymphatic nodes under the arm are not included. In the modified radical mastectomy 
procedure, the breasts and the axillary contents are removed but the pectoral muscles 
are retained while in radical mastectomy pectoral major and minor muscles are 
removed as well. Radical mastectomy is now used less frequently as the other forms 
of surgery are more effective and less disfiguring (79). In skin sparing mastectomy, 
breast tissues are removed through conservative incision around the areola to 
preserve the skin for breast reconstruction surgery. This surgery is not applied to 
cancers that involve the skin such as inflammatory breast cancer. In nipple sparing 
mastectomy breast tissues are removed but the nipple-areola complex is preserved. In 
both lumpectomy and mastectomy regional lymph nodes are sometimes removed to 
test whether the breast cancer cells have spread beyond the breast tissues. The 
presence of breast cancer cells in lymph nodes will determine which subsequent 
therapies will be applied. Unfortunately, surgery on the axillary lymph nodes may 
cause serious swelling of the arm. There is an option called Sentinel lymph node 
biopsy in which two or three key lymph nodes are removed for the test before the 
others are removed to lower the need for full axillary lymph nodes excision (80). 
Sentinel lymph nodes are the first axillary lymph nodes into which the metastatic 
breast cancer cells are believed to drain. 
 
Radiotherapy 
Radiotherapy is used to kill residual cancer cells remaining in the breast tissues, 
chest wall or the area under the arm after surgery or to shrink the tumour size before 
surgery through use of ionizing radiation (81). Radiotherapy is often applied to 
‘local’ cancers but is not effective for metastatic cancers since it is not feasible to 
irradiate the whole body. It not only destroys cancer cells but also normal tissue cells 
so more specific target radiation would reduce the side effects dramatically. 
 
Systemic therapies 
Systemic therapies are used alongside surgery and radiotherapy to kill the 
undetectable cancer cells or those cancer cells metastasizing to other places within 
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the body. They are also used in the neoadjuvant setting to reduce tumour size before 
surgery or radiotherapy to make the main treatment easier or more likely to succeed.  
 
Chemotherapy 
Chemotherapy of breast cancer involves administrating cytotoxic drugs such as 
alkylating agents, anti-metabolites, taxanes, plant alkaloids and terpenoids, vinca 
alkaloids, podophyllotoxin, and topoisomerase inhibitors to kill the cancer cells. It 
often results in side effects including hair loss, fatigue, compromise of immune 
system, nausea & vomiting and tendency to bleed easily (82). Since cancer cells are 
generally more proliferative than normal cells, cytotoxic drugs damage the 
replicating DNA in cancer cells more easily than in normal cells and DNA damage 
kills the cancer cells. 
 
Endocrine therapy 
Approximately 60% of breast cancers diagnosed in premenopausal women and 80% 
of those diagnosed in postmenopausal women are hormone receptor positive, which 
means that growth of these cancer cells can be driven by oestrogen and/or 
progesterone (83). Tamoxifen as a selective oestrogen receptor modulator (SERM) 
has been used to treat breast cancer for many years. Tamoxifen is an antagonist of 
ER. It competitively binds the ER and blocks the access of oestrogen to ER. 
Aromatase inhibitors block the synthesis of oestrogen from the precursor in ovaries 
and in other tissues. These drugs include letrozole and anastrozole and are highly 
effective in breast cancers that are dependent on the growth effects of oestrogen. 
 
Biological therapy 
HER-2 over-expression accounts for 20-25% of invasive breast cancers (38). 
Trastuzumab (Herceptin®) is a monoclonal antibody drug targeting HER-2 and is 
used against metastatic HER-2-overexpressing breast cancers in the clinic (84). 
Another monoclonal antibody drug pertuzumab also targets HER-2 but binds a 
different domain (dimerisation arm) from trastuzumab (85). Its anti-tumour activity 
is through the blocking of the cellular signalling mediated by HER-2. The detailed 
information of both drugs including mechanism of action, function and drug 
resistance will be presented in the following section. 
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In summary, these differing therapies are generally used in combination. Most 
patients will undergo surgery and this will generally be followed by radiotherapy. 
Similarly, most patients will receive either endocrine therapy or chemotherapy with 
those breast cancers expressing high HER-2 also receiving trastuzumab. 
1.9 Cell signalling pathways in breast cancer 
 
De-regulation of receptor tyrosine kinase mediated pathways is frequently involved 
in the occurrence and development of breast cancer and drug resistance. For example, 
acquired resistance to tamoxifen in ER-positive tumours is often linked to the over-
activated human epidermal growth factor receptor (HER)-mediated pathways (86, 
87). These pathways are being intensively studied at present in this disease. This 
study will focus on HER-2.   
1.9.1 HER receptor tyrosine kinase family and therapy of breast 
cancer 
 
The HER family receptors are key signalling regulators in breast cancer cells and act 
by transducing extracellular stimuli into intracellular signals (88-90). The ensuing 
intracellular signalling cascades modulate gene expression patterns and allow cells to 
make decisions regarding proliferation, differentiation, cell cycle control, survival, 
apoptosis suppression and resistance to therapies (88, 91-95). There are four 
members in this family (Figure 5): HER-1 (EGFR, ErbB1), the founding member of 
this family, HER-2 (ErbB2, neu), HER-3 (ErbB3) and HER-4 (ErbB4). HER 
receptors have four major domains: an extracellular ligand binding domain which is 
glycosylated, a transmembrane helix, a cytoplasmic kinase domain and a C-terminal 
tail. Exclusively, HER-3 has no intrinsic kinase activity due to substitutions in 
crucial residues in kinase domain (90, 96, 97). The extracellular domain is divided 
into 4 sub-domains: I, II, III, and IV. A variety of EGF-like ligands activate these 
receptors: EGF, TGFα, amphiregulin and epiregulin bind HER-1; betacellulin, 
epiregulin and heparin-binding EGF bind both HER-1 and HER-4; neuregulin-1, 
neuregulin-2, and glial growth factor bind both HER-3 and HER-4; neuregulin-3 and 
-4 only bind HER-4 (Figure 6 ) (90). The binding of ligands causes the receptors to 
undergo a conformational change, homo- and/or hetero-dimerisation, 
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phosphorylation in specific tyrosine residues within the kinase domain and 
recruitment of signalling molecules which activate such signalling pathways as the 
Raf/MEK1&2/ERK1&2 and PI3K/Akt pathways (90). Deregulation of these 




Figure 5 Four members of the HER family. HER-1 is the founding member of this family. HER-2 
is an ‘orphan’ receptor and HER-3 has no intrinsic kinase activity.  
 
 
Figure 6 HER receptors and their cognate ligands (reproduced from ref (90)).  EGF (epidermal 
growth factor), TGFα (transforming growth factor α), AR (amphiregulin), BTC (betacellulin), HB-
EGF (heparin-binding EGF), EPR (epiregulin) and NRG (neuregulin). 
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Distinct from the other HER receptors, HER-2 has no known ligands and is 
constitutively activated for homo- (when HER-2 is over-expressing) or hetero-
dimerisation with other HER family members (38, 90) . It has a conformation similar 
to other ligand-bound HER receptors, which explains why HER-2 is the preferred 
dimerisation partner (101, 102). In HER-2 over-expressing cells, it spontaneously 
forms homo-dimers and activates the downstream signalling cascades in the absence 
of ligands.  
 
HER-2 has been intensively studied as a therapeutic target due to several features. 
1) The over-expression of HER-2 protein is an adverse prognostic marker for 
breast cancer (103-106). 
2) HER-2 over-expression is found not only in metastatic cancers but also in 
primary tumours (107), meaning that the therapies targeting HER-2 are 
effective in different stages and sites.  
3) Normal adult tissues usually have much lower HER-2 expression than breast 
cancers, so therapies targeting HER-2 have high specificity. 
 
As stated previously, HER-2 prefers to undergo hetero-dimerisation with other 
ligand-activated HER receptors. It is also known that distinct ligands govern 
different cell fate decisions (91, 108). This suggests that therapeutics based on 
blockade of HER-2’s action may inhibit the effects of diverse ligands on cell fate. 
Hetero-dimerisation with HER-2 can enhance ligand binding affinity (109) and also 
ligand induced tyrosine phosphorylation (110). HER-2 over-expression is associated 
with approximately 20-25% of invasive breast cancers (38) and it has been shown to 
be associated with poor rates of disease free survival and increase the resistance to 
chemotherapeutic drugs (103, 111). Therefore, HER-2 is an attractive therapeutic 
target in breast cancer treatment (112).  
 
One of the recombinant humanised anti-HER-2 monoclonal antibody drugs, 
trastuzumab (Herceptin®) developed by Genentech has been approved for clinical 
use to treat HER-2 over-expressing metastatic breast cancers since 1998 by the US 
Food and Drug Administration (113). It was humanised by replacing the antigen 
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binding region of human IgG with the hyper-variable antigen binding region of the 
potent murine anti-HER-2 monoclonal antibody (114). Trastuzumab is generally 
used as the first-line treatment of HER-2 over-expressing metastatic breast cancer 
patients (84). However, its exact mechanism of action in vivo remains unclear. 
Studies have shown that, to inhibit tumour progression, trastuzumab binds HER-2 on 
the cell surface and then triggers the internalization and degradation of receptors 
(115, 116), which block downstream signalling pathways (117, 118), such as Raf/ 
MEK 1&2/ERK 1&2 and PI3K/Akt pathways. Trastuzumab can inhibit the shedding 
of HER-2 by blocking the metalloproteinase activity (119). When over-expressed, 
HER-2 undergoes proteolytic cleavage by metalloproteinase. This cleavage causes 
the release of extracellular domain (ECD) of HER-2 and a truncated membrane-
bound fragment (p95) (120). The shedding of HER-2’s ECD was detected in 
conditioned media of HER-2 over-expressing cell lines (121-124) and could also be 
found in serum of cancer patients (125-127). High serum levels of ECD correlate 
with poor prognosis and lowered sensitivity to endocrine therapy and chemotherapy 
(128-130). Investigators found that trastuzumab could inhibit the shedding of ECD 
by inhibiting metalloproteinase activity (119). Clinical studies demonstrated that the 
decrease of serum levels of ECD during trastuzumab treatment improved 
progression-free overall survival, supporting indirectly the hypothesis that 
trastuzumab may act through inhibiting ECD of HER-2 shedding (131, 132). It also 
induces cell cycle arrest in the G1 phase through down-regulation of the proteins 
involving the sequestration of cyclin E/CDK2 complex inhibitor p27Kip1, increased 
association of p27 with CDK2 and CDK2 inactivation (133, 134). Trastuzumab is 
not only cytostatic but also cytotoxic. It recruits immune effector cells onto the 
tumour cells which are then killed by immune cells through antibody dependent 
cellular cytotoxicity (ADCC) (135-138). It may also act through an anti-angiogenic 
effect (139). In adjuvant settings, trastuzumab sensitised the HER-2 over-expressing 
cells to apoptosis when treated by standard chemotherapy such as taxol or etoposide 
(140, 141) and also induced apoptosis in primary breast cancers in neoadjuvant 
settings (107). Although it has some side effects including flu-like symptoms, low 
white or red blood cell counts, diarrhoea, heart attacks, lung dysfunction, etc, 
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trastuzumab is widely used with great efficacy  in women patients with HER-2 over-
expression and increases overall survival.  
 
Although trastuzumab is considered as one of the most effective treatments for HER-
2 over-expressing metastatic breast cancers at present (38) , it is very common that 
some patients may have no response or some patients who initially respond to this 
drug may acquire drug resistance within one year (142), which will cause the 
treatment to fail. Understanding resistance mechanisms is crucial for developing 
more effective therapeutic strategies and multiple mechanisms have already been 
identified. Three possible mechanisms are described as follows: oncogenic mutations 
of the catalytic domain of the PI3 Kinase (PIK3CA), constitutively active Akt and 
the activity loss of PTEN (143-145). The low level of p27kip1 which is a cyclin-
dependent kinase inhibitor is also a reported possibility (146). As aforementioned, a 
truncated p95 HER-2, which is the intracellular part of HER-2 and has the kinase 
activity but doesn’t possess the trastuzumab binding site, is a possible factor which 
could confer resistance. Hyper-activation of the metalloproteinase which catalyses 
the release of HER-2’s ECD would make tumours resistant to trastuzumab since 
binding for trastuzumab site is removed (139). It is also possible that the steric 
inaccessibility or masking of the trastuzumab binding site on HER-2 explains the 
resistance (147, 148).  
 
Nagy et al (147) demonstrated that in JIMT-1, a HER-2 over-expressing breast 
carcinoma cell line with primary trastuzumab resistance, the expression of MUC4 
was higher than in trastuzumab-sensitive cell lines. MUC4 is a membrane associated 
mucin that was reported to play a role in masking the membrane protein and the 
expression level of MUC4 was inversely correlated with the binding capacity of 
trastuzumab with HER-2. Additionally, the ligands of other HER members, such as 
TGF-α and HB-EGF which trigger the homo-dimerisation of HER-1 and hetero-
dimerisation with HER-2, possibly bypasses inhibition produced by trastuzumab 
(149, 150).  
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Activation of alternative pathways has also been observed in tumours resistance to 
trastuzumab and the insulin like growth factor-I (IGF-I) receptor mediated pathways 
have been investigated as causes of resistance (151). Lu et al (151) demonstrated that 
trastuzumab inhibited the proliferative growth of MCF-7/HER2-18 cells which over-
expresses HER-2 and expresses IGF-I receptor when the IGF-I receptor mediated 
signalling was minimised, but when cells were grown in 10% FBS or under the 
stimulation of IGF-I, the growth inhibition by trastuzumab was blocked. In contrast 
to MCF-7/HER2-18 cells, trastuzumab inhibited the proliferation of SKBR3 cells 
which over-express HER-2 and have low IGF-I receptor expression, regardless of the 
addition of IGF-I. When SKBR3 cells were genetically altered to over-express IGF-I 
receptor and cultured with IGF-I, trastuzumab had no effects on proliferation. 
However, when IGF binding protein-3 was added to the media, the trastuzumab 
induced growth inhibition was restored (151). The involvement of IGF-I receptor in 
the development of resistance may be due to the interaction of IGF-I receptor with 
HER family members, which enhances the activation of downstream signalling 
pathways (152). Huang, Gao et al (152) demonstrated recently that interaction 
between IGF-I receptor and HER-2 or HER-3 exclusively occurred in trastuzumab 
resistant cell lines, where enhanced interaction of HER-2 and HER-3 was also 
observed. What’s more, the heterotrimer of HER-2, HER-3 and IGF-I receptor was 
also observed in resistant cells. The knockdown of HER-3 or IGF-I receptor 
resensitised the cells to trastuzumab in this study. Finally, the decreased immune 
function of patients caused by the disease and the medical therapies, such as radio- 
and chemotherapy may also result in non-responsiveness to trastuzumab (153). 
 
In contrast to trastuzumab which is only effective clinically in HER-2 over-expressed 
breast cancer, another humanized monoclonal antibody drug pertuzumab (Omnitarg, 
rhuMAb 2C4) developed by Genentech is known to inhibit HER-2 dimerisation by 
targeting the dimerisation arm (sub-domain II) in HER-2 expressing breast cancer 





Figure 7 : Pertuzumab and trastuzumab bind different domain of HER-2 (reproduced from 
ref(90)). 
 
Pertuzumab is the first in a new class of targeted anti-tumour therapies known as 
HER-2 dimerisation inhibitors and is now undergoing clinical trials (154, 155). 
Dimerisation is essential for the HER family to activate the intracellular signalling 
cascades governing proliferation, survival and differentiation. As previously 
mentioned, HER-2 is the preferred dimerising partner for all other members in the 
family (101). Therefore, inhibition of HER-2 dimer pairing may prevent the 
activation of several signalling pathways. In the laboratory setting, pertuzumab had 
shown excellent anti-tumour activity in vitro and in vivo against HER-2-positive 
breast and prostate cancers (156). Scheuer et al (157) showed that the combination of 
pertuzumab and trastuzumab or the addition of pertuzumab after the progression on 
trastuzumab in breast cancer xenografts synergistically increased the inhibition of the 
tumour growth compared with single drugs. They also observed that the metastasis of 
breast cancer cells to the lung was dramatically decreased by the combination of 
pertuzumab and trastuzumab compared with single drugs. These results suggested 
that pertuzumab and trastuzumab may have complementary mechanisms of action. 
These researchers confirmed by near-IR fluorescence imaging in their study that 
pertuzumab as well as trastuzumab could activate ADCC. A recent phase II clinical 
trial demonstrated that the combination of pertuzumab and trastuzumab was active 
and well tolerated in patients with HER-2 positive metastatic breast cancer who 
experienced progression during prior trastuzumab-based therapy (154). Therefore, 
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pertuzumab is a promising anti-HER-2 based drug in the clinic and further clinical 
development is likely. 
 
In addition to the antibody agents, small molecule tyrosine kinase inhibitors (TKIs) 
are also attractive drugs in cancers (90, 158). These small molecules can enter the 
cytoplasm and inhibit receptors’ auto-phosphorylation activity by impeding the 
binding of GTP with tyrosine kinase domain. For example, lapatinib is an oral dual 
TKI against HER-1/HER-2. Studies have shown that the addition of lapatinib to 
capecitabine improves the progression-free survival and increases the overall 
survival in patients with metastatic HER-2 over-expressing breast cancers which are 
resistant to trastuzumab (159). Its combined use with letrozole improves the 
progression-free survival compared to letrozole alone in patients with ER and HER-2 
positive metastatic breast cancers (159).  
 
To gain more effective treatments, it is reasonable to develop combined targeted 
therapies. It was shown that the combined treatment of trastuzumab, pertuzumab and 
gefitinib (a TKI against HER-1) in inhibiting the tumour growth of HER-2 over-
expressing xenografts is statistically significantly better than single agent and dual 
combination therapies (160). The clinical trials combining trastuzumab and lapatinib 
have also investigated the new treatment approach beyond the progression on 
trastuzumab. O'Shaughnessy et al (161) demonstrated in their clinical study 
improved clinical outcomes with the combination of lapatinib and trastuzumab vs 
lapatinib alone in patients who progressed on prior trastuzumab-contained treatment 
regimes, but no significant changes in side effect profiles. The combination of 
trastuzumab and chemotherapy had an overall response rate ranging from 50% to 
80% (162), while trastuzumab as a single agent had a response rate of only 15% to 
30% (163). As mentioned above, the combination of pertuzumab and trastuzumab 
can bypass trastuzumab resistance.  
 
It has been reported that one mechanism of endocrine resistance in ER+ breast cancer 
is HER-1/HER-2 over-expression or hyper-activation of HER-1/HER-2 mediated 
signalling which results in ERα activation in an oestrogen independent manner (164). 
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Combined treatments targeting ERα and HER-1/HER-2 have shown high efficacy in 
preclinical models and clinical trials (165). Massarweh et al (87) demonstrated that 
gefitinib improved tamoxifen response and delayed acquired resistance in MCF-7 
xenografts. Chu et al (166) demonstrated that combined use of tamoxifen and 
lapatinib effectively inhibited the growth of tamoxifen-resistant, HER-2 over-
expressing MCF-7 xenografts. The phase III clinical trial led by Johnston et al (167, 
168) demonstrated that compared with letrozole alone the combined targeted therapy 
of letrozole and lapatinib significantly enhanced progress free survival, objective 
response rate  and clinical benefit rate in patients with metastatic breast cancer that 
co-expresses ER and HER-2. Some clinical trials have investigated the efficacy of 
the combination of trastzumab and endocrine therapy on HER-2+-ER+ metastatic 
breast cancer patients (169, 170). In TAnDEM (170) which was the first randomized 
phase III trial to study the combination of anastrozole and trastuzumab vs anastrozole 
as a treatment of  HER-2+-ER+ metastatic breast cancers, investigators observed 
improved outcomes of patients treated with the combination compared with 
anatrozole alone.  All the above studies suggested that the combined therapies may 
be more effective than single target therapies.  
1.9.2 Raf/ MEK 1&2/ERK 1&2 and PI3K/Akt pathways and 
feedback loops in breast cancers 
 
The Raf/ MEK1&2/ERK1&2 and PI3K/Akt pathways are the two primary signalling 
cascades mediated by HER receptors (38). Once activated, both pathways relay the 
extracellular signals to the nucleus through tiered phosphorylation cascades to induce 
nuclear gene expression. These pathways play pivotal roles in cell proliferation, anti-
apoptosis, differentiation, growth arrest and drug resistance (38). Apart from the core 
phosphorylation cascades, complex feedback regulation is also induced. So even 
within the same core pathways different cell responses can be induced, depending on 
the external stimuli types, timing, duration and strength of signal and cell types (93). 
The aberrant activation of these pathways is associated with the development and 
progression of cancers (90).  For example, loss of PTEN and oncogenic mutation of 
PIK3CA are often found in breast cancers which are resistant to trastuzumab therapy 
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(171). Both pathways are key therapeutic targets for cancer treatment (172, 173). A 





Figure 8 Schematic overview of Raf/MEK1&2/ERK1&2 (174) and PI3K/Akt pathways. The 
scheme of the PI3K/Akt pathway is produced through modifying the online image 
(http://knol.google.com/k/protein-kinase-b#). 
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In the response of mitogenic stimuli, receptor tyrosine kinases are auto-
phosphorylated. The phosphorylated residues become the docking sites for adaptor 
proteins (Grb2). Grb2 recruits the guanine exchange protein SOS to the cell 
membrane, where SOS activates Ras from the GDP-bound inactive state to the GTP-
bound active state. This exchange of Ras state elicits a conformational change in Ras, 
enabling it to bind to Raf-1 and recruit it from the cytosol to the cell membrane, 
where Raf-1 activation takes place. Raf-1 activation is a multi-step process that 
involves the dephosphorylation of inhibitory sites by protein phosphatase 2A (PP2A) 
as well as the phosphorylation of activating sites by PAK (p21rac/cdc42-activated kinase), 
Src-family and yet unknown kinases (174). Raf is considered the first kinase in the 
cascade leading to activation of the MAPKs (ERK1 and ERK2). The best 
characterized substrates of ERK1/2 are ternary complex factors (TCFs) (175-177) 
such as Elk-1 and SAP-1 which are transcription factors and activate the expression 
of multiple mitogen inducible immediate early genes responsible for cell 
proliferation.  
 
PI3K is a lipid kinase and consists of two subunits: catalytic subunit p110 and 
regulatory subunit p85. p85 binds and inhibits p110 when PI3K is inactivated. PI3K 
is activated through binding of the regulatory subunit p85 with the phosphorylated 
tyrosine residues on receptors. Meanwhile, p110 is dissociated from p85 and 
recruited to the membrane to catalyse the conversion of PIP2 to PIP3, which is bound 
to the cell membrane. Once Akt binds PIP3 correctly through the PH (Pleckstrin 
Homology) domain, it is activated by phosphoinositide dependent kinase 1 (PDK1 at 
T308) and PDK2 (at S473) (178). Then, activated Akt stimulates the activation or 
inactivation of their target molecules. PI3K can also be activated in a p85-
independent manner. Ras interacts with p110 on the Ras binding domain (RBD) and 
tethers it to the membrane for activation (179, 180). 
 
The Ras/Raf/MEK/ERK pathway plays a critical role in breast cancer tumourigenesis 
and cancer progression. This pathway is often involved in the regulation of oestrogen 
receptor α (ERα)-positive breast cancers. In oestrogen-dependent breast cancer cells, 
oestrogen can regulate in a non-genomic way the ERK1/2 pathway through binding 
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to the extracellular domain of the cell membrane-bound ERα and initiating a cascade 
involving Shc, Grb2 and SOS to activate ERK1/2 which in turn enhances the 
transcriptional activity of nuclear ERα (181). In this way, ERK1/2 is rapidly 
activated by the stimulation of oestrogen. In a genomic manner, oestrogen can also 
increase the expression level of some growth factors and their receptors such as IGF-
I and IGF-I receptor which in turn activate the ERK1/2 pathway and play important 
roles in growth and differentiation (182). Reddy et al (183) demonstrated the 
expression of transforming growth factor-α (TGF-α) which was a specific ligand of 
HER-1 induced by oestrogen and the enhancement of proliferation. Hyper-activation 
of Raf/MEK/ERK pathway is often involved in drug resistance in breast cancers 
(184). Oestrogen-dependent breast cancers which initially respond to tamoxifen 
treatment frequently become resistant. This responsiveness alteration was suggested 
to be due to the shift from ERK1/2-independence to ERK1/2-dependent cell growth 
(185). Tamoxifen resistance can be produced by the hyper-activation of ERK1/2 
through over-expression of HER-2 (87, 186). It was shown that the proliferation of 
ERα-positive breast cancer cells could be induced by oestrogen through the 
activation of ERα (187). The antiestrogen drug tamoxifen has been used extensively 
for decades in ER-positive patients. Tamoxifen blocks oestrogen’s proliferation 
action through competing for the binding of oestrogen with ERα and then 
suppressing ERα’s transcriptional activity (188). ERα activation could also be 
induced through the hormone-independent phosphorylation of S118 in the hormone-
independent transcription activation function-1 (AF-1) domain by ERK1/2 and the 
phosphorylation of this site enhanced the transcriptional activity of ERα (189-191). 
Therefore, the hormone-independent activation of ERα by ERK1/2 may contribute to 
tamoxifen resistance. The study by Thomas et al (192) indicated that phosphorylation 
of another two residues S104 and S106 by ERK1/2 were also required for ER α activity. 
Glaros et al (86) showed that phosphorylation of S167 in the AF-1 domain of  ERα in 
MCF-7 cells by over-expressed HER-1 enhanced the interaction of ERα with its co-
activator in the presence of tamoxifen and led to resistance to tamoxifen. In addition, 
resistance to tamoxifen is also enhanced by the increased expression of ERα co-
activator AIB1, which can be activated by HER-2 signalling (184, 193). Jaime et al 
(194) showed that the transcriptional activity of AIB1 was enhanced by ERK1/2 
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phosphorylation. The hyper-activation of ERα by ERK1/2 in a hormone-independent 
manner may contribute to tamoxifen resistance in breast cancer patients. 
 
Activation of the PI3K/Akt pathway is considered to play a crucial role in breast 
cancer cell growth (195) and the high proportion (72%) of aberrant activation of this 
pathway is associated with poor clinical outcomes and progressive tumour properties 
such as high histological grade, basal-like phenotype, ER/PR negative status and 
correlation with HER-2 over-expression (196-198). The best known aberrant genetic 
alterations within this pathway in breast cancers are the oncogenic mutation of 
PI3KCA, the loss of PTEN and the mutation of AKT1 (179, 198). The mutations in 
PI3KCA, the gene encoding p110α are somatic and often involve three ‘hotspots’ 
(180). The first two reside on exon 9. E 542 and E545 in the helical domain are 
mutated to lysine. These two mutations lower the inhibitory interaction of p85 with 
p110α. The third ‘hotspot’ is on exon 20. H1047 in the kinase domain is mutated to 
arginine, which increases the access of p110α to cell membrane. All three mutations 
increase catalytic activity and lead to growth factor independent activation of Akt 
(180). PTEN is a dual lipid/protein phosphatase. The loss of phosphatase activity in 
PTEN occurs in 28% of invasive breast cancers (198). It can be produced by gene 
deletion in chromosome 10 (199), somatic mutations which are rarely documented 
(200) and epigenetic silencing such as promoter hyper-methylation (201). The loss of 
activity results in accumulation of the amount of PIP3 and produces growth factor-
independent proliferation of non-tumourigenic mammary cells in vitro but is 
insufficient to promote anchorage-independent growth (202). The correlation of loss 
of PTEN with prognosis is controversial. Some studies showed no prognostic value 
of PTEN loss (197, 203) but some showed a correlation with poor prognosis (204-
206). AKT1 mutations have been reported in 1-8% of breast cancers (207). It has 
been shown that the hotspot mutation (E17K) in the PH domain of AKT1 conferred 
constitutive localization of Akt to the cell membrane regardless of the ligand 
stimulation, caused marked increased phosphorylation at both T308 and S473 and 
kinase activity, activated downstream signalling and transformed cells in culture 
(208). The PI3K/Akt pathway also plays a critical role in breast cancer treatment. 
The activation of PI3K/Akt pathway has been implicated in conferring resistance to 
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conventional chemotherapy. Knuefermann et al (209) demonstrated that the 
activation of PI3K/Akt pathway by HER-2 over-expression increased the resistance 
of MCF-7 cells to multiple chemotherapeutic drugs (paclitaxel, doxorubicin, 5-
fluorouracil, etoposide, and camptothecin). Vitolo et al (202) showed the increased 
susceptibility of MCF-10A cells with deleted/reduced PTEN to chemotherapeutic 
drug doxorubicin. The hyper-activation of PI3K/Akt pathway also confers resistance 
to endocrine therapy (210, 211). As aforementioned, the aberrant activation of this 
pathway could confer resistance to trastuzumab-contained therapy as well.  
 
The intracellular signalling that regulates cellular behaviour in ‘normal’ cells must be 
precisely controlled to avoid dangerous disorders. Signals produced at the wrong 
time or in the wrong place will lead to inappropriate cell fate or may cause 
tumourigenesis. Moreover, even produced at the correct time and places, signals 
must be robust enough to ensure cells receive them at high enough levels against 
background signal to respond. Signalling not only operates in different cell types 
with different environments but also functions with different spatial and kinetic 
properties. This is defined as versatility.  Feedback loops play critical roles in 
maintaining the three signalling properties-- precise regulation, robustness and 
versatility. Both the Raf/MEK/ERK and the PI3K/Akt pathways are regulated tightly 
through the spatiotemporally coordinated action of positive and negative feedback 
loops at multiple levels of the cascades (212). Feedback loops are the processes that 
link output signals back to input signals. Positive feedback loops are those with 
which output signals can enhance input signals as opposed to negative feedback 
loops which attenuate input signals. Both types of loops are very common 
modulatory elements in cellular signalling processes. Many components in signalling 
pathways have multiple upstream effectors and downstream targets which would 
form a complex web of connectivity within and between pathways. The presence of 
feedback loops poses a challenge to understanding how the extracellular signals 
through receptors modulate cellular behaviour (213). Perhaps the most obvious 
function of negative feedback is to restrain signalling duration and amplitude. 
Negative feedback can produce stability even when systems confront environmental 
fluctuations (212, 214). In some cases, this homeostatic function of negative 
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feedback plays an important role in protecting cells from out of control growth and 
cancer development. Sprouty (Spry) proteins are ligand-inducible negative feedback 
modulators of HER-mediated ERK1/2 signalling pathways. Four mammalian 
isoforms are identified in this family: Spry1, Spry2, Spry3 and Spry4. When the 
Raf/MEK/ERK pathway is activated by activated HER receptors, the transcription of 
Spry proteins is induced (215). In turn, they specifically inhibit the Raf/MEK/ERK 
pathway, leaving the PI3K/Akt pathway and other MAPK pathways unaffected, but 
the action mode is unclear and the point at which Spry blocks the activation of  
Raf/MEK/ERK is controversial (216, 217). Spry proteins play important roles in 
breast cancers. Lo et al (218) showed that expression levels of Spry1 and Spry2 were 
down-regulated consistently in breast cancers. Real time PCR assay confirmed this 
demonstration and showed gene expression suppression of Spry1 and Spry2 in more 
than 90% of patient samples. They also showed in this study that the abrogation of 
endogenous Spry activity in MCF-7 cells enhanced proliferation and anchorage-
independent growth in vitro and dramatically increased the tumourigenesis potential 
of the cells in nude mice in vivo. To date these results suggested Spry proteins as 
possible tumour suppressors in breast cancers.  
 
Another family of ligand-inducible negative feedback regulators of ERK1/2 pathway 
is the dual specificity phosphatase (DUSP) family. Dual specificity refers to 
phospho-serine/threonine and phospho-tyrosine. DUSPs are induced by the 
activation of ERK1/2 pathway and act to attenuate the signalling by 
dephosphorylating activated ERK1/2. Noticeably, not all DUSPs are inducible. The 
following are identified as ERK1/2-activating inducible /immediate-early DUSPs: 
DUSP1, DUSP2, DUSP4 and DUSP5 and these phosphatases except DUSP1 
modulate the kinetics of ERK1/2 in the nucleus (219-222). Among this family, 
DUSP1 is the most investigated in breast cancers. The preference substrate of 
DUSP1 is JNK or p38 MAPK over ERK1/2. The over-expression of DUSP1 was 
observed in a large percentage of breast cancers (223). Over-expression of this 
phosphatase is a mediator of chemotherapy resistance (224) and an independent 
prognosis predictor in breast cancers (225). This is because the chemotherapy drugs 
use proapoptotic signalling through JNK activity to exert their anticancer activities 
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(224). DUSP4 preferentially dephosphorylates ERK1/2 and JNK over p38 MAPK.  
Wang et al (223) observed a 3-fold increase of its expression in breast cancer 
samples against non-malignant samples. Additionally, they also observed the sharp 
increase of expression and activity of ERK1/2 and p38 MAPK. Although the over-
expression of JNK was observed, the activity was reduced by 35%. The over-
expression of DUSP4 may inhibit the proapoptotic signalling through JNK. DUSP2 
has highly selective dual phosphatase activity towards ERK1/2 over p38 MAPK and 
JNK and it is a transcription target of the tumour suppressor protein p53 in signalling 
apoptosis and cell growth suppression (226, 227). Knockdown of DUSP2 inhibited 
p53-mediated apoptosis and over-expression increased the susceptibility to apoptosis 
and growth suppression (227). Wu et al (228) demonstrated the cell killing role of 
DUSP2 in E2F-1-mediated apoptosis in breast cancer cells following treatment with 
a chemotherapeutic agent N-4-hydroxyphenylretinamide and that the increased 
expression of DUSP2 inhibited the activation of ERK1/2 and mediated cell killing. 
DUSP5, whose specific substrate is ERK1/2, was demonstrated to have reduced gene 
expression in breast carcinomas (229). Hence, DUSP2 and DUSP5 the negative 
regulators of ERK1/2 signalling play key roles in controlling cellular growth and are 
favourable factors in preventing cancer development and progression. In addition to 
these de novo negative feedback regulators, activated ERK1/2 attenuates the 
signalling from itself by acting back to inhibit phosphorylation of SOS and this 
inhibitory phosphorylation leads to the dissociation of SOS from Grb2 resulting in 
Ras inactivation (230-233). This negative feedback loop was reported to play a 
critical role in oscillation of ERK1/2 (234, 235). In addition to ERK/SOS negative 
feedback, multiple site inhibitory phosphorylation of Raf-1 by ERK1/2 was reported 
(236). The hyper-phosphorylation at these sites of Raf-1 blocked the association 
between Ras and Raf-1 and desensitized Raf-1 to additional stimuli, which protected 
cells from aberrant growth. The third negative feedback loop resulted from the 
inhibitory phosphorylation of Grb2-associated-binding protein 1 (GAB1) by 
activated ERK1/2 (237-239). This phosphorylation blocked the interaction of GAB1 
with Grb2-SOS complex and thereby led to Ras inactivation. Activated ERK1/2 
could also attenuate the signalling through feedback to phosphorylate MEK1 at T292 
(240). Phosphorylation at this site prevents the further enhancement (through 
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phosphorylation at S298 in MEK1 by PAK1 (p21-activated kinase 1)) of MEK1/2-
ERK1/2 complex formation (241) and thereby reduces ERK1/2 activity.  
 
The simplest use of positive feedback is to enhance and prolong signals and produce 
instability. An example of positive feedback loop regulating ERK1/2 activity is the 
phosphorylation of cytosolic DUSP6 (DUSP6 specifically deactivates ERK1/2 and is 
a non-inducible DUSP (219)) at S159/197 by ERK1/2 and this phosphorylation 
sensitized DUSP6 to degradation in proteosome (242). Amplified positive feedback 
loops often result in tumour formation and progression. A good example of this in 
cancers occurs in the hyper-activation of HER receptors by autocrine or paracrine 
production of EGF family ligands (90). To date, there are very limited studies of 
positive feedback loops in HERs-mediated signalling pathways in breast cancers. In 
summary, the loss of negative feedback loops or amplification of positive feedback 
loops can be an adverse factor of controlled cell growth.  
1.9.3 Oscillatory dynamics in Raf/MEK 1&2 /ERK 1&2 pathway 
 
Oscillations occur in diverse areas of cellular biology, from mechanotransduction to 
circadian control. There has been a growing body of evidence showing oscillation in 
protein levels (243-246). Hilioti et al (243) demonstrated the oscillation of yeast p-
Fus3 MAPK induced by pheromone regulated periodic mating-gene expression and 
periodic formation of mating projections. Each peak coincided with the formation of 
projections. Once the oscillation was severely dampened only the first projection 
formed. As well, they showed the requirement of negative regulator for the formation 
of oscillation. Fus3 is a MAPK in yeast mediating the mating signalling. It has more 
than 50% sequence identity as human ERK1/2. In their studies oscillations were 
observed to be correlated with periodic formation of projections, suggesting that 
oscillation may be a regulator of cycling cellular behaviours. Wee et al (244) 
demonstrated that the oscillation of tumour suppressor p53 expression level 
sensitized cells to apoptosis induced by ionic radiation. Compared to non-oscillatory 
p53, oscillatory p53 increased the target gene expression, thus influencing the cell 
fate decisions between cell cycle arrest/DNA repair and apoptosis.  Nakayama et al 
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(234) also observed the FGF-induced oscillation of activated ERK1/2 in Hela and 
NIH 3T3 cells, but the significance was not elucidated by the authors.  
 
Oscillation of active ERK1/2 levels in breast cancer cells was not demonstrated 
before the observations presented in this thesis. Their physiological, pathological, 
and therapeutic significance in breast cancer remains undetermined. The simplest 
way to produce an oscillation is by negative feedback with delay (247-249). 
However, many oscillators have positive feedback loops embedded as well, raising 
the question of what the advantages of the positive feedback loops are. Mathematical 
models show that it is generally difficult to modulate the frequencies of negative 
feedback oscillation without changing amplitude (249). The involvement of positive 
feedback loops generates the oscillator with tuneable frequency and robust amplitude. 
The tunability and robustness make the oscillator suitable for those biological 
rhythms which need constant output over a range of frequencies such as cell cycles 
and heart beats (249). Computational modelling studies pioneered by Kholodenko et 
al (235, 250-252) have described models of the oscillation dynamics in 
Raf/MEK/ERK pathways. In their models, they suggested that negative feedback, 
ultra-sensitivity, multi-site phosphorylation and competitive inhibition were able to 
cause oscillation dynamics. They hypothesized that MEK and MAPK were 
phosphorylated at two specific residues by two separate collisions, as presented (252) 
in Figure 9. Ultra-sensitivity refers to the signal amplification through kinase 
cascades which means a tiny change in a stimulus results in a large change in 
response. They predicted two types of oscillatory dynamics as well. The first 
example was called relaxation oscillation, assuming that the fully phosphorylated 
form of the kinases in the cycle represses the formation of the upstream 
phosphorylated kinases. The second example is ring oscillation in which a cascade of 
two cycles was considered. In this oscillator the fully phosphorylated kinases of the 
first layer activated the second layer and induced a feedback loop from the second 
layer. In this feedback loop, the fully active kinases of the second layer competitively 
bound and inhibited the kinases phosphorylating the first layer. They predicted that 
the periodicity could range from minutes to hours and the phosphorylation level 
could vary between base level to almost 100% of total protein (235). To date the 
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oscillation of p-ERK1/2 expression level in mammalian cells are intensively 
investigated theoretically through computational modelling with ordinary differential 
equations. Here in this thesis, the oscillations of p-ERK1/2 and p-Akt expression 
levels are observed experimentally in breast cancer cells. Raw data have been 
subjected to mathematical modelling (in collaboration with Dr. Alexey Goltsov, 
SIMBIOS Centre, University of Abertay), but the modelling is not included in this 
thesis. Oscillations in breast cancer cells presented in this thesis may be an adverse 
factor indicating malignancy. 
 
Figure 9 MAPK modules: hierarchical 3-tiered typical MAPK module. Raf is phosphorylated in a 
single site. MEK and MAPK are phosphorylated at double sites by two collisions. In each tier, 
forward reactions are catalyzed by kinases and reverse reactions by phosphatases (252).  
1.10  Aims 
 
The general aim of this thesis was to investigate how growth factor-induced 
dynamics of ERK1/2 and Akt pathways in breast cancer cells are regulated.  
 
First of all, to achieve this goal, it was necessary to elucidate what type of dynamics 
would be induced by growth factors, so the following experiments were undertaken. 
EGF and HRG were used to stimulate MCF-7 cells and expression levels of p-
ERK1/2 and p-Akt within a 2h time course were analysed. Oscillatory 
dynamics of Raf/MEK/ERK and PI3K/Akt pathways were observed.  
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Secondly, to elucidate the characteristics of signalling oscillations including 
feedback and feedforward regulating factors, the following experiments were 
undertaken. 
MCF-7 cells were stimulated with either EGF or HRG in the presence of 
cycloheximide (CHX, a protein synthesis inhibitor) and expression levels of p-
ERK1/2 and p-Akt within a 2h time course were analysed to test whether 
transcriptional feedback loops can modulate oscillations. 
 
HER-2 over-expressing MCF-7 cells were stimulated with HRG either in the 
presence or the absence of pertuzumab and expression levels of p-ERK1/2 and 
p-Akt within a 2h time course were analysed to test whether feedforward drive 
can regulate oscillations.  
 
Thirdly, to find out whether signalling oscillations are influenced by serum 
deprivation and whether they are a cell line-dependent phenomenon, the following 
experiments were conducted. 
MCF-7 cells were stimulated with HRG±CHX in serum deprivation or in the 
presence of 5% DCSS and expression levels of p-ERK1/2 and p-Akt within a 
2h time course were analysed to elucidate whether oscillations were dependent 
upon serum. 
 
BT474 cells were treated with HRG±CHX and the expression levels of p-Akt 
and p-ERK1/2 were assayed to find out whether oscillations were a general 
phenomenon across breast cancer cell lines. 
 
Fourthly, to identify which molecules may act within the transcriptional feedback 
loops, the following experiments were conducted. 
PTPN13 might be a possible oscillation candidate which could regulate 
oscillations based on the published studies and the effect of this phosphatase on 
signalling was investigated by knockdown with RNAi. The correlation of its 
expression levels with clinical parameters in a series of breast cancers was 
investigated as well. 
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To identify candidate molecules exerting transcriptional feedback in a high 
throughput manner, MCF-7 cells were treated with HRG for 5, 10, 20 and 40 
min respectively and mRNA was extracted from each sample for gene 
expression array analysis.  
 
Using these experimental data, an ordinary differential equation-based mathematical 
model has been established through collaboration with Dr. Alexey Goltsov from the 
SIMBIOS Centre, University of Abertay, Dundee to help predict the mechanisms of 
oscillation.  
 
Finally, to elucidate which types of signalling dynamics can be generated by the 
intervention of trastuzumab and pertuzumab and how the signalling is regulated, the 
following experiments were undertaken. 
Cell growth of MCF-7, MCF-7/HER2-18 and BT474 cells driven by either 
HRG or EGF in the presence or absence of trastuzumab, pertuzumab or their 
combination was investigated. 
 
Time course profiles of p-ERK1/2 and p-Akt in the above three cell lines 
stimulated with HRG or EGF in the presence or absence of trastuzumab, 
pertuzumab or their combination was assessed. 
 
The mechanism of action of trastuzumab on the alteration of signalling 
dynamics in Akt and ERK1/2 pathways in HRG-stimulated MCF-7 cells was 
studied through assessing whether the crosstalk between p38 MAPK and 
ERK1/2 exists and analysing the gene expression in MCF-7 cells treated with 
HRG, trastuzumab and HRG+trastuzumab for 5, 10, 20 and 40 min 
respectively.  
 47
Chapter Two: Materials and Methods 
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2  Materials and Methods 
 
Chemicals and reagents were obtained from Sigma unless otherwise stated.  
Materials are listed according to the order in which the methods are described.  
2.1 Materials 
2.1.1 Tissue culture reagents and inhibitors 
Reagents Manufacturer or supplier/Catalogue No. 
DMEM with phenol red Invitrogen /31885 
DMEM without phenol red Invitrogen/11880 
Foetal Calf Serum Harlan Sera-Lab LTD/S-0001 AE 
Penicillin/streptomycin Invitrogen/15140-122  
G418 Invitrogen/11811-023 
PBS tablets OXOID/BR0014G 
Trypsin/EDTA Invitrogen/25300 
DMSO BDH Laboratory supplies /282164K 
HRG R & D systems/396-HB/CF 
LY294002 Calbiochem/440204 
UO126 Calbiochem/662005 
Trastuzumab kindly donated by Roche Pharmaceuticals 
Pertuzumab kindly donated by Roche Pharmaceuticals 
2.1.2 Reagents used for the preparation of double charcoal 
stripped serum 
Reagents Manufacturer or supplier/catalogue No. 
Foetal Calf Serum Harlan Sera-Lab LTD/S-0001 AE 
Dextran T70 Pharmacia /17-0280-01 
2.1.3 Reagents used in the Sulphorhodamine B (SRB) assay 
Reagents Manufacturer or supplier/catalogue No. 
Acetic acid BDH Laboratory supplies /10001CU 
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2.1.4 Reagents and other materials used in protein detection in 
cell lines 
Reagents and other 
materials 
Manufacturer or supplier/catalogue No. 
Mini complete protease 
inhibitor cocktail tablets 
Roche Applied Science/11836153001 








Protein Extraction Kit 
Biochain Institute, Inc., CA, USA/K3013010 
30% acrylamide/Bis 
acrylamide  stock solution 
Severn Biotech Ltd/20-2100-05 
TEMED BioRad/161-0801 
2-Propanol BDH Laboratory supplies /102246L 
Methanol BDH Laboratory supplies /261296H 
Tween-20 BioRad/170-6531 
Odyssey Blocking Buffer LI-COR Biosciences/927-40000 
Anti-rabbit IgG, HRP-
linked Antibody  
CST/7074 
PVDF membrane Millipore/IPVH304F0 
BM Chemiluminescence 
Blotting Substrate (POD) 
kit 
Roche Applied Science/11500708001 
Fuji Super RX medical X-
ray film 




Continued for 2.1.4 
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CSA ⅡA Biotin free 
Tyramide Signal 
Amplification System for 




CSA ⅡRabbit Link  Dakocytomation/K1501 
Normal goat serum Invitrogen/16210-064 
Black-wall, clear-bottom 
96-well microplate 
BD Biosciences/ 353948 
2.1.5 Reagents and other materials used in protein detection in 
tumours 
Reagents and other 
materials 
Manufacturer or supplier/catalogue No. 
DAKO Protein Block 
Serum Free  
Dako/X0909 
DAKO Antibody Diluent  Dako/S0809 
Dako Envision+System-




HRP labelled polymer 
Anti-mouse 
Dako/ K4001 




Goat anti-mouse Alexa555 
antibody  
Invitrogen/A21422 
Aquantiplex™ assay kit  HistoRX/AQ-EMR1-0001 
Prolong Gold anti-fade 
reagent with DAPI  
Invitrogen/P36931 
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2.1.6 Primary Antibodies used in Western Blot 
Antibody name Working 
dilution 
Host species Manufacturer /Catalogue No.
Anti-p-ERK1/2 
(T202/Y204) 
1:1000 rabbit CST/9101 
Anti-ERK1/2 1:1000 rabbit CST/9102 
Anti-p-Akt 
(S473) 
1:2000 rabbit CST/4060 
Anti-Akt 1:1000 rabbit CST/9272 
Anti-GAPDH 1:2000 rabbit CST/2118 
Anti-p-MEK1/2 
(S217/221) 
1:1000 rabbit CST/9154 
Anti-p-Raf-1 
(S259) 
1:1000 rabbit CST/9421 
Anti-p-HER-2 
(Y877) 
1:1000 rabbit CST/2241 
Anti-p-HER-3 
(Y1289) 




1:1000 rabbit CST/9215 
Anti-PTPN13 1:800 rabbit  SCB/sc-15356 
Anti-GAPDH 1:5000 mouse Abcam/Ab8245 
Anti-α-tubulin 1:6000 mouse Abcam/ab7291 
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2.1.7 List of primary antibodies used in RPPA 
Antibody name Dilution Host species Manufacturer/Catalogue No. 
Anti-p-ERK1/2 
(T202/Y204) 
1:100 rabbit CST/9101 
Anti-ERK1/2 1:150 rabbit CST/9102 
Anti-p-Akt 
(S473) 
1:50 rabbit CST/4060 
Anti-Akt 1:150 rabbit CST/9272 
Anti-GAPDH 1:100 rabbit CST/2118 
2.1.8 Near-infrared fluorophore conjugated secondary antibodies 


























1:15,000/1:2000 mouse 680nm 926-32220 
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2.1.9 Kits used in the gene expression analysis 
Kits Manufacturer or supplier/catalogue No. 
STRATAGENE 
Absolutely RNA® 
Miniprep Kit  
Agilent Technologies/400800 
Illumina® TotalPrep™ 
RNA Amplification Kit 
AMBION INC/AMIL1791 
2.1.10 Reagents and other materials used in the cell cycle 
analysis 
Reagents and other 
materials 
Manufacturer or supplier/catalogue No. 
Trisodium citrate BDH Laboratory supplies/301287F 
DMSO BDH Laboratory supplies/140214P 
BD Falcon tube BD Biosciences/352052 
2.2 Methods 
2.2.1  Cell Culture  
 
All the cell lines were grown at 37ºC in a humidified atmosphere of 5% CO2 for both 
routine maintenance and drug treatment. 
2.2.1.1  Routine cell line culture 
 
Breast carcinoma cell lines MCF-7 and BT474 cells were routinely maintained in 
Dulbecco’s modified Eagle’s medium (DMEM) containing phenol red supplemented 
with 10% FCS and 0.1 mg/ml penicillin/streptomycin. A HER-2 over-expressing cell 
line, MCF-7/HER2-18 which was routinely maintained in DMEM supplemented 
with 0.5 mg/ml G418 along with 10% FCS and 0.1 mg/ml penicillin/streptomycin 
was obtained from the Osborne/Schiff lab, Baylor College of Medicine, Houston, 




2.2.1.2  Cell line culture for drug treatment 
 
All the experiments involving drug treatment of cell lines adopted this procedure 
unless otherwise stated. 
Cells were grown in DMEM without phenol red supplemented with 5% DCSS, 0.1 
mg/ml penicillin/streptomycin and 2 mM L-glutamine (for MCF-7/HER2-18 cells, 
0.5 mg/ml G418 was contained in the media as well) for 48 h before drug or stimuli 
treatment. For those experiments involving the treatment of inhibitors, cells were 
pre-incubated with inhibitors for 20 min before EGF or HRG treatment. 
2.2.1.3  Subculturing of cells 
 
Cells were trypsinised when the cell number reached roughly 80% confluence for 
continuing growth. Medium was discarded before the wash with pre-warmed PBS 
and then cells were incubated with trypsin/EDTA for 5 min at 37 ºC in the incubator. 
The reaction was stopped by addition of serum-containing medium to the dish or 
flask when the cells had detached. Cell suspension was transferred to a sterile spin 
tube and centrifuged for 4 min at 1200 rpm. The medium containing trypsin/EDTA 
was discarded and the cell pellet was re-suspended with medium. Cells were seeded 
into a new dish or flask at an appropriate dilution. 
2.2.1.4  Cryopreservation and recovery of cells from liquid nitrogen 
 
Cells were harvested when cell number reached roughly 80% confluence in a 175cm2 
flask.  After centrifugation, the cell pellets were re-suspended with 10ml freezing 
media (10% DMSO in FCS). The cell suspension (2 ml) was aliquoted into 
cryopreservation vials. These vials were then transferred to a liquid nitrogen storage 
tank for long-term storage. To recover cells from liquid nitrogen, these vials were 
taken out and defrosted as rapidly as possible in a 37ºC water bath. The cell 
suspension in the vials was transferred to 25ml warmed-up medium when completely 
defrosted. The DMSO was removed by centrifugation and the supernatant was 
discarded. Cell pellets were re-suspended in 25 ml of warmed-up medium and 
transferred into a 175-cm2 flask for routine growth. 
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2.2.2 Double charcoal stripped serum preparation 
 
To study the functionality of the cell lines, it was necessary to grow cells in phenol 
red free medium containing charcoal stripped FCS in order to remove endogenous 
stimuli that may influence the signalling. These endogenous steroids from FCS were 
stripped using dextran-coated charcoal and type Ⅳsulphatase (EC 3.1.6.1).  
After being thawed at room temperature, 1L FCS was heat inactivated at 56 ℃ for 30 
min and was then incubated with 2000 U sulphatase for 2 h at 37℃. The pH of the 
serum was adjusted to pH 4.2 using 2 M HCl. Pre-prepared charcoal mix (for 1 L, 
charcoal mix consists of 5 g charcoal and 25 mg dextran T70 in 50 mL H2O) was 
added prior to stirring overnight in a cold room. Charcoal was removed from the 
serum via centrifugation at 10,000 rpm, 30 min, at 4℃. The pH was re-adjusted to 
pH 4.2 as above. A second charcoal mix was added and stirred overnight in the cold 
room once more. Charcoal was removed by centrifugation as above. To remove 
residual charcoal, it was necessary to spin further. The pH was adjusted back to pH 
7.2 using 2 M NaOH before 0.2 µm filter sterilising serum.  The serum then was 
aliquoted and stored at -20℃. 
2.2.3  SRB assay for growth studies 
2.2.3.1  Cell preparation 
 
When cell growth reached 80% confluence, cells were harvested and 2,500 MCF-7 
cells per well ( 6,000 for MCF-7/HER2-18 cells) were seeded in 96-well flat bottom 
plates and incubated in 10% FCS DMEM for 48 h at humidified 5% CO2, 37℃. The 
medium was replaced by 200 µl/well phenol red free DMEM containing 5% DCSS 
after one wash of each well using warmed up PBS. Cells were incubated for another 
48 h before drug treatments for a variety of days. 
2.2.3.2  Relative cell numbers determined by SRB assay 
 
96-Well plates were taken out of the incubator and 50 µl of cold 25% trichloracetic 
acid (TCA) was added to each well to fix the cells for 60 min in the cold room. TCA 
was discarded and wells were washed 10 times under running tap water followed by 
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drying in a 50 ℃ oven. 50 µl 0.4% SRB dye solution was added into each well and 
plates were left at room temperature for 30 min. The SRB dye was discarded and 
wells were rinsed by 1% acetic acid for 4 times and dried in a 50℃ oven. Finally, 
150 µl of 10 mM Tris solution, pH 7.5 was added to each well and plates were left on 
a shaker at room temperature for 60 min before reading at 540 nm with the 
microplate reader (BP800, BIOHIT). 
2.2.4 Protein detection in cell lines 
2.2.4.1  Knockdown of PTPN13 in MCF-7 with RNAi 
 
Reverse transfection for MCF-7 cells was conducted in 6-well plates. 
RNAi duplex-Lipofectamine™ RNAMax complexes were prepared for each well to 
be transfected as follows. 
1) 30 pmol RNAi duplex was diluted by mixing gently in 500 µl Opti-MEM I 
Medium without serum in the well of the tissue culture plate. 
2) Lipofectamine™ RNAMax was gently mixed before use and then 5 µl was 
added to each well containing the diluted RNAi molecules followed by 
mixing gently. The mixture was incubated for 20 min at room temperature. 
During the incubation time, MCF-7 cells in complete growth media without 
antibiotics were diluted to 2.4×105 cells /2.5 ml so that cells the would reach 30-50% 
confluence 24 h after plating. To each well with RNAi duplex-Lipofectamine™ 
RNAMax complexes, 2.5 ml of the diluted cells was added and then mixed gently by 
rocking the plate back and forth. This gave a final volume of 3 ml and a final RNAi 
concentration of 10nM. The cells and the complexes were incubated for 48 h at 37ºC 
in full serum without antibiotics. Before HRG stimulation the cell monolayer was 
washed with warmed-up PBS twice and incubated in phenol red- and antibiotic-free 
DMEM supplemented with 5% DCSS. 
2.2.4.2  Total protein extraction from tissue cultured cell lines 
 
Cells treated with drugs were rinsed with ice cold PBS immediately after discarding 
the medium and lysed with ice cold lysis buffer (50 mM Tris, pH 7.5, 5 mM EGTA, 
150 mM NaCl, 1 mini complete protease inhibitor cocktail tablet (Roche in 10 ml), 
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50 µl/10ml aprotinin, 100 µl/10 ml Sigma phosphatase cocktail 1 and 100 µl/10 ml 
Sigma phosphatase cocktail 2). Cells were scraped and left on ice for 20 min. Cell 
debris was removed by spinning down at 13,000 rpm, at 4℃  for 6 min and 
supernatant was collected. Protein concentration was determined by BCA assay. 
2.2.4.3  Compartmental protein extraction 
 
The compartmental protein extraction was implemented using the CNMCS 
Compartmental Protein Extraction Kits as per the manufacturer’s instruction. This 
kit was used to extract cytoplasmic (C), nuclear (N), membrane (M) and cytoskeleton 
(CS) proteins, but in this study CS proteins were not needed. 
50×PI (protein inhibitor) was added to buffer C, N, M, and CS to working 
concentration (1 ×) before usage. Culture cells were pelleted using routine cell 
culture techniques. Ice cold buffer C was then added to cell pellets at 2.0 ml per 
2×107 cells. Cells were mixed well with buffer C and the mixture was then rotated at 
4˚C for 20 min.  A syringe was prepared with a needle gauge between 26.5 and 30. 
The needle tip was removed by bending the needle several times and only the needle 
base was left on the syringe. The cell mixture was passed through needle base 50-90 
times to disrupt the cell membrane and release the nuclei from the cells. The degree 
of cell membrane disruption and nucleus release was monitored by microscope.  90-
95% of the nuclei should be released from the cells. The cell mixture was then spun 
at 15,000 g at 4˚C for 20 min. The cytoplasmic proteins were in the supernatant and 
were taken out and saved in another tube. The pellet was re-suspended with ice cold 
buffer W at 4.0 ml per 2×107 cells and rotated at 4˚C for 5 min.  Mixture was spun at 
15,000 g at 4˚C for 20 min and the supernatant was then drained. Ice cold buffer N 
was added at 1.0 ml per 2×107 cells to re-suspend pellet. The mixture was rotated at 
4˚C for 20 min and then spun at 15,000 g at 4˚C for 20 min.  The nuclear proteins 
were in the supernatant and were taken out and saved in another tube. Ice cold buffer 
M was added at 1.0 ml per 2×107 cells to re-suspend pellet from the above step. The 
mixture was rotated at 4˚C for 20 min and then spun at 15,000 g at 4˚C for 20 min.  
The membrane proteins were in the supernatant and were taken out and saved in 
another tube. Protein concentrations of the three fractions were measured.  The three 
fractions were aliquoted and labelled and stored at -70˚C. 
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2.2.4.4  Measurement of protein concentration by BCA assay 
 
Total protein concentration was determined with this method. A 1 mg/ml protein 
standard was used and an 8-point standard curve was set up as in the following table. 
µg/ml µl of 1 mg/ml protein 
standard 
µl of distilled water 
Tube 1     0 0 50 
Tube 2     50 2.5 47.5 
Tube 3     75 3.75 46.25 
Tube 4     100 5 45 
Tube 5     250 12.5 37.5 
Tube 6     500 25 25 
Tube 7     750 37.5 12.5 
Tube 8     1000 50 0 
Samples were diluted 10 fold with 5 µl samples in 45 µl distilled water. After 
dilution, assay reagent was prepared as 1 volume of copper (Ⅱ) sulphate solution 
(Sigma Aldrich, C2284) in 50 volumes of BCA solution (Sigma Aldrich, B9643). To 
each tube, 1ml of assay reagent was added and then incubated at 60℃ for 15 min. 
200 µl of standards and samples in duplicate were transferred to a 96-well flat 
bottomed plate. The plate was read at 540 nm. 
2.2.4.5  Western blot 
 
Protein samples were resolved by SDS-PAGE and transferred to a PVDF membrane. 
The kit BM Chemiluminesecence Blotting Substrate (POD) from Roche was used for 
ECL detection of the endpoint. Membranes were blocked with the 1% Roche 
blocking reagent at room temperature for 60 min. After blocking, primary antibodies 
diluted in 0.5% Roche blocking reagent were incubated with membrane overnight at 
4 ℃ . Then, the membrane was rinsed 2 times with TBS/Tween-20 (0.1%) and 
washed 3 times for 5 min each. Before the HRP-linked secondary antibody 
incubation at room temperature for 60 min, the membrane was washed 2 times for 5 
min each with 0.5% blocking reagent. ECL substrate solution A and solution B 
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(Roche) were taken out from the fridge to warm up to room temperature.  The 
membrane was washed as above followed by another 3 washes (5 min each) with 
TBS. During the wash, the ECL substrate was prepared with 1 volume of solution A 
in 100 volumes of solution B. The membrane was incubated with ECL substrate at 
room temperature for 1 minute before development in the dark room with Fuji Super 
RX medical X-ray film. For the detection with the near-infrared imaging system (as 
shown in Figure 10), membranes were blocked with 50% Odyssey blocking buffer 
diluted in PBS at room temperature for 60 min. After blocking, primary antibodies 
were incubated in the diluted blocking buffer with membranes overnight at 4 ℃. 
Before the incubation with secondary antibodies in the dark for 45 min, the 
membrane was rinsed 2 times with TBS/Tween-20 (0.1%) and washed 3 times for 5 
min each. After the wash, membranes were left in the dark to dry before scanning. 
Different secondary antibodies from those used in ECL detection were used for the 
infrared imaging system. In this study, the target proteins were detected with the 
primary antibodies raised in rabbit and the loading controls such as GAPDH and α-
tubulin were detected with the primary antibodies raised in mouse. Therefore, near-
infrared fluorophore conjugated goat anti-rabbit secondary antibodies were used for 
detecting target proteins and goat anti-mouse secondary antibodies were used for 
detecting loading controls. There are two near-infrared fluorophores commercially 
available: 680nm and 800nm. So, in this study, 680 and 800 nm conjugated goat anti-
rabbit/mouse secondary antibodies were used. However, the same fluorophores 
weren’t used for both targets and loading controls. For example, 680 nm was used 
for target and 800nm for loading controls and vice versa. In correspondence with the 
fluorophores of secondary antibodies there are two scanning channels in the scanner: 
680 nm and 800 nm. 
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Figure 10 Odyssey Infrared Imaging System manufactured by LI-COR Biosciences. 
2.2.4.6  Reverse phase protein array (RPPA) 
 
RPPA is a high throughput protein quantitative detection technique that involves 
spotting small amount of hundreds of samples onto a single nitrocellulose 
membrane-coated glass slide and analyzing these samples simultaneously in a very 
short time with primary and secondary antibodies, usually over two days. Initially, I 
used a manual arrayer (Microcaster Microarray System, Whatman, Figure 11) to spot 
samples at the start of these studies and then later an automated microarrayer (as 
shown in Figure 12) was introduced.  
 
Figure 11 Whatman manual micro-arrayer (Microcaster 8-pin System) and the FAST 
nitrocellulose coated glass slides. 
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Figure 12 MicroGrid II automated microarrayer and the spotted slide. 
 
Preparation of cell lysates and spotting. Cells were lysed as described above. The 
cell lysates were adjusted to 2 mg/ml with 4×SDS/2-ME sample buffer (35% 
glycerol, 8% SDS, 0.25 mol/L Tris-HCl, pH 6.8; with 10% β-mercaptoethanol added 
before use) and heated at 60oC for 1 h. 2-fold serial dilutions were conducted in 
round bottom 96-well plates. Three replicates were spotted per sample in four two-
fold dilutions. 
 
Probing. In this study two probing methods and systems were compared. At the 
beginning of these studies, the DAKO signal amplification system and brown 
staining were used. Later on since the LI-COR Odyssey infrared imaging system was 
purchased and available, I used the near-infrared fluorophore conjugated secondary 
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antibodies to amplify signals. The two individual probing methods are described 
respectively as follows.  
 
After printing, slides were hydrated in PBS for 5 min, 1% Roche Blocking reagent 
for 1 h, DAKO peroxidase Block (to deactivate endogenous peroxidase activity) for 
10 min and then incubated with previously optimised primary antibodies in 0.5% 
Roche Blocking reagent overnight at 4oC in a sealed box containing a damp paper 
towel. The following day, slides were washed in PBS/Tween-20 (0.1%) at room 
temperature for 5 min (X3) before signal amplification with DAKO CSAⅡBiotin-
free Tyramide Signal Amplification System. This commercially available kit 
catalyzed the deposition of tyramide-fluorescein and used 3, 3’-diaminobenzidine 
tetrachloride as the substrate to amplify the signal detected by the primary antibody. 
An HRP-conjugated second antibody was attached to the primary antibody and 
catalysed the in situ deposition of tyramide-fluorescein which was then bound by 
HRP conjugated anti-fluorescein antibody. The HRP cleaves 3, 3’-diaminobenzidine 
tetrachloride, giving a stable brown precipitation with excellent signal-to-noise ratio. 
Slides were dried and scanned as TIFF files for further analysis. The signal intensity 
was analysed with ImageQuant (GE Healthcare).  
 
For the detection with the LI-COR Odyssey infrared imaging system, slides were 
blocked with 50% Odyssey Blocking buffer in PBS at room temperature for 1 h after 
printing. Slides then were incubated with previously optimised primary antibodies in 
50% Odyssey Blocking buffer overnight at 4 oC in a sealed box containing a damp 
paper towel. The following day, slides were washed in PBS/Tween-20 (0.1%) at 
room temperature for 5 min (X3) before incubation in the dark with near infrared 
fluorophore conjugated secondary antibodies in 50% Odyssey Blocking buffer 
diluted in PBS/Tween-20 (0.1%) for 45 min at room temperature. In this study 
secondary antibodies were diluted 1:2000. After incubation with secondary 
antibodies, slides were protected from light and dried at room temperature before 
subjecting to the scan with the Odyssey imaging system.   
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RPPA analysis was performed using MicroVigene RPPA analysis module 
(VigeneTech, Carlisle, MA, USA). Spots were quantified by accurate single 
segmentation, with actual spot signal boundaries determined by the image analysis 
algorithm. Each spot intensity was quantified by measuring the total pixel intensity 
of the area of each spot (volume of spot signal pixels), with background subtraction 
of 2 pixels around each individual spot. The mean of the replicates was used for 
normalisation and curve fitting. Curve fitting was performed using four parameter 
logistical non-linear regression using a joint estimation approach (‘supercurve 
method’), with quantification y0 (intensity of curve) of sample dilution curves used 
in subsequent analysis. 
2.2.4.7  In-cell Western analysis 
 
Preparation of solutions: 10X PBS was prepared by dissolution of ten PBS tablets 
in 100 ml ddH2O. Methanol was cooled at -20°C for at least for 1 h before use. 4% 
Formaldehyde was made up in PBS before use.  Blocking Buffer was prepared (25 
mL) by adding 2.5 mL 10X PBS, 1.25 mL normal serum from the same species as 
the secondary antibody (eg. normal goat serum in this study) to 21.25 mL dH2O and 
was mixed well. While stirring, 75 µL Triton X-100 was added. For the preparation 
of the antibody dilution buffer (40 ml), 4 ml 10×PBS was added to 36 ml dH2O and 
mixed. 0.4 g BSA was added and mixed well. While stirring, 120 µl Triton X-100 
was added. 
 
Specimen Preparation: Cells were grown in black-walled, clear-bottom 96-well 
microplates for the drug treatment. Media were discarded immediately once the 
treatment was completed and was followed by fixing cells with 100 µl of 4% 
formaldehyde in each well for 15 min at room temperature. Fixed cells were rinsed 
three times in 200 µl/well of PBS for 5 min each after the fixative was aspirated. 
Cells were permeabilised with 100 µl of ice cold 100% methanol for 10 min in -20°C 
freezer followed by three washes in 200 µl/well of PBS for 5 min each. 
  
Immunostaining: All subsequent incubations were carried out at room temperature, 
unless otherwise noted, in a humid light-tight box or covered dish/plate to prevent 
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drying and fluorochrome fading. Specimens were blocked in 40 µl/well of Blocking 
Buffer for 60 min. After blocking, diluted primary antibodies were applied with 
40µl/well. For double-labelling, a cocktail of the primary antibodies was applied at 
their appropriate dilution in Antibody Dilution Buffer. Specimens were incubated 
with primary antibodies overnight at 4°C in a sealed wet box followed by three 
washes in PBS for 5 min each.  Specimens were then incubated with 40 µl/well of 
the cocktail of 1:800 of IRdye680 anti-mouse IgG (for the normaliser) and 1:800 of 
IRdye800CW anti-rabbit IgG (for the target) diluted in Antibody dilution buffer for 1 
h at room temperature in dark. Specimens were washed three times for 5 min each 
before scanning with Odyssey Infrared Imaging System (dry samples generate 
stronger signals than wet ones). 
2.2.5 Protein detection in tumours 
2.2.5.1  Immunohistochemistry of the paraffin embedded tissue for the 
optimization of antibody dilution 
 
The paraffin embedded sections were dewaxed in xylene twice for 5 min each and 
rehydrated for 2 min respectively in 99%, 99%, 80% and 50% alcohol and for 
another 2 min in tap water. After rehydration, antigen retrieval was performed on 
slides by treating them with either boiled 0.1M sodium Citrate/0.1M Citric Acid 
pH6.0 or Tris/EDTA buffer pH9.0 (1.21g Tris, 0.37g EDTA, pH9.0, 0.5ml Tween-20 
in 1L) for 5 min in a microwavable pressure cooker in a microwave. Thereafter slides 
were put aside to cool for 20 min. Slides were then washed in PBS/Tween-20 (0.05%) 
twice for 5 min each before treatment in 1% H2O2 for 10 min in the coplin jar. The 
same wash as above was repeated once the treatment finished. Sections were then 
loaded to Sequenza (a slide staining rack) for non-specific blocking with DAKO 
Protein Block Serum Free for 10 min followed by the primary antibody incubation in 
DAKO Antibody Diluent for either 1 h at room temperature or overnight at 4°C. 
Slides were washed again as the above before the incubation with Dako 
Envision+System-HRP labelled polymer Anti-rabbit or Anti-mouse for 30 min at 
room temperature. Washes were performed again before and after visualization with 
DAB for 10 min. Sections were counterstained in haematoxylin for 2 min followed 
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by Scot’s tap water for 2 min. Before mounting, sections were dehydrated for 2 
minutes respectively in 50%, 80%, 99%, and 99% alcohol sequentially. 
2.2.5.2  Immunofluorescence  
 
Immunofluorescence shares the same methods of de-waxing and rehydration, antigen 
retrieval, blocking and primary antibody incubation with imunohistochemistry as 
described above, but the primary antibody cocktail of anti-cytokeratin antibody 
(murine) as tumour mask and anti-target protein antibody (rabbit) replaced the single 
antibody incubation. After the primary antibody incubation, the goat anti-mouse 
Alexa555 antibody diluted at 1:25 in ready-to-use Dako Envision+System-HRP 
labelled polymer Anti-rabbit was incubated with sections for 1 h at room temperature. 
After incubation, 3 washes for 5 min each in PBS/Tween-20 (0.05%) were 
performed. The target visualisation was implemented with the Aquantiplex™ assay 
kit. Sections were incubated with Cy5-tyramide diluted in signal amplification 
diluent at 1:50 in the dark at room temperature for 10 min and then washed 3 times 
for 5 min each. Sections were dehydrated in 80% ethanol for 1 min and air dried in 
the dark. For the counterstaining, 45 µl of Prolong Gold anti-fade reagent with DAPI 
was applied to the tissue sections. Images were acquired with AQUA imaging system 
(as shown in Figure 13) after drying. Data were analyzed with AQUAnalysis™ 





Figure 13 HistoRX AQUA imaging system and examples of acquired images. These images are 
acquired from Tumour Microarray (TMA) cores with the imaging system. Blue indicates DAPI 
staining of nucleus. Green indicates cytokeratin staining as tumour mask of tumour epithelial cells. 
Red indicates target staining. 
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2.2.6 Gene expression analysis  
2.2.6.1  Total RNA extraction 
 
The RNA extraction was implemented with STRATAGENE Absolutely RNA® 
Miniprep Kit from Agilent Technologies as per the manufacturer’s instruction. 
 
Briefly, after drug treatment, MCF-7 cells grown in 92-mm petri dishes were lysed 
by incubating with 600 µl lysis buffer. Cell lysates were transferred to 1.5 ml 
microcentrifuge tubes and vortexed to decrease the viscosity. Up to 700 µl of 
homogenate was transferred to a seated Prefilter Spin Cup and spun at maximum 
speed for 5 min.  The spin cup was discarded and the filtrate was retained for further 
processing. To the filtrate an equal volume of 70% ethanol was added and mixed 
thoroughly by vortexing the tube for 5 s. Up to 700 µl of the mixture was transferred 
to a seated RNA Binding Spin Cup and spun at the maximum speed for 60 s.  The 
Spin Cup was retained. 
 
The Spin Cup was washed by adding 600 µl 1×Low-Salt Wash Buffer and spinning 
in a microcentrifuge tube at the maximum speed for 60 s. The filtrate was discarded 
and the Spin Cup was retained for a further spin at the maximum speed for 2 min to 
dry the matrix. 50 µl reconstituted RNase-Free DNase I was added directly onto the 
matrix and incubated at 37°C for 15 min. After the incubation, 600 µl of 1×High-Salt 
Wash Buffer was added to the Spin Cup and spun in a microcentrifuge tube at the 
maximum speed for 60 s. The Spin Cup was retained for the addition of 600 µl 
1×Low-Salt Wash Buffer and spun in a microcentrifuge tube at the maximum speed 
for 60 s. A further 300 µl of 1×Low-Salt Wash Buffer was applied to the Spin Cup 
and spun for 2 min to dry the matrix. Finally, 80 µl of Elution Buffer was added 
directly onto the matrix of the Spin cup which was seated in a 1.5-ml microcentrifuge 
tube and incubated for 2 min at room temperature before spinning down for 60 s to 
collect the RNA solution. The concentration of the RNA solution was then measured 




2.2.6.2  RNA amplification 
 
The RNA amplification was implemented with Illumina® TotalPrep™ RNA 
Amplification Kit as per the manufacturer’s instruction. The working flow is shown 




2.2.6.3  Gene expression analysis 
 
The measured cRNA was subjected to gene expression array analysis based on 
HumanHT-12 Expression Beadchips purchased from Illumina®, which was carried 
out by Welcome Trust Clinical Research Facility, Western General Hospital in 
Edinburgh. Data processing was conducted with the assistance of the 
bioinformatician, Dr. Andrew H. Sims in Breakthrough Breast Cancer Research Unit, 
the University of Edinburgh. Gene expression analysis was performed using the open 
source statistical programming language, R (253), and associated Bioconductor 
package (254). Data was quantile normalised using the Lumi packages (255). 
Differentially expressed genes were identified with the siggenes package which 
implements Significance analysis of Microarrays (SAM) (256)  and Rank Products 
(257). A minor batch effect was eliminated using empirical Bayes batch-correction 
methods (ComBat) (258) as described previously (259, 260). The Cluster and 
TreeView programs (261) were used to generate heatmaps. 
2.2.7 Flow cytometric analysis for cell cycle 
 
The preparation of solutions 
Citrate Buffer was prepared by dissolution of 85.5 g Sucrose and 11.76 g Trisodium 
Citrate in 800 mL distilled water.  50 mL DMSO was added and the pH was adjusted 
to 7.6. Finally, the solution was made up to 1000 mL with distilled water and was 
stored at 4ºC. This is stable for up to 2 years. 
 
Stock solution was prepared by dissolution of 2000 mg trisodium citrate, 121 mg 
Tris base, 1044 mg spermine tetrahydrochloride and 2 mL Nonidet NP40 in 1800 mL 
distilled water.  The pH of the solution was adjusted to 7.6 and the solution was 
made up to 2000 mL with distilled water. 
 
Solution A was prepared by dissolution of 15 mg trypsin type IX-S in 500 mL stock 
solution pH7.6. The solution was dispensed into 25 x 20mL aliquots which were 
labelled and frozen at -20ºC. 
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Solution B was prepared by dissolution of 250 mg trypsin inhibitor and 50 mg 
RNAse A in 500 mL stock solution pH7.6. The solution was dispensed into 25 x 20 
mL aliquots which were labelled and frozen at -20ºC. 
 
Solution C was prepared by dissolution of 208 mg propidium iodide and 500 mg 
spermine tetrahydrochloride in 500 mL stock solution pH7.6. The solution was 
dispensed into 25 x 20mL aliquots which were labelled and frozen at -20ºC.  
 
Cells were trypsinised as described above and transferred to 5mL (12 x 75mm) ‘BD 
Falcon’ tubes. Cells were collected by centrifugation at 1600 rpm for 5min and tubes 
were inverted to allow excess moisture to be absorbed onto a paper towel.  Cells 
were re-suspended in citrate buffer (100 µl) and tubes were covered with Parafilm 
and stored at -20ºC prior to analysis. For the analysis, solutions A, B and C were 
defrosted (keeping solution C on ice after thawing) and were kept at room 
temperature. 450 µL of solution A was added to the sample tubes, whirl mixed and 
incubated at room temperature for 2 min (mixing throughout the incubation). Then, 
375 µL of solution B was added, briefly whirlimixed and incubated at room 
temperature for a further 10 min. Finally, 250µL of solution C was added, briefly 
whirlimixed and incubated on ice in the dark for a further 10 min.  Samples were 
kept on ice and in the dark prior to analysis.  Samples were run using the Flow 
Cytometer according to the appropriate settings, templates, etc. Cell cycle analysis 
was performed using FlowJo7 software. 
2.2.8 Statistics 
 
 One-way ANOVA followed by Tukey HSD post HOC test was used to conduct 
multiple comparisons of groups with equal variance. The homogeneity of variances 
was tested with the Levene’s test run by SPSS17.0. The ANOVA and Tukey HSD 
post HOC test are based on normal distribution and equal variances.  
 
For the multiple comparisons of groups with unequal variance, the Brown-Forsythe 
test followed by Games-Howell post HOC test was conducted. Brown-Forsythe test 
is an equivalent to ANOVA based on unequal variances. The Games-Howell post 
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HOC test designed for unequal variances is an equivalent to Tukey HSD post HOC 
test. 
 
For experiments, in which there were only two groups, the Student’s t-test was used. 
 
For the gene expression analysis, the Student’s t-test was used to find out whether 
individual genes were significantly induced by HRG treatment for 20 min or 40 min 
compared with control. 
 
For correlation analyses between Roche and DAKO blocking buffers and spotting 
reproducibility between slides in the RPPA technique, a 2-tailed Pearson correlation 
test was used. 
 
For correlation analysis between biomarkers, a 2-tailed Spearman correlation test 
was used. For analysis of PTPN13 expression in the wild-type versus mutated 
PI3KCA groups, a Mann-Whitney U-test was used to compare groups. 
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Chapter Three: Methodology Development 
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3 Methodology development 
3.1 RPPA development 
 
Reverse phase protein array (RPPA) is so termed in contrast to traditional FPPA 
(Forward Phase Protein Array). The working principles are shown in Figure 14. 
 
 
Figure 14 the schematic representation of forward phase protein array and reverse phase 
protein array (reproduced from http://www.microarray.prostatecentre.com/Services_Proteins.htm). 
 
 In FPPA, a variety of antibodies are immobilised on slides and incubated with 
fluorescein-tagged protein samples such as cell lysates and for higher specificity, 
fluorescein-tagged secondary antibodies are often applied to form a sandwich. 
Antibody array and ELISA are the most common versions of FPPA. The advantage 
of FPPA is that depending on the number of antibodies immobilised, hundreds or 
thousands of proteins in one protein sample can be analysed simultaneously on one 
chip. In contrast in RPPA, hundreds or thousands of protein samples are immobilised 
on membrane-coated slides and then incubated with one primary antibody to analyse 
the difference of one target under a variety of treatments. FPPA is often used in the 
screening of therapeutic targets from hundreds of proteins. RPPA is used to detect 
the changes of a known protein under different conditions. For example, in this study 
RPPA is used to profile signalling components in PI3K/Akt and Raf/MEK/ERK 
pathways under the stimulation of HRG or EGF with or without inhibitors. One 
major concern of RPPA is the specificity of primary antibodies which are required to 
be validated by Western Blot.  Hundreds of antibodies by which only specific bands 
are recognised have been validated but the antibodies listed in section 2.1.7 were 
used for this study.  Another major concern is the level of sensitivity as it is 
necessary to amplify the signal intensity to a detectable level. At the very beginning 
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of the development of RPPA in our laboratory, the entry-level manual arrayer (as 
shown in Figure 11) was used to optimise various conditions before the application 
of automated robotics. The manual arrayer is competent to deal with small number of 
samples. Apart from the validation of primary antibodies and sensitivity, there are 
other different conditions requiring optimisation including sample preparation, 
application of automated robotic microarrayer, blocking buffer application and 
ending point detection. 
3.1.1 Sample preparation 
 
In this section, native vs reduced denatured samples were compared for the end point 
detection. To optimise the sample preparation procedure, cells were lysed with the 
lysis buffer mentioned in section 2.2.4.2. Cell lysates were then measured and 
adjusted to the same concentration with either lysis buffer (for native samples) or 
SDS/2-ME sample buffer (for reduced denatured samples, it is very similar to the 
loading buffer of SDS-PAGE). Only samples adjusted with SDS/2-ME sample buffer 
were heated at 60 ºC for 1 h (the same heating procedure as used for western 
blotting). The procedures for RPPA are exactly the same for both sample preparation 
methods. The largest difference between lysis buffer and SDS/2-ME sample buffer is 
that the reducing reagent β-mercaptoethanol and glycerol are supplemented in the 
latter one. Additionally, the commercial antibodies for western blot are generally 
developed for reduced denatured samples. The reduced denaturation makes linear 
epitopes more exposed to antibodies. So the reduced denatured samples in RPPA 
make the RPPA approach comparable with western blot. It was observed in Figure 
15 that reduced samples generated stronger signals than non-reduced ones. It was 
evident that reduced samples had better circular shape and inter-spot separation than 
non-reduced ones. Since glycerol was included in the reduced sample buffer, reduced 
sample spots were less spreadable than non-reduced samples. The spread would 
cause sample contamination between dilutions and interfere with the inter-dilution 
signal. In conclusion, denaturing the samples in a reduced sample buffer by heating 
60 ºC for 1 h appeared useful for RPPA. The reduced preparation method was 
adopted for the entire study. 
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Figure 15 Effects of sample preparation procedures on the signal intensity of GAPDH and spot 
shapes. Non-reduced (native) samples were not heated in lysis buffer (2-ME and glycerol free) and 
reduced samples were heated in a reduced sample buffer (2-ME and glycerol positive) at 60 ºC for 1 h 
followed by exactly the same procedures for both sample preparation methods. Samples were diluted 
in a 2-fold serial dilution for 3 times from the top row to the bottom on the manual arrayer spotting 
slide. The reversed triangles indicate the dilution direction. Signals were amplified with DAKO CSA
ⅡBiotin-free Tyramide Signal Amplification System and scanned as TIFF files. 
3.1.2  Application of automated robotic microarrayer 
 
Although a manual arrayer is very useful and convenient for entry-level use, it is not 
competent for high throughput application which is one of the strengths of RPPA. 
Automated robotics was introduced into the laboratory as shown in Figure 12. 
Compared with robotics, the primary weaknesses of the manual arrayer include the 
following.   
1) A limited number of samples can be arrayed by manual arrayer due 
to the large pin size of 0.457 mm diameter and the fixed pin 
configuration. In contrast, the diameter of the robotic pin is 0.2mm. 
The pin configuration of the robotic arrayer is flexible. Pins of 
manual arrayer are fixed into the hand tool which means pins are 
undetachable and irreplaceable. This also restricts the number of 
spots which are able to be printed on slides. While pins of robotics 
are separate from the pin head, investigators can put a couple of 
types of pins including solid pins and split pins in the head with 
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different pin layouts. So, different layouts of spots are available for 
robotics rather than for manual arrayer. The spot layout is also a 
key factor influencing the number of samples spotted on slides. 
Therefore, thousands of samples can be spotted onto a single slide 
by the robotic arrayer while only hundreds are feasible for the 
manual arrayer. 
2) It is hard to control the dwelling time of the pins on the membrane 
by hand. The dwelling time determines the amount of samples 
absorbed by the membrane. So, the inter-slide reproducibility is 
poor. 
3) The spot shape is not a regular circle, which causes problems for 
the analysis software to quantify precisely. 
4)  It is time consuming for large number of samples and not suitable 
for high throughput array. 
 
The robotic arrayer was used for the following optimisation. 
3.1.3  Application of different blocking buffers 
 
After spotting samples onto the slides with the robotic arrayer, slides were blocked 
for non-specific binding sites on the membrane with blocking buffer. Two blocking 
buffers were compared in this study. One is the DAKO Protein Block Serum Free 
(Copenhagen, Denmark, CAT No K1497) which comes with the DAKO CSAⅡ
Biotin-free Tyramide Signal Amplification System and the other is the Roche 
Blocking reagent (Roche Applied Science, Mannheim, Germany, CAT No 
11500708001). The expression level of p-ERK1/2 (T202/Y204) was analysed. The 
anti-p-ERK1/2 (T202/Y204) primary antibody was validated for application in RPPA 
with no non-specific bands in Western Blot in which the membrane was blocked 
with Roche Blocking Reagent. It was observed in Figure 16 that most of the 
individual values were above the y=x line and the trend line had a slope of 2.0387 
(R2=0.9186), which meant the intensities of spots blocked by the Roche blocking 
reagent were nearly 2-fold higher than those blocked by DAKO blocking buffer 
(Pearson correlation coefficient is 0.963, p value is 0.000). So the Roche Blocking 
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Reagent resulted in a one-more-dilution higher sensitivity. Therefore, Roche 
Blocking Reagent was accepted to use in RPPA with DAKO CSAⅡBiotin-free 
Tyramide Signal Amplification System. 
 
 




















Pearson correlation coefficient P value (2-tailed) 
0.963 0.000 
Figure 16 Effects of Roche and DAKO blocking buffers on the spots’ intensities. These spots 
were probed with anti-p-ERK1/2 (T202/Y204) primary antibody and the signals were amplified with the 
DAKO CSA Ⅱ Biotin-free Tyramide Signal Amplification System. The spots’ intensities were 
measured with the array module of ImageQuant TL from GE Healthcare using ‘average spot edge’ 
background method. The anti-p-ERK1/2 (T202/Y204) primary antibody was validated for application in 
RPPA with no non-specific bands in Western Blot in which the membrane was blocked with Roche 
Blocking Reagent. 
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3.1.4  The application of LI-COR imaging system in RPPA 
 
The application of the LI-COR imaging system requires the use of the near infrared 
flurophore for end point detection. Since the LI-COR imaging system can perform 
simultaneously a two-channel scan, 680nm and 800nm, it becomes possible to 
normalize the target protein expression against the normaliser such as tubulin, 
GAPDH and actin in a single slide. This would be more accurate than normalization 
against the normaliser on another slide. Meanwhile, compared with chromogen-
based colourimetry, the application of LI-COR imaging system saves half the 
number of slides. The application of LI-COR imaging system requires fewer steps 
than chromogen-based colourimetry, which would reduce the chances of introducing 
errors. In theory, the near infrared fluorescence has a broader dynamic range than 
chromogen-based colourimetry (communication with LI-COR® Biosciences). 
Additionally the near infrared red region in the spectrum has low noise response to 
both the membrane and the printed samples which have visual auto-fluorescence. If 
protected from light properly, the fluorescence on slides can be maintained for a 
couple of months without signal fading.  Therefore, it was judged reasonable to use 
the LI-COR imaging system in the RPPA analysis. In this system, 50% Odyssey 
Blocking buffer in PBS is used as the blocking reagent as well as the antibody 
diluent. The protocols are described in ‘2.2.4.6 Reverse Phase Protein Array 
(RPPA)’. 
3.2 In-cell Western development 
 
The In-cell Western is a technique based on detecting immunofluorescence in fixed 
cell lines and the availability of the LI-COR imaging system. It detects the protein 
expression level directly in formaldehyde-fixed cells in 96-well microplates. The In-
cell Western doesn’t require the lysate preparation, SDS-PAGE and membrane 
transfer which are required in the regular western blot procedure. The In-cell 
Western technique saves time and can more easily allow analysis of large numbers of 
replicates than standard Western blotting. This technique uses the same principle as 
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immunofluorescence. However, four differences from immunofluorescence should 
be noted. 
1) All the procedures are performed in 96-well plates rather than on cover slides. 
2) It is more quantitative in a higher throughput manner. 
3) The final signal is captured by the LI-COR imaging system which acquires 
fluorescence rather than by microscope. 
4) Secondary antibodies linked to near-infrared fluorophore rather than visible 
wave-length fluorophore are applied. 
For this technique clear bottom and black wall 96-well plates are required to remove 
the noise from autofluorescence at 680 nm which is present in the commonly used 
clear 96-well plates. The immunofluorescence protocol was followed in the In-cell 
Western. As shown in Figure 17, both ERK1/2 and Akt were activated by 1nM EGF 
at a very early time and the signals then gradually decreased to the base line. This 
observation was consistent with previous reports (91). Since in this experiment the 
‘normal’ tissue culture 96-well plate was applied, autofluorescence in 680 nm was 
detected from the wall of each well not from the bottom. However, when black 
wall/clear bottom plates were used, the autofluorescence disappeared (Figure 18). In 
this example, MCF-7 cells were stimulated by 1nM HRG in the presence of 10 µM 
CHX. It was observed that ERK1/2 was activated and the level of p-ERK1/2 reached 
a maximum at the10-min point and was then sustained during the rest of the whole 
time course, which supported the previous findings (91). Albeit more quantitative, 
In-cell Western is not as sensitive as ‘normal’ western blot, since oscillation was less 
easily observed by In-cell Western in MCF-7 cells treated with HRG+CHX. As 
presented later in this thesis, the oscillation was observed and confirmed by both 





Figure 17 In-cell Western analysis of the stimulation of MCF-7 by 1nM EGF.  MCF-7 cells were 
grown in DMEM supplemented with 10% FCS in 96-well plates for 48 h and then in phenol red free 
DMEM supplemented with 5% DCSS for another 48 h. Cells were stimulated with 1nM EGF for the 
time indicated. The treatment was stopped by adding 4% formaldehyde to the wells. After being fixed 
in 4% formaldehyde for 15 min at RT, cells were permeabilised in methanol for 10 min at -20°C 
before blocking at RT for 1 h. Primary antibodies were incubated overnight with cells at the optimal 
dilution at 4°C before the incubation with secondary antibodies at RT for 1 h. Images were acquired 
with LI-COR imaging system when plates were dry. The 680nm channel (red) was for p-ERK1/2 and 
p-Akt and the 800nm channel (green) was for α-tubulin. The OD was measured by In-cell Western 
module of the analysis software supplied along with the imaging system. The ratio of OD of p-
ERK1/2 or p-Akt against that of α-tubulin at each time point was applied to compare the signal 













































































Figure 18 In-cell Western analysis of the stimulation of MCF-7 by 1nM HRG in the presence of 
10 µM CHX.  MCF-7 cells were grown in DMEM supplemented with 10% FCS in 96-well plates for 
48 h and then in phenol red free DMEM supplemented with 5% DCSS for another 48 h. Cells were 
stimulated with 1nM HRG in the presence of 10 µM CHX for the time indicated. The treatment was 
stopped by adding 4% formaldehyde to wells. After being fixed in 4% formaldehyde for 15 min at RT, 
cells were permeabilized in methanol for 10 min at -20°C before blocking at RT for 1 h. Primary 
antibodies were incubated overnight with cells at the optimal dilution at 4°C before the incubation 
with secondary antibodies at RT for 1 h. Images were acquired with LI-COR imaging system when 
plates were dry. The 680nm channel (red) was for α-tubulin and the 800nm channel (green) was for 
p-ERK1/2. The OD was measured by In-cell Western module of the analysis software supplied along 
with the imaging system. The ratio of OD of p-ERK1/2 against that of α-tubulin at each time point 
was applied to compare the signal intensity.  The results are presented as the average of the ratio ±SD. 
‘bkg’ denotes background, in which HRG stimulation and primary antibody were absent. 
 
Time (min)  10    20    30   40   50   60   70   80    90   0    bkg 
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Chapter Four: Results  
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4 Results  
 
The behaviour of cells is reflected by the complex dynamics of molecular signalling 
spatiotemporally.  In this study I explored the effects of different interventions on 
signalling through the application of inhibitors after stimulation with HRG and EGF 
over a time course and linking the dynamics with outcome.   
4.1 The oscillatory dynamics of phospho-ERK1/2(T202/Y204) 
and phospho-Akt (S473)     
4.1.1 Characteristics of the cell line models used 
 
Before starting the oscillation studies, it was necessary to characterize the MCF-7 
and MCF-7/HER2-18 cell lines to confirm that their responsiveness was consistent 
with the published data.  
 
All the cell lines used were breast carcinoma cell lines. The MCF-7 cell line was 
originally isolated from the pleural effusion of a 69-year-old woman in 1970 and is a 
luminal epithelial cell line (262). The name of this cell line refers to the acronym of 
Michigan Cancer Foundation-7. This cell line is ER positive, and has a proliferative 
response to 17β-estradiol (Figure 19) (262). As one of the Selective oestrogen 
receptor modulators (SERMs), tamoxifen blocked the effect of 17β-estradiol in this 
cell line as reported (263).  MCF-7 cells were also growth stimulated by HRG and 
EGF (Figure 19). Trastuzumab inhibited the growth of MCF-7 cells stimulated by 
1nM EGF (EGF+trastuzumab vs EGF 84.0%) but did not inhibit the growth 
stimulated by 1nM HRG. Pertuzumab inhibited the growth stimulated by both 
growth factors (HRG+pertuzumab vs HRG 79.3%, EGF+pertuzumab vs EGF 62.3%). 
The combination of trastuzumab and pertuzumab produced a further inhibition of the 
growth stimulated by HRG than either single agent (HRG+trastuzumab+pertuzumab 
vs HRG 43.5%). The combination also inhibited the growth stimulated by EGF 
(EGF+trastuzumab+pertuzumab vs EGF 67.2%) and had a stronger inhibitory effect 
than trastuzumab alone, but the inhibitory effect of the combination was not 
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statistically different compared with that of pertuzumab alone under the stimulation 


















































Brown-Forsythe test for all-group comparison (N=6, unequal variances), p=0.000 
Games-Howell Post Hoc test run by SPSS 17.0 



























control -- 0.008 0.004 0.667 0.094 0.948 0.021 0.002 0.010
E2 (1nM) 0.008 -- 0.145 0.004 0.027 0.008 0.998 0.356 0.820
E2 (0.1nM) 0.004 0.145 -- 0.001 0.355 0.006 0.184 0.929 0.064
Tam 0.667 0.004 0.001 -- 0.026 0.392 0.014 0.000 0.007
E2 (1nM)+Tam 0.094 0.027 0.355 0.026 -- 0.322 0.059 0.079 0.022
E2 (0.1nM)+Tam 0.948 0.008 0.006 0.392 0.322 -- 0.024 0.002 0.011
HRG 0.021 0.998 0.184 0.014 0.059 0.024 -- 0.335 0.996
EGF 0.002 0.356 0.929 0.000 0.079 0.002 0.335 -- 0.115
10%FCS/DMEM 0.010 0.820 0.064 0.007 0.022 0.011 0.996 0.115 -- 
 
 





















































One-way ANOVA for all-group comparison (N=6, equal variances), p=0.000 
Tukey HSD Post Hoc test run by SPSS 17.0 


























control -- 0.000 0.000 0.000 0.000 0.000 0.000 0.352 0.016
HRG 0.000 -- 0.988 0.000 0.000 0.000 0.000 0.000 0.000
HRG+tras 0.000 0.988 -- 0.000 0.000 0.000 0.000 0.000 0.000
HRG+pert 0.000 0.000 0.000 -- 0.000 0.000 0.000 0.000 0.000
HRG+tras+pert 0.000 0.000 0.000 0.000 -- 0.000 0.554 0.007 0.203
EGF 0.000 0.000 0.000 0.000 0.000 -- 0.002 0.000 0.000
EGF+tras 0.000 0.000 0.000 0.000 0.554 0.002 -- 0.000 0.001
EGF+pert 0.352 0.000 0.000 0.000 0.007 0.000 0.000 -- 0.905
EGF+tras+pert 0.016 0.000 0.000 0.000 0.203 0.000 0.001 0.905 -- 
Figure 19 Growth responses of MCF-7 cells to 17β-estradiol (E2, 1 nM & 0.1 nM), tamoxifen 
(Tam, 10 µM), HRG (1 nM), EGF (1 nM), 10% serum/90% medium, trastuzumab (tras, 100 
nM), pertuzumab (pert, 100 nM) and their combinations. 2500 cells/well in 96-well microplates 
were grown in phenol-red positive DMEM supplemented with 10% FCS for 48 h followed by 48 h in 
phenol-red negative DMEM supplemented with 5% DCSS before incubation with the above agents 
for 3 days. After the treatment, cells were fixed with TCA for the SRB assay. The Optical Density 
(OD) was acquired at the wavelength of 540 nm. The results are shown as the average ±SD. 
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MCF-7/HER2-18 cell line is a HER-2 stably transfected MCF-7 cell line which over-
expresses HER-2. It had the same response as MCF-7 to estrogen and tamoxifen 
(Figure 20).  Tamoxifen also blocked the proliferative effect of 17β-estradiol. In a 
similar manner to MCF-7 cells, the growth of MCF-7/HER2-18 cells was stimulated 
by both HRG and EGF. Trastuzumab blocked the growth stimulation of EGF 
(EGF+trastuzumab vs EGF 72.0%) but not that of HRG. Pertuzumab blocked the 
growth effects of both EGF and HRG (HRG+pertuzumab vs HRG 82.5%, 
EGF+pertuzumab vs EGF 44.9%). Under the stimulation of HRG, the combination 
of trastuzumab and pertuzumab had a stronger inhibitory effect than pertuzumab 
alone (HRG+trastuzumab+pertuzumab vs HRG 63.7%). Under the stimulation of 
EGF, the combination of trastuzumab and pertuzumab had a stronger inhibitory 
effect than trastuzumab alone althogh not statistically significant (p>0.05), but a 
weaker effect than pertuzumab alone (EGF+trastuzumab+pertuzumab vs EGF 
61.2%). The above results suggested that it would be interesting to study the 

























































Brown-Forsythe test for all-group comparison (N=6, unequal variances), p=0.000 
Games-Howell Post Hoc test run by SPSS 17.0 































control -- 0.000 0.475 0.000 0.001 0.001 0.077 0.000 0.000 0.000 0.000 0.000
E2 0.000 -- 0.000 0.000 1.000 0.001 0.000 0.000 0.000 0.000 0.049 0.362
Tamoxifen 0.475 0.000 -- 0.028 0.001 0.000 0.884 0.001 0.000 0.000 0.000 0.000
E2+Tam 0.000 0.000 0.028 -- 0.005 0.009 0.371 0.117 0.000 0.000 0.000 0.000
EGF 0.001 1.000 0.001 0.005 -- 0.057 0.001 0.011 0.006 0.003 0.329 0.943
EGF+tras 0.001 0.001 0.000 0.009 0.057 -- 0.001 0.245 0.000 0.000 0.000 0.012
EGF+pert 0.077 0.000 0.884 0.371 0.001 0.001 -- 0.012 0.000 0.000 0.000 0.000
EGF+tras+pert 0.000 0.000 0.001 0.117 0.011 0.245 0.012 -- 0.000 0.000 0.000 0.000
HRG 0.000 0.000 0.000 0.000 0.006 0.000 0.000 0.000 -- 0.268 0.008 0.000
HRG+tras 0.000 0.000 0.000 0.000 0.003 0.000 0.000 0.000 0.268 -- 0.002 0.000
HRG+pert 0.000 0.049 0.000 0.000 0.329 0.000 0.000 0.000 0.008 0.002 -- 0.005
HRG+tras+pert 0.000 0.362 0.000 0.000 0.943 0.012 0.000 0.000 0.000 0.000 0.005 -- 
Figure 20 Growth responses of MCF-7/HER2-18 cells to 17β-estradiol (E2, 1nM), tamoxifen 
(Tam, 1µM), HRG (1nM), EGF (1nM), trastuzumab (tras, 100nM), pertuzumab (pert, 100nM) 
and their combinations. 6000 cells/well in 96-well microplates were grown in phenol-red positive 
DMEM supplemented with 10% FCS for 48 h followed by 48 h in phenol-red negative DMEM 
supplemented with 5% DCSS before incubation with the above agents for 5 days. After the treatment, 
cells were fixed with TCA for the SRB assay. The Optical Density (OD) was acquired at the 
wavelength of 540 nm. The results are shown as the average ±SD. 
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4.1.2 Observation of signalling oscillation and experimental 
confirmation 
 
Signalling oscillation is a very common phenomenon in biological systems occurring 
in a wide spectrum of organisms from bacteria to humans (264). It is often observed 
in relation to the biological clock, e.g. circadian rhythm, somite segmentation (265) 
and cell division (243). However, experimentally induced oscillation with minutes of 
periodicity in the components of HER-mediated signalling pathways has not been 
demonstrated prior to the start of these studies. 
 
In initial studies, I observed oscillations of the expression levels of both p-Akt (S473) 
and p-ERK1/2(T202/Y204) in MCF-7 cells stimulated by either HRG or EGF. 
Oscillation of p-ERK1/2 level across time was previously predicted by 
computational modelling (235, 250, 252). Treatment of MCF-7 cells with 1nM HRG 
or 1nM EGF produced oscillation of both p-Akt and p-ERK1/2 expression over a 2h 
time course (Figure 21). Cycling periodicity was around 20 min for p-ERK1/2 and 
30 min for p-Akt. These results were confirmed in 5 further repeat experiments with 
cell lysates from independent experiments by Western Blotting. To attempt to 
minimise the possibility of artefactual differences, samples were randomised on the 
Western blots. The oscillation of both p-Akt and p-ERK1/2 was also observed in 
MCF-7/HER2-18 cells stimulated by 1nM HRG (Figure 22). However, the 
oscillation wasn’t observed in BT474 cells stimulated by 1nM HRG which is also a 



















Figure 21 Oscillation across the time course indicated in the expression levels of p-Akt (S473) and 
p-ERK1/2 (T202/Y204) induced by the stimulation of either HRG (1nM) or EGF (1nM) in MCF-7 
cells. In the Western blot, samples were loaded in a random sequence when resolved by SDS-PAGE 
in order to remove potential artefactual edge effects. The targets were detected with ECL in a dark 


































































































































































Figure 22 Effects of HER-2 over-expression on the oscillation of p-Akt and p-ERK1/2 expression. 
Time-course oscillatory profiles of p-Akt (S473) and p-ERK1/2 (T202/Y204) in MCF-7/HER2-18 cells 
stimulated by HRG (1nM) for the time period as indicated. The targets were detected with the LI-
COR infrared imaging system. ‘M’ denotes protein marker.  Results are indicated as the ratio of the 
OD of phospho-targets to that of α-tubulin.  
 M     0    10    20    30   40    50     60    70     80   90   100   110 120 Time (min) 








Figure 23 Time course profile of p-Akt (S473) and p-ERK1/2 (T202/Y204) induced by the 
stimulation of HRG (1nM) with or without cycloheximide (CHX, 10µM) in BT474 cells. The 
targets were detected with LI-COR infrared imaging system. ‘M’ denotes protein marker. Results are 

























































4.1.3 Transcriptional feedback further modulated the oscillation 
 
In MCF-7 cells stimulated by either 1 nM EGF or 1 nM HRG, the levels of both p-
Akt and p-ERK1/2 demonstrated cycling. In the presence of the protein synthesis 
inhibitor 10 µM cycloheximide (CHX), the higher level of p-Akt and p-ERK1/2 
initially produced oscillation with greater y-axial distance between peaks and troughs 
with sustained periodicity (Figure 24). These results were further confirmed by the 
use of the RPPA high throughput quantification method (Figure 25). The observation 
of p-Akt oscillation is novel since there is no computational model prediction yet or 
published experimental observation for the p-Akt oscillation prior to these results. 
The oscillation elicited by EGF dampened across this 2h time course while sustained 
by HRG. The clear peaks and troughs of oscillation caused by CHX suggested a 
contribution of transcriptional feedback in the modulation of oscillation. The 
expression level of p-Akt was increased by CHX initially at an early (10-20 min) 
time point. The increase of the expression level of p-ERK1/2 produced by CHX 
commenced between the 20- and 30-min points. This suggested that the 
transcriptional feedback modulated the oscillation at a very early time. However, 


















Figure 24 Oscillation in the levels of p-Akt (S473) and p-ERK1/2 (T202/Y204) induced by the 
stimulation of either HRG (1nM) or EGF (1nM) with or without CHX (10µM) in MCF-7 cells. 
In the Western blot, samples were loaded randomly when resolved by SDS-PAGE in order to remove 
the edge effects. The targets were detected with ECL in a dark room. Results are indicated by the ratio 







































































































































































































































































Correlation is significant at the 0.01 level
(2 t il d)
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B. Normalized p-ERK1/2 time course profile 
Figure 25 Oscillatory level of p-ERK1/2 (T202/Y204) was also observed by RPPA. MCF-7 cells 
were stimulated with HRG (1nM) with or without CHX (10µM) for the time course indicated. A, high 
reproducibility was observed between two slides printed at the same time with the robotics. This 
allows the level of p-ERK1/2 observed from one slide to be normalised against the level of ERK1/2 
observed from another slide. B, Normalised p-ERK1/2 time course profile. Data were analyzed with 
Microvigene RPPA modules. The dilution curve intensity (Y0) of p-ERK1/2 was normalized to that of 
total ERK1/2. Results were shown as the normalized Y0. Error bars show the 95% confidence interval. 
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Interestingly, the phosphorylation profile of MEK1/2 (the upstream activator of 
ERK1/2) over the whole time course differed from that of ERK1/2 (Figure 26). 
There were three appreciable cycles with a periodicity of between 20-30 min within 
the whole time course under the stimulation of 1nM HRG alone. The addition of 
CHX caused the periodicity to double and two minimal cycles were observed within 
the whole time course. After the level of p-MEK1/2 reached the second peak (the 70-
min point), the level of p-MEK1/2 commenced decreasing until the 90-min point 
when the level increased again. The level of p-MEK1/2 was sustained after treatment 
for 110 min with HRG plus CHX within this time course. The addition of CHX 
caused a longer duration of p-MEK1/2 signalling. 
 
It was interesting that 1nM HRG induced the oscillation of p-HER-3 (Y1289) in MCF-
7 cells with 2 cycles within 2 h (Figure 27). The phosphorylation of HER-3 at Y1289 
was induced by HRG and the level of p-HER-3 (Y1289) was increased to the first peak 
at the 30-min point. After treatment with HRG for 30 min, the level of p-HER-3 
(Y1289) kept decreasing for 30 min. The first complete cycle was observed up to this 
time point. Subsequently, the phosphorylation level increased to a second peak after 
treatment with HRG for 80 min. After the 80-min point the level of p-HER-3 (Y1289) 
was decreased with two different rates till the end of the time course. The first rate is 
higher (until the 90-min point) than the second one (from the 90-min point to the 
end). The level of p-HER-3 (Y1289) expression during the whole time course was 
reduced by the addition of CHX. In the presence of CHX, it reached a peak when 































Figure 26 Expression profile of p-MEK1/2 (S217/221) within the whole time course in MCF-7 cells 
stimulated by 1nM HRG plus/minus CHX. MCF-7 cells were incubated with 10 µM CHX for 20 
min prior to the treatment of 1nM HRG for the time course indicated. Lysates were resolved with 
SDS-PAGE and analysed with Western Blotting. ‘M’ denotes protein marker. Results are 





























Figure 27 Expression profile of p-HER-3 (Y1289) within the 2h time course in MCF-7 cells 
stimulated by 1nM of HRG plus/minus CHX. MCF-7 cells were incubated with 10µM CHX for 20 
min prior to the treatment of 1nM HRG for the time course indicated. Lysates were resolved by SDS-
PAGE and analysed by Western Blot. Results are demonstrated as the ratio of OD of p-HER-3 (Y1289) 
to that of α-tubulin. 
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Since the generation of oscillation requires the involvement of negative feedback in 
ERK1/2 cascades and a simple negative feedback loop of interactive genes or 
proteins has the potential to generate a sustained oscillation (235, 247, 249, 266), the 
transcriptional feedback could result from dual specificity phosphatases (DUSPs) 
which inactivate MAPKs through dephosphorylating phospho-threonine, phospho-
serine or phospho-tyrosine residues. In order to identify possible candidates that may 
modulate oscillation, gene expression analysis was conducted. Gene candidates were 
selected from the top 100 genes whose expression was induced significantly (p<0.05) 
after treatment for 20 min with HRG (Table S1 in the Supplement). Those 100 genes 
were selected according to the following criteria. The whole gene list of the array 
was sorted by fold-change (highest to lowest, 20’HRG vs control). The top 100 genes 
with p value less than 0.05 were selected. These 100 genes were put into DAVID 
Bioinformatics Resources 6.7 (267, 268) for functional annotation clustering; 9 genes 
were found to be involved in MAPK signalling pathway within the 
KEGG_PATHWAY database. These genes are: DDIT3, DUSP1, DUSP2, DUSP4, 
DUSP5, JUN, SRF, FOS and MYC. Since the DUSP family can dephosphorylate p-
ERK1/2, this family was selected as candidate genes which might regulate oscillation 
of p-ERK1/2. DDIT3, JUN, SRF, FOS and MYC act as early transcription factors, 
which might regulate the production of feedback loops.  
 
Takeshi Nagashima et al in 2007 (91) published a list of early transcription products 
(Table S2 in the Supplement) which might modulate the HER signalling pathways 
through positive and negative feedback loops. Nineteen out of 100 genes in the gene 
candidate pool (Table S1 in the Supplement) overlapped with the gene list proposed 
by Takeshi Nagashima et al (Table S2 in the Supplement). These genes are identified 
in blue in tables S1 and S2. Among the 19 genes, DUSP1, DUSP2, DUSP4, DUSP5, 
JUN, SRF, FOS and MYC identified above to be involved in MAPK signalling are 
also included. In addition to the 19 overlapping genes, 6 other genes proposed by 
Nagashima were also modulated significantly by HRG in this study (Table S3 in the 
Supplement). Among the 6 genes, AKAP9 and PPP1R3C were down regulated, 
which was consistent with Nagashima’s report. AKAP9 and PPP1R3C as well as 
PPP1R15A encode regulatory subunits of serine/threonine protein phosphatase 
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1(PP1) which promotes the dephosphorylation of HER activated Akt (269). AKAP9 
is also called CG-NAP (centrosome and Golgi localized PKN-associated protein) and 
encodes the protein that can interact with and promote PP1 activity (270). PPP1R3C 
is also called PPP1R5 (protein phosphatase 1 regulatory subunit 5) or PTG (protein 
targeting to glycogen) and encodes the glycogen-targeting subunit of PP1, which can 
increase PP1 activity (271). PPP1R15A, also called GADD34 (growth arrest and 
DNA-damage-inducible 34), can also promote PP1 activity (272). PPP1R15A was 
up-regulated by HRG in this study. So, the phosphatase activity of PP1 may be 
regulated by HRG negatively through down regulation of AKAP9 and PPP1R3C and 
positively through up-regulation of PPP1R15A. The expression levels of p-Akt were 
regulated indirectly by AKAP9, PPP1R3C and PPP1R15A.  
 
HRG also induced genes of several autocrine growth factors (AREG, HB-EGF and 
VEGFA). AREG codes for the protein called amphiregulin which is a specific ligand 
of HER-1 and HB-EGF codes for heparin-binding EGF-like growth factor which is a 
specific ligand for HER-1 or HER-4 (Introduction section 1.7.1). VEGFA codes for 
vascular endothelial growth factor A. Guo et al (273) observed that VEGF could 
promote tyrosine phosphorylation of SH2 domain containing signalling mediators 
such as PI3K and Ras GTPase activating protein (GAP). The product of SPRED2 has 
been shown to inhibit ERK1/2 signalling through negatively regulating Raf activity 
(274). In addition to the genes mentioned above, CYR61, CTGF and RASD1 were 
also investigated due to their dramatic induction compared to other genes in the 100-
gene pool (above 10-fold change, 20’HRG vs control). Gene products of CYR61 and 
CTGF can modulate the ERK1/2 and Akt pathways through binding of alphav-beta3 
integrin (275-277) which is reported to be involved in the activation of the HER-
mediated pathway (278, 279). So CYR61 and CTGF were selected as candidates.  
 
Those genes (29 in total) whose products might regulate the dynamics of HER-
mediated signalling are listed in Table 4. Time course profiles of individual genes are 
shown in Figure S1 in the Supplement. Among the 29 candidate genes, only AKAP9 
and PPP1R3C were down regulated and all the other genes were induced 
significantly by HRG. These genes might regulate HER-mediated signalling at three 
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primary levels. The first level is the activation of HER receptors by autocrine growth 
factors. The second level is the regulation of signalling molecules such as Raf, 
ERK1/2 and Akt. The third level is transcriptional regulation. 
 
Table 4 Twenty nine gene candidates which might regulate HER-mediated signalling dynamics 
(p<0.05, 20’HRG vs control, Student’s t-test) 
Genes Description Change fold Functions 
AKAP9 A kinase (PRKA) anchor protein (yotiao) 9 -1.10302 
PPP1R3C protein phosphatase 1, regulatory subunit 3C -1.23493 
PPP1R15A protein phosphatase 1, regulatory  subunit 15A 2.07285 
PP1 regulatory 
subunits to promote 
dephosphorylation of 
p-Akt 
AREG amphiregulin 1.16968 
CTGF connective tissue growth factor 19.8639 
CYR61 cysteine-rich, angiogenic inducer, 61 11.0838 
HBEGF heparin-binding EGF-like growth factor 1.15978 
VEGFA vascular endothelial growth factor A 1.11145 
Autocrine growth 
factors or stimulators 
to activate HER-
mediated signalling 
DUSP1 dual specificity phosphatase 1 3.45639 
DUSP2 dual specificity phosphatase 2 1.96664 
DUSP4 dual specificity phosphatase 4 1.29122 
DUSP5 dual specificity phosphatase 5 2.00690 
SPRED2 sprouty-related, EVH1 domain containing 2 1.16878 
ERK1/2 pathway 
regulators 
ATF3 activating transcription factor 3 1.84061 
BHLHB2 basic helix-loop-helix domain containing, class B, 2 1.31653 
DDIT3 DNA-damage-inducible transcript 3 1.56236 
EGR1 Early growth response 1 7.80240 
EGR2 Early growth response 2 12.66171 
EGR3 Early growth response 3 2.26183 
EGR4 Early growth response 4 2.81039 
FOS v-fos FBJ murine osteosarcoma viral oncogene 
homolog 
18.0963 
JUN jun oncogene 6.62094 
KLF10 Kruppel-like factor 10 1.31216 
KLF2 Kruppel-like factor 2 5.90560 
KLF6 Kruppel-like factor 6 2.21098 
MYC v-myc myelocytomatosis viral oncogene homolog 
(avian) 
1.48810 
NR4A2 nuclear receptor subfamily 4, group A, member 2 1.27107 
NR4A3 nuclear receptor subfamily 4, group A, member 3 3.73471 
SRF serum response factor (c-fos serum response 
element-binding transcription factor) 
1.72515 
Transcription 





Since protein synthesis inhibitors and transcriptional inhibitors can both block the de 
novo protein production, I expected CHX and actinomycin D (a transcriptional 
inhibitor) would have the same effects on the oscillation, but it was not true (Figure 
28). Actinomycin D decreased the signal amplitude of p-Akt and p-ERK1/2 induced 
by HRG rather than increased as CHX did. However, it made the level of both p-Akt 
and p-ERK1/2 more sustained than HRG alone did. Clear cycles of the level of p-
ERK1/2 across the time course were generated in the presence of actinomycin D with 
longer-than-20-min periodicity. It may be that CHX and actinomycin D affect the 






























































Figure 28 Effects of actinomycin D on the time course profile of p-Akt (S473) and p-ERK/12 
(T202/Y204) in MCF-7 cells. MCF-7 cells were incubated with 2 µg/ml of Actinomycin D for 20 min 
prior to the treatment of 1nM HRG for the time course indicated. Lysates were resolved by SDS-
PAGE and analysed by Western Blot. Results are demonstrated as the ratio of OD of phospho-targets 























4.1.4 HER-2 over-expression induces oscillation in a cell line 
dependent manner 
 
It was observed that positive feedforward signalling also played a role in the 
modulation of oscillation. Similar to observations in MCF-7 cells in the presence of 
CHX, levels of both p-Akt and p-ERK1/2 expression oscillated with a periodicity of 
roughly 20 min in HER-2-overexpressing MCF-7/HER2-18 cells stimulated by HRG 
alone (Figure 22). It was interesting that 1nM HRG alone induced an oscillation of p-
ERK1/2 expression level with clearer peaks and troughs than it did in MCF-7, 
suggesting that the over-expression of HER-2 played a key role in the modulation of 
oscillation in MCF-7/HER2-18. 
 
 However, no detectable oscillation was observed in BT474 cells stimulated by HRG 
either in the presence or absence of CHX (Figure 23). The p-Akt level was reduced 
by CHX rather than increased. These results suggest that oscillation is cell line or 
intrinsically cellular signalling network dependent. Since BT474 is a HER-2 
amplified and over-expressing cell line, HER-2’s effects on the oscillation as 
aforementioned on MCF-7/HER2-18 cells were cell line dependent. 
4.1.5 Role of crosstalk with the PI3K/Akt pathway in the 
modulation of oscillation of p-ERK1/2 
 
In addition to transcriptional feedback and HER-2 over-expression, the crosstalk 
between the PI3K/Akt and Raf/MEK1/2/ERK1/2 pathways also influenced the 
oscillation. It has been demonstrated that p-Akt inhibits the Raf/MEK1/2/ERK1/2 
pathway through phosphorylation of c-Raf at S259 (280, 281). In this study, I 
confirmed not only that this crosstalk was present but also observed its role in 
oscillation. When MCF-7 cells were treated with 5µM LY294002, an inhibitor of 
Akt phosphorylation, for 20 min prior to HRG stimulation, the oscillation of p-
ERK1/2 came to have clear peaks as well as troughs and the amplitude became 
higher than that caused by 1nM HRG alone (Figure 29), which demonstrated the 
effect of pathway crosstalk on oscillation. However, the oscillation pattern caused by 
LY294002 which caused a decaying periodicity was different from that produced by 
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CHX (Figure 24). Distinct from the one caused by HRG or HRG+CHX which had a 
constant periodicity of 20 min, the oscillation of p-ERK1/2 produced by HRG plus 
LY294002 had two different lengths of periodicity: the first cycle was 80 min and 























































Figure 29 Effects of crosstalk with PI3K/Akt pathway on oscillation of the level of p-ERK1/2 
(T202/Y204) in MCF-7 cells.  MCF-7 cells were stimulated with HRG (1nM) for the time indicated in 
either the presence or absence of LY294002 (5µM). The targets were detected with the LI-COR 
infrared imaging system.  Results are indicated as the ratio of the OD of phospho-targets to that α-
tubulin. 






















4.1.6 Effects of EGF concentration on the oscillation 
 
To assess how the oscillation was regulated by the concentration of the stimulus, 
MCF-7 cells were treated for the time course indicated in Figure 30 with 0.1, 1 and 
10 nM EGF respectively in the presence of 10 µM CHX. p-Akt expression level 
oscillated throughout the 90-min time course with 2 cycles in a similar pattern after 
stimulation with any of the three concentrations. 0.1 nM EGF induced the highest 
first peak at the 10-min point, but the highest peak of the second cycle was produced 
by 10 nM EGF. It was very interesting that 1 nM EGF induced the lowest level of p-
Akt expression across the whole time course. Moreover, the second cycle had a much 
longer cycling time than the first. The first cycle was roughly 20 min and the second 
one roughly 60 min.  
 
The level of p-ERK1/2 expression had a clear oscillation after stimulation with 1 nM 
EGF and cycled four times across the whole time course with a periodicity of 
approximately 20 min. The oscillation of p-ERK1/2 expression induced by 10 nM 
EGF was much weaker. However, there was no oscillation observed through the 
whole time course stimulated by 0.1 nM EGF and the signal was delayed to around 
the 60-min point where there was a single peak. Thereafter, the signal of p-ERK1/2 
came down to the base line. These results demonstrated that the oscillation was 
regulated by the concentration of EGF through variation in amplitude, the signal 



































































Figure 30 Effects of EGF concentration in the presence of CHX on the oscillatory level of p-Akt 
(S473) and p-ERK1/2 (T202/Y204) expression in MCF-7 cells. MCF-7 cells were incubated with 10 
µM CHX for 20 min prior to the treatment of concentrations (0.1, 1 and 10 nM) of EGF for the time 
course indicated (90 min in total). Samples were collected at each time point and subjected to western 
blot. Samples were randomly loaded into the gel for the avoiding of edge effects and the x-ray films 
were developed in the dark room. The results are shown as the ratio of the OD of p-Akt or p-ERK1/2 
to that of GAPDH, which was used as a loading control. 
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4.1.7 Serum deprivation affected the generation of oscillation 
 
The oscillation mentioned above was observed in cells which were incubated in 
DMEM supplemented with 10% FCS for 48 h and then incubated in phenol red-free 
DMEM supplemented with 5% DCSS for another 48 h before drug treatment.  When 
MCF-7 cells were grown in DMEM supplemented with 10% FCS for 48 h and 
starved in phenol red-free DMEM supplemented with no serum for 20 h, no 
significant oscillation was observed regardless of the addition of CHX (Figure 31). 
The level of p-Akt expression increased after stimulation with HRG alone to a peak 
at the 40-min point and then came down at the 70-min point. The level of p-Akt 
expression was sustained from the 70-min point until the end of the time course. The 
phosphorylation of ERK1/2 was stimulated by HRG alone. The level of p-ERK1/2 
expression increased to a peak at the 40-min point and then was reduced until the 60-
min point after which the level remained constant until the 100-min point. The level 
of p-ERK1/2 expression then kept decreasing until the end of the time course.  In the 
presence of CHX, the level of p-Akt expression was increased to a high level at the 
20-min point and then came down until the 30-min point. After 30 min the level of p-
Akt expression was increased again to the highest level at the 40-min point. 
Afterwards, the expression level was decreased until the 60-min point and then 
sustained until the end of the time course.  The phosphorylation of ERK1/2 was 
induced very quickly by HRG in the presence of CHX. It reached the highest level 
after 10 min of induction. The level of p-ERK1/2 expression then came down for 20 
min until the 30-min point. After the 30-min point, the level went up again to the 
second highest level between the 40-min and 50-min points. Afterwards, the level of 
p-ERK1/2 expression dampened until the 70-min point and then remained constant 






























































Figure 31 Effects of growth condition on the formation of oscillation. MCF-7 cells were grown in 
DMEM supplemented with 10% FCS for 48 h and then in DMEM supplemented with no serum for 
another 20 h before HRG plus/minus CHX treatment. CHX was incubated with cells for 20 min prior 
to HRG treatment. Cell lysates from each treatment were resolved in SDS-PAGE. p-Akt (S473) and p-
ERK1/2 (T202/Y204) were detected by Western Blotting. α-tubulin was a loading control. The images 
were acquired by scanning the membrane with LI-COR imaging system. The results are demonstrated 
as the ratio of the OD of p-Akt or pERK1/2 to that of corresponding α-tubulin. 
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4.1.8 Discussion on the oscillatory dynamics of p-Akt and p-
ERK1/2 
 
In this study, I have demonstrated the oscillatory dynamics of p-Akt and p-ERK1/2 
under variable conditions in differing cell types, and evaluated the nature and 
concentration of ligands, and inhibitors that influence the oscillation. The oscillation 
is regulated by a variety of factors including transcriptional feedback loops, crosstalk 
with other pathways and over-expression of HER-2 as feedforward drive. The 
growth conditions also influenced the generation of oscillations.  
 
According to the time course profile of p-HER-3 (Y1289), the addition of CHX 
decreased the level of p-HER-3 within the whole time course, suggesting that the 
addition of CHX enhanced the negative feedback loop to HER-3. CHX is a protein 
synthesis inhibitor and I speculated that CHX enhanced the negative feedback loop 
through the loss of some protein synthesis. From the other angle, CHX could weaken 
positive feedback through the inhibition of protein synthesis. In Figure 27, under the 
stimulation of HRG alone, the level of p-HER-3 (Y1289) oscillated, but the addition of 
CHX caused the oscillation to disappear. It implied that the inhibition of positive 
feedback caused the loss of oscillation. Results from another study support this 
conclusion. Nakakuki et al (282) found that the absence of a repressor caused the 
level of c-fos mRNA to oscillate when pulsed for the second time with EGF. The 
formation of oscillation is likely to involve either enhancement of positive feedback 
or loss of negative feedback, otherwise after the first decrease of the level of p-HER-
3 (Y1289) the level would not increase again. Therefore, there may be a transcriptional 
positive feedback to HER-3. This positive feedback could cause the oscillation of p-
HER-3 (Y1289). This conclusion was supported by Takeshi, Hidetoshi and colleague’s 
study (91). In their study they proposed positive feedback to HER receptors through 
the de novo production of ligands. According to the gene expression analysis, HB-
EGF which is a ligand for HER-1 and HER-4 and amphiregulin which is a specific 
ligand of HER-1 was induced significantly by HRG. HB-EGF and amphiregulin can 
activate HER-3 through triggering the dimerisation of HER-1-HER-3 or HER-4-
HER-3. Moreover, genes of two molecules CTGF and CYR61 were also induced by 
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HRG. Both molecules can activate the Akt and ERK1/2 pathways through binding 
alphav-beta3 integrin (275-277). Integrin pathway and growth factor pathway can 
crosstalk and synergize to enhance Akt and ERK1/2 pathways (283) which in turn 
modulate HER-3. So HB-EGF, amphiregulin, CTGF and CYR61 may act in an 
autocrine manner to activate HER-3.   
 
 According to the hypothesis above, the oscillation of p-MEK1/2 (S217/222) before 90 
min under the treatment of HRG alone is explainable due to the positive feedback 
loop induced by HRG. Since CHX would block this positive feedback, the oscillation 
for HRG+CHX was weak. After 90 min, the level of p-MEK1/2 (S217/222) was higher 
for HRG+CHX treatment than that for HRG treatment. It suggested that the addition 
of CHX inhibited the late negative feedback.  
 
In contrast to the oscillations of p-HER-3 and p-MEK1/2 which were produced with 
the treatment of HRG without CHX, the oscillation of p-ERK1/2 was very 
appreciable under the treatment of HRG+CHX. As mentioned above, the 
enhancement of positive feedback or the loss of negative feedback can cause the 
formation of oscillation. Here, CHX will block the production of negative feedback 
molecules such as those from DUSP family. The expression of DUSPs was 
confirmed by gene expression analysis. In this study, the expression of DUSP1, 
DUSP2, DUSP4 and DUSP5 were significantly induced by HRG. 
 
The involvement of signalling enhancer in the generation of oscillation was also 
supported by observations from MCF-7/HER2-18 cells. MCF-7/HER2-18 is a HER-
2 over-expressing cell line. Oscillation of the level of p-ERK1/2 in MCF-7/HER2-18 
cells treated with HRG alone was more appreciable than that in MCF-7 cells treated 
with HRG alone. It suggested that over-expression of HER-2 as a signalling enhancer 
was a modulator of oscillation. 
 
Briefly, in terms of the above statements and the findings in Sections 4.1.2-4.1.7, I 
hypothesize that after the stimulation of HRG positive feedback loops to HER-3 
were induced. Early positive and late (90 min) negative feedback loops to MEK1/2 
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were induced. Negative feedback loop to ERK1/2 was induced. The feedback loops 
are summarised in Figure 32. 
 
Figure 32 Scheme of the hypothesized HRG-induced transcriptional feedback loops. Blue lines 
denote the negative feedback loops and red lines denote the positive feedback loops. 
 
It was interesting that the level of p-Akt and p-ERK1/2 was increased by CHX while 
the phosphorylation of HER-3 was attenuated. It suggested the involvement of 
feedback loops or crosstalk or that HRG activated ERK1/2 through other means such 
as the integrin-mediated pathways (278) besides HER-mediated pathways.  
 
In a previous study, Nagashima et al (91) did not observe oscillation of p-ERK1/2 in 
MCF-7 cells treated with HRG with/without CHX. In their study, MCF-7 cells were 
serum-starved for 16-24 h before HRG treatment. In my study oscillation was 
observed in MCF-7 cells grown in medium with 5% DCSS. I hypothesized the 
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different observations about the oscillation was due to the different cell culture 
conditions. In my study, when MCF-7 cells were grown in phenol red-free DMEM 
without serum for 20 h before HRG treatment, oscillation of p-ERK1/2 (T202/Y204) 
was not observed regardless of CHX. This observation was consistent with the 
previous findings. The loss of oscillation may be due to the alteration of 
transcriptional negative feedback loops to ERK1/2 caused by serum-deprivation 
(220).   
 
The oscillation of p-Akt expression has not been previously reported or predicted to 
the best of my knowledge. The oscillation was induced by both HRG and EGF in 
MCF-7 cells in either the presence or absence of CHX, while, the oscillation of p-
ERK1/2 was appreciable only in the presence of CHX. The oscillation of p-Akt had a 
higher early response in the presence of CHX than that in the absence of CHX. This 
might be due to the oncogenic mutation of PI3K, which would amplify the signalling. 
It was demonstrated by Saal et al (284) that MCF-7 cells harboured an E545K 
mutation in PIK3CA. The MCF-7 cell line used in this study harbours an E545K 
mutation in PIK3CA which has been confirmed by my colleague (personal 
communication- Ms Charlene Kay, Breakthrough Breast cancer Unit, Edinburgh) 
using pyrosequencing. This mutation has been demonstrated to have oncogenic 
transforming activity and this transforming activity was related to the increased 
kinase activity (285) of PIK3CA. So this mutation is likely to be a signalling 
enhancer. 
 
Additionally, negative feedback loops could be involved in the formation of 
oscillation as well. Kholodenko (235) predicted in his mathematical model that 
delayed negative feedback from p-ERK1/2 to the activation of Raf along with ultra-
sensitivity could bring about sustained oscillation of p-ERK1/2. The sensitivity of the 
cellular targets to external stimuli increases multiplicatively with the number of 
cascade’s tiers. So, a small change from external stimuli can result in a large change 
in the response. This is called ultrasensitivity. Nakayama et al (234) had observed the 
oscillation of Ras and ERK1/2 activity in FGF-stimulated NIH 3T3 cells. They 
demonstrated that the oscillation present there required the negative feedback 
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phosphorylation of SOS by active ERK1/2, which supported Kholodenko’s 
hypothesis.  
 
Since the transcriptional feedback loops could modulate the oscillation of p-Akt and 
p-ERK1/2, I undertook gene expression analysis to identify possible gene candidates 
which may be involved in the modulation. These candidates could all modulate the 
HER-mediated signalling dynamics through positive or negative feedback loops and 
were induced by HRG at an early time (at 20 min). DUSP1, DUSP2, DUSP4 and 
DUSP5 dephosphorylate p-ERK1/2. As mentioned above, CYR61 and CTGF can 
activate Akt and ERK1/2 through binding integrin. PPP1R15A could inhibit the 
dephosphorylation of p-Akt by protein phosphatase 1 (286). Further studies will be 
required to assess the role of these candidates in the modulation of oscillation. 
 
In this study, the inhibitory crosstalk between the PI3K/Akt and Raf/MEK/ERK 
pathways was observed and this crosstalk can occur via inhibitory phosphorylation of 
Raf at S259 by activated Akt (281). It was reasonable that the inhibition of the 
phosphorylation of Akt by LY294002 could induce the more appreciable oscillation 
of p-ERK1/2 since the inhibitory crosstalk from Akt to Raf was blocked by 
LY294002, suggesting a loss of signalling attenuator. As mentioned above, the 
enhancement of positive signalling or the loss of signalling attenuator would cause 
oscillation. 
 
Apart from the temporal regulation of the oscillation, Shankaran et al (287) reported 
that the oscillation was also modulated spatially. The authors demonstrated that p-
ERK1/2-GFP oscillated with a periodicity of approximately 15 min between 
cytoplasm and nucleus after stimulation by EGF in individual human mammary 
epithelial cell line 184A1. This periodicity was very close to that observed in my 
study (roughly 20 min).  The shift of p-ERK1/2 between different compartments may 
correlate with the oscillation of the total level of p-ERK1/2 (which was observed in 
my study) since the shifting could cause the concentration of p-ERK1/2 in the 
compartments to vary. I postulated that the varying concentrations might be a 
feedback to the input. If the concentration is higher than the cells’ requirement, the 
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system would dephosphorylate p-ERK1/2. If the concentration is lower than that 
needed, the system would activate more ERK1/2 molecules. Hence, this process 
would cause the oscillation of total p-ERK1/2 in the whole cell across the time.  
 
In this study, two different detection methods for western blot were used. One 
method uses HRP-conjugated secondary antibodies and ECL as substrate of HRP to 
generate chemiluminescent signals. Signals are captured with x-ray film in a dark 
room. The other method uses fluorophore-conjugated secondary antibodies. 
Fluorescent signals are captured by scanning western membranes with the LI-COR 
imaging system. The differences between these two methods are the involvement of 
biochemical reactions and signal characteristics. Although the latter method can save 
more time and detect total and phosphorylated cognates simultaneously, the 
inconsistency between the two methods introduces difficulties into interpreting 
results since secondary antibodies may have different affinities and the two detection 
methods may have different linear ranges of signal intensities against protein amount. 
This will make the results non-comparable. To resolve this problem, the two 
different systems of western blot can be run with serially diluted purified proteins. A 
standard curve of signal intensities (y axis) against protein amount (x axis) can be 
generated for each of these two systems and then a linear range can be determined 
for each system. Ideally, both linear curves should go through the point (0, 0) at the 
intersection of the axes. So based on the linear ranges, fitted linear curves which 
intersect at point (0, 0) as well as the curve functions can be generated. According to 
the fitted linear curves, ODs can be transformed to protein amount. Alternatively, the 
ratio of the fitted curve slopes can be used to normalise the band ODs of the target 
proteins (same as the standard proteins) between the two systems. The normalisation 
will make the results comparable. Additionally, two different internal controls 
(GAPDH and tubulin) were used in the western blots, which will also make the 
results non-comparable since the abundance of the two proteins in a cell may be not 
the same and the antibody affinities may be different as well. To resolve this problem, 
western blots can be run for serially diluted purified GAPDH and tubulin. Standard 
curves of band ODs (y axis) against protein molar amount (x axis) for each protein 
can be generated. Linear ranges and fitted linear curves (intersecting at (0, 0)) can be 
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determined as well. Ratio of the slopes between the two fitted linear curves can be 
used to normalise ODs of GAPDH and tubulin on the basis of the same molecule 
numbers. Therefore, the normalised ODs of GAPDH or tubulin can be used to 
normalise the ODs of target proteins. After the final normalisation, results from the 
experiments with different internal controls are comparable. For comparing the 
results from western blot and RPPA, standard curves for each method can be 
generated and ODs then can be transformed to concentration (μg/ml). 
 
In light of the investigations on the signalling oscillation as well as the regulating 
factors, the following conclusions can be made. 
1) Signalling oscillations for p-Akt and p-ERK1/2 were observed 
experimentally for the first time in breast cancer cells. 
2) Oscillations were cell line dependent and were observed in serum 
supplemented media instead of serum deprived media. 
3) HER-2 over-expression could augment p-ERK1/2 oscillation and the 
HER-2 dimerisation inhibitor (pertuzumab) could block the 
oscillation of p-ERK1/2. 
4) Transcriptional feedback loops could regulate the oscillations of both 
p-Akt and p-ERK1/2. Based on the results in this study, it was 
hypothesized that there was a transcriptional positive feedback to 
HER-3, an early positive and a late negative feedback loop to 
MEK1/2 and finally a negative feedback loop to ERK1/2. Based on 
gene expression analysis, twenty-nine genes were identified which 
might regulate the oscillations transcriptionally through positive or 
negative feedback loops. 
5) Crosstalk between ERK1/2 and Akt pathway could also regulate 
oscillations. 
6) In conclusion, oscillations were produced by interlinked positive 
feedback/feedforward and negative feedback loops. Functional 
consequences of changes in oscillations might have fundamental 
consequences in oncogenesis and therapy efficacy. 
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4.2 Effects of trastuzumab, pertuzumab and their 
combination in breast cancer cell lines  
4.2.1 Growth inhibitory effects of trastuzumab, pertuzumab and 
their combination 
 
Trastuzumab is an established therapy for patients with HER-2 over-expressing 
metastatic breast cancers. However, in vitro, this drug also inhibited the HER-2 
low/medium expressing MCF-7 cell growth when stimulated by 1nM EGF in phenol 
red-free DMEM supplemented with 5% DCSS for 5 days. This contrasted with no 
growth inhibition of HRG-stimulated growth (Figure 33A&B). In order to test 
whether trastuzumab itself had any effect on HRG stimulation or whether the 
saturation of cell number masked trastuzumab’s effects, I carried out a time course 
growth assay with different concentrations of HRG (1nM, 0.1nM and 0.01nM) and 
observed that cells treated with HRG plus trastuzumab grew at a slower rate than 
those treated with HRG alone but finally both groups of HRG alone and HRG plus 
trastuzumab reached the same cell numbers at the stationary phase (Figure 34). 
Therefore, under the stimulation of HRG, trastuzumab slowed down the growth rate 
but did not impact on final cell numbers. In contrast, MCF-7 cells treated with EGF 
plus trastuzumab grew at a slower rate through the whole time course indicated and 
achieved a lower cell density at the stationary phase than those treated with EGF 
alone (Figure 34). I concluded that trastuzumab slowed down the growth rate under 
the stimulation of HRG and inhibited the growth under the stimulation of EGF in 
MCF-7, but without stimulation trastuzumab alone did not have detectable effects on 
the growth of cells (compared to the control at Day 7 in Figure 34, student’s t-test, 
p>0.05) of which 96.5%±0.0012 (average±SD, N=6) was synchronized to G0-G1 
phase (data not shown).  
 
Pertuzumab which is a HER-2 dimerisation inhibitor caused lower cell numbers after 
3-day stimulation by both HRG and EGF (Figure 33B). Under the stimulation of 
1nM HRG, the combination of trastuzumab and pertuzumab had more potent effects 
than each drug alone. Under the stimulation of 1nM EGF, the combination had a 
similar effect to that of pertuzumab on growth. The combination of pertuzumab and 
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trastuzumab had a more potent inhibition under the stimulation of HRG than under 
that of EGF.  It was also observed that trastuzumab was working over a broad range 
of concentrations from at least 10 to 1000 nM (Figure 35) in MCF-7 cells. 10, 100 
and 1000 nM trastuzumab respectively produced no significant differences in the 































One-way ANOVA for all-group comparison (N=6, equal variances), p=0.000 
Tukey HSD Post Hoc test run by SPSS 17.0 














control -- 0.000 0.000 0.000 0.000 
HRG 0.000 -- 0.764 0.000 0.000 
HRG+tras 0.000 0.764 -- 0.000 0.000 
EGF 0.000 0.000 0.000 -- 0.000 


























































One-way ANOVA for all-group comparison (N=6, equal variances), p=0.000 
Tukey HSD Post Hoc test run by SPSS 17.0 


























control -- 0.000 0.000 0.000 0.000 0.000 0.000 0.352 0.016
HRG 0.000 -- 0.988 0.000 0.000 0.000 0.000 0.000 0.000
HRG+tras 0.000 0.988 -- 0.000 0.000 0.000 0.000 0.000 0.000
HRG+pert 0.000 0.000 0.000 -- 0.000 0.000 0.000 0.000 0.000
HRG+tras+pert 0.000 0.000 0.000 0.000 -- 0.000 0.554 0.007 0.203
EGF 0.000 0.000 0.000 0.000 0.000 -- 0.002 0.000 0.000
EGF+tras 0.000 0.000 0.000 0.000 0.554 0.002 -- 0.000 0.001
EGF+pert 0.352 0.000 0.000 0.000 0.007 0.000 0.000 -- 0.905
EGF+tras+pert 0.016 0.000 0.000 0.000 0.203 0.000 0.001 0.905 -- 
B 
Figure 33 Effects of trastuzumab (tras), pertuzumab (pert) and their combination on the growth 
of MCF-7 under the stimulation of EGF (1nM) or HRG (1nM). MCF-7 cells were grown in 
phenol red positive DMEM supplemented with 10% FCS in 96-well microplate for 48 h before being 
grown in phenol red free DMEM supplemented with 5% DCSS for another 48 h. Cells were then 
treated with EGF or HRG plus/minus the drugs indicated for 5 days (A) and 3 days (B). The working 
concentration of either trastuzumab or pertuzumab was 100 nM. The results are presented as the 
















































Figure 34 Dose effects of EGF or HRG on the growth inhibition of trastuzumab for MCF-7 cells. 
Cells were treated with 1nM, 0.1nM and 0.01nM HRG or EGF for a 7-day time course with the one-
day interval under the intervention of 100nM of trastuzumab. The results are presented as the average 
of the OD540 value ±SD.  
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One-way ANOVA for all-group comparison (N=6, equal variances), p=0.000 
Tukey HSD Post Hoc test run by SPSS 17.0 
P value  















EGF -- 0.000 0.000 0.000 0.000 
EGF+1000nM tras 0.000 -- 0.913 0.876 0.000 
EGF+100nM tras 0.000 0.913 -- 0.399 0.000 
EGF+10nM tras 0.000 0.876 0.399 -- 0.000 


























One-way ANOVA for all-group comparison (N=6, equal variances), p=0.000 
Tukey HSD Post Hoc test run by SPSS 17.0 
P value  























HRG -- 0.011 0.004 0.002 0.000 
HRG+1000nM tras 0.011 -- 0.989 0.970 0.000 
HRG+100nM tras 0.004 0.989 -- 1.000 0.000 
HRG+10nM tras 0.002 0.970 1.000 -- 0.000 
control 0.000 0.000 0.000 0.000 -- 
Figure 35 Growth inhibitory effects of different concentrations of trastuzumab in MCF-7 cells. 
Cells were stimulated with 0.1nM HRG or 0.1nM EGF plus the treatment of 10, 100 and 1000nM 
trastuzumab (tras) respectively for a 7-day time course with the one-day interval. The results are 
presented as the average of OD540 value ± SD. The p values for Day 7 were shown. 
 
A similar growth time course profile for MCF-7/HER2-18 cells was also observed.  
The growth of MCF-7/HER2-18 induced by 1, 0.1 and 0.01nM EGF was inhibited 
by 100nM trastuzumab (Figure 36), but 100nM trastuzumab just slowed down the 
growth rate induced by 1 and 0.1nM HRG. Distinct from the effect of trastuzumab 
on the growth of MCF-7 stimulated by HRG, trastuzumab inhibited the growth of 
MCF-7/HER2-18 stimulated by 0.01nM HRG rather than slowing down the growth 





















phenol red free DMEM supplemented with 5% DCSS. This inhibition would be 

















































Figure 36 Dose effects of EGF or HRG on the growth inhibition of trastuzumab for MCF-
7/HER2-18 cells. Cells were treated with 1nM, 0.1nM and 0.01nM HRG or EGF for a 7-day time 
course with the one-day interval under the intervention of 100nM trastuzumab. The results are 
presented as the average of the OD540 value ±SD.  
 
Similar to the effects on MCF-7 and MCF-7/HER2-18 cells, trastuzumab inhibited 
the growth of BT474 cells stimulated by 1nM EGF but not HRG (Figure 37). 
Trastuzumab had no effects on the growth stimulated by HRG within the entire 7-day 
time course. Pertuzumab inhibited the growth of BT474 cells stimulated by both 
EGF and HRG, but it had more potent effects on the stimulation of EGF than on that 
of HRG. At Day 7, pertuzumab inhibited the growth driven by EGF by nearly 50%, 
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down to the control level but inhibited only about 18% of the growth driven by HRG. 
The combination of trastuzumab and pertuzumab had no statistically significant 
difference with pertuzumab alone on the growth driven by HRG but further inhibited 
the growth driven by EGF, compared with either trastuzumab or pertuzumab. It was 
interesting that the combination inhibited the growth driven by EGF below the 
control level, particularly at day 7 about 3.6-fold inhibition against control level. 
Across the time course, the cell numbers were reduced under the treatment of 
‘EGF+trastuzumab+pertuzumab’, roughly 2-fold fewer at day 7 than at day 1, which 
may be in part due to the increased apoptosis (288). 
 
It was mentioned above that trastuzumab alone had no detectable or ambiguous 
effects on growth, but there was a possibility that the cell number seeded for the time 
course growth assay in Figure 34 was not high enough to show the growth 
differences between trastuzumab-treated and the control group. Therefore, the cell 
numbers were increased to 10,000/well for MCF-7 and 16,000/well for MCF-
7/HER2-18. In Figure 38, statistically significant differences were observed between 
trastuzumab treated and control groups in both MCF-7 and MCF-7/HER2-18 but the 
differences were small.  
 
In summary, trastuzumab had growth inhibitory effects in vitro on MCF-7, MCF-












































































































Brown-Forsythe test for all-group comparison (N=6, unequal variances), p=0.000 
Games-Howell Post Hoc test run by SPSS 17.0 
P value 


























control -- 0.000 0.071 0.817 0.000 0.000 0.000 0.008 0.143
EGF 0.000 -- 0.000 0.000 0.000 1.000 0.675 0.145 0.002
EGF+tras 0.071 0.000 -- 0.293 0.000 0.000 0.000 0.001 0.013
EGF+pert 0.817 0.000 0.293 -- 0.000 0.000 0.000 0.005 0.068
EGF+tras+pert 0.000 0.000 0.000 0.000 -- 0.000 0.000 0.000 0.000
HRG 0.000 1.000 0.000 0.000 0.000 -- 0.126 0.083 0.004
HRG+tras 0.000 0.675 0.000 0.000 0.000 0.126 -- 0.026 0.001
HRG+pert 0.008 0.145 0.001 0.005 0.000 0.083 0.026 -- 0.318
HRG+tras+pert 0.143 0.002 0.013 0.068 0.000 0.004 0.001 0.318 -- 
B 
Figure 37 Effects of trastuzumab (tras), pertuzumab (pert) and their combination on the growth 
of BT474 cells under the stimulation of EGF (1nM) or HRG (1nM). BT474 cells were grown in 
phenol red positive DMEM supplemented with 10% FCS in 96-well microplate for 48 h before being 
grown in phenol red free DMEM supplemented with 5% DCSS for another 48 h. Cells were then 
treated with EGF or HRG plus/minus the drugs indicated for a 7-day time course with the one-day 
interval (A). The working concentration of either trastuzumab or pertuzumab was 100nM. B 
represents the cell density of the last day (Day 7) treatment within the time course. The results are 




Figure 38 Inhibition of basal growth by 100 nM trastuzumab in MCF-7 and MCF-7/HER2-18 
cells. MCF-7 and MCF-7/HER2-18 cells were seeded in 96-well microplate. The effects of 
trastuzumab on both MCF-7 and MCF-7/HER2-18 cells which were cultured in phenol red-free 
DMEM supplemented with 5% DCSS were analyzed with SRB assay. The results are presented as the 
average of the OD540 value±SD. The p values for Day 7 were shown. The student’s t-test was applied 






































4.2.2 Trastuzumab regulates gene expression 
 
HRG induced expression of hundreds of genes in MCF-7 cells when cells were 
treated with HRG for 40 min and generally, HRG and HRG+trastuzumab induced 
similar gene expression patterns (Figure 39), but among the 300 significantly 
(p<0.05) induced genes by HRG (Table S4 in the Supplement), 29 genes were 
modulated by trastuzumab (Table 5). These 300 genes are selected according to the 
following criteria. The whole gene list of the array was sorted by fold-change 
(highest to lowest, 40’HRG vs control). The top 300 genes with p value less than 





Figure 39 Gene expression patterns of MCF-7 cells treated with trastuzumab (tras), HRG or 
HRG plus trastuzumab for 5, 10, 20 and 40 min respectively and controls. HRG and trastuzumab 
were used at 1nM and 100nM respectively. Individual rows highlighted are a cluster of genes that 
were increased over the time course expression profile. There are four replicates for each treatment. 
Colours are relative expression across the samples the brightest red is for most highly expressed genes 
and green for reduced expression, relative to the mean (black).  
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Table 5 Twenty nine genes regulated significantly by trastuzumab (p<0.05, 40’HRG+trastuzumab vs 
HRG, student’s t -test) 
Gene Description Fold change 
RCAN1 regulator of calcineurin 1 1.24096 
MESDC1 mesoderm development candidate 1 1.21774 
CNTD2 cyclin N-terminal domain containing 2 1.20362 
PPP1R10 protein phosphatase 1, regulatory subunit 10 1.19679 
PIM3 pim-3 oncogene 1.15688 
FVT1 3-ketodihydrosphingosine reductase 1.13937 
LOC201164 unknown 1.13512 
INSIG1 insulin induced gene 1 1.11095 
C11orf56 unknown 1.10295 
C12orf44 unknown 1.08569 
TRIM26 tripartite motif-containing 26 1.07298 
NT5DC3 5'-nucleotidase domain containing 3 -1.09757 
VGF VGF nerve growth factor inducible -1.10285 
ZNF274 zinc finger protein 274 -1.10831 
DUSP1 dual specificity phosphatase 1 -1.11174 
ERRFI1 ERBB receptor feedback inhibitor 1 -1.11981 
PHLDA1 pleckstrin homology-like domain, family A, member 1 -1.16008 
C20orf111 unknown -1.17105 
JUN jun oncogene -1.17573 
KLF2 Kruppel-like factor 2 -1.21052 
KLF6 Kruppel-like factor 6 -1.23382 
KLF10 Kruppel-like factor 10 -1.24995 
FZD9 frizzled homolog 9 (Drosophila) -1.25084 
CCNL1 cyclin L1 -1.26052 
LOC651621 unknown -1.26450 
MEF2D myocyte enhancer factor 2D -1.29517 
LRRC8A leucine rich repeat containing 8 family, member A -1.39029 
UBC ubiquitin C -1.40686 
FOSB FBJ murine osteosarcoma viral oncogene homolog B -1.40732 
 
Among the 29 genes, 11 genes were up-regulated and 18 genes were down regulated.  
The functions of the 3 genes (C11orf56, C12orf44 and LOC201164) among the 11 
up-regulated genes and 2 genes (LOC651621 and C20orf111) among the 18 down-
regulated genes have not been described. Among the 16 (LOC651621 and C20orf111 
excluded) down-regulated genes, expression products of the following 10 genes 
FOSB, KLF10, KLF2, KLF6, CCNL1, JUN, MEF2D, PHLDA1, UBC and ZNF274 
were clustered in the group of nuclear proteins. Among these 10 genes, 9 genes 
excluding PHLDA1 were clustered in regulation of transcription. Five genes (KLF10, 
DUSP1, JUN, PHLDA1 and UBC) were clustered as positive regulators of apoptosis 
using the functional annotation tool of DAVID Bioinformatics Resources 6.7 (267, 
268). ERRFI1 which is also called RALT interacts with HER-2 directly and is a 
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transcriptionally controlled feedback inhibitor of HER receptor-mediated signalling 
(289) which can inhibit HER-2 mitogenic and transforming activity (290). According 
to the DAVID functional annotation tool, DUSP1, JUN and ERRFI1 are involved in 
HER-mediated signalling regulation and FZD9 is involved in activation of Wnt/β-
catenin pathway. NT5DC3 is a novel gene. Little is known about this gene which 
may contribute to development/progression of human pancreatic cancer (291). 
Similarly, little is known about LRRC8A a novel gene which is required for B cell 
development (292). The 11 up-regulated genes could not be clustered in any 
functional category. The protein product of RCAN1 can inhibit calcineurin signalling 
and inhibit angiogenesis (293).  Little is known about MESDC1 and CNTD2. 
PPP1R10 is a hypoxia inducible gene and its expression product is a nuclear 
targeting subunit of PP1. Over-expression of this protein markedly increases cell 
death to hypoxia through increasing the nuclear localization, phosphorylation and 
transcriptional activity of p53 as well as the ubiquitin-dependent proteosomal 
degradation of MDM2 (294). Aberrantly expressed serine/threonine kinase Pim-3 
can cause autonomous proliferation or prevent apoptosis of human hepatoma cell 
lines (295). The protein product of PVT1 plays a role in the synthesis of 
sphingolipids which are essential membrane components of eukaryotic cells (296). 
The protein product of INSIG1 is a membrane bound protein of endoplasmic 
reticulum and plays a role in feedback control of lipid synthesis in cultured cells 
(297). The protein encoded by TRIM26 is a member of the tripartite motif (TRIM) 
family which contains one B box-type zinc finger, one B30.2/SPRY domain and one 
RING-type zinc finger, but its function is unknown (from NCBI gene database, gene 
ID: 7726). So, it is likely that growth rate reduction of HRG-stimulated MCF-7 cells 
by trastuzumab might be due to down-regulation of transcription. 
4.2.3 Effects of trastuzumab, pertuzumab and their combination 
on signalling dynamics 
 
To assess how these differential growth profiles were reflected in signalling, I 
analyzed the dynamics of p-Akt and p-ERK1/2 under the stimulation of 1nM EGF 
and 1nM HRG with the aforementioned drugs in MCF-7, MCF-7/HER2-18 and 
BT474 cell lines.  
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In MCF-7 cells, 1nM HRG alone induced a sustained p-ERK1/2 level throughout the 
time course indicated, but in the presence of 100nM trastuzumab, p-ERK1/2 level 
became transient (Figure 40). However, the p-ERK1/2 level was higher than that in 
HRG alone treatment within the first one hour and then decreased to a comparable 
level. Pertuzumab greatly inhibited the p-ERK1/2 expression level. The combination 
of trastuzumab and pertuzumab brought down p-ERK1/2 expression to a baseline 
value (Figure 40). The p-Akt expression level was reduced by trastuzumab, 
pertuzumab and their combination. Pertuzumab had a much stronger reduction effect 
than trastuzumab (Figure 41). Among the interventions the combination of 
trastuzumab and pertuzumab had the strongest reduction effect on the level of p-Akt 
as well as on that of p-ERK1/2 (Figure 41). It was interesting that the activity of 
MEK1/2 which is the molecule upstream of ERK1/2 was reduced by trastuzumab 
while the level of p-ERK1/2 was increased within the first hour (Figure 41 & 42).  
Both antibodies and their combination had no detectable effects on the level of p-
ERK1/2 under EGF stimulation, but all reduced the level of p-Akt (Figure 43). Here, 
pertuzumab had a stronger inhibition than trastuzumab. The effects of the 
combination of both drugs on p-Akt were not simply the sum of individual drugs. 
Trastuzumab partially reversed the inhibitory effect of pertuzumab. The addition of 
pertuzumab facilitated trastuzumab’s ability to inhibit p-Akt further within the first 
20 min but thereafter had little added impact. It demonstrated that under the drive of 
EGF, growth inhibition by trastuzumab, pertuzumab and their combination was 
primarily through altering dynamics of the PI3K/Akt pathway and through that of 





























Figure 40 Time-course profile of p-ERK1/2(T202/Y204) in MCF-7 cells treated with 1nM HRG 
plus/minus trastuzumab (tras, 100nM), pertuzumab (pert, 100nM) and their combination.  α-



























































































Figure 41 Time-course profile of p-Akt (S473) and p-MEK1/2 (S217/221) expression in MCF-7 cells 
treated with HRG (1nM) plus/minus trastuzumab (tras, 100nM), pertuzumab (pert, 100nM) 
and their combination. α-tubulin was used as the loading control. The results are presented as the 



























































Figure 42 Repeat of the time-course profile of p-Akt (S473) and p-MEK1/2 (S217/221) in MCF-7 
cells treated with HRG (1nM) plus/minus trastuzumab (tras, 100nM).  ‘M’ denotes protein ladder. 
α-tubulin was used as the loading control. The results are presented as the ratio of OD of phospho-































































Figure 43 Time-course profile of p-Akt (S473) and p-ERK1/2(T202/Y204) expression in MCF-7 cells 
treated with EGF (1nM) plus/minus trastuzumab (tras, 100nM), pertuzumab (pert, 100nM) and 
their combination. ‘M’ denotes protein ladder. GAPDH was used as the loading control. Results are 
presented as the raito of OD of phospho-targets to that GAPDH. 
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In MCF-7/HER2-18 cells, HRG alone elicited a sustained oscillatory activation of p-
ERK1/2 during the whole time course for 2 h. Trastuzumab, pertuzumab and their 
combination reduced the level of p-ERK1/2 to different degrees (Figure 44). 
Trastuzumab triggered a shift of timing of the early activation peak from 20-min to 
10-min point. Trastuzumab reduced not only the magnitude of the p-ERK1/2 signal 
but also the number of cycles from four to two. After trastuzumab treatment, only 2 
cycles in the first hour were observed. Interestingly, there was only one cycle in the 
pertuzumab treatment group which was generated in the first 40 min. The magnitude 
of the first cycle was not reduced much. The combination of trastuzumab and 
pertuzumab brought down the level of p-ERK1/2 nearly to the basal line, which was 
consistent with the result from MCF-7 cells. For p-Akt, trastuzumab had no large 
effects on the magnitude before the 90-min point but reduced the level later. 
Noticeably, pertuzumab had a totally different effect on the level of p-Akt in MCF-
7/HER2-18 cells compared to that in MCF-7 cells.  In MCF-7 cells, pertuzumab 
reduced the level of p-Akt almost to background levels (Figure 41), while in MCF-
7/HER2-18 cells it increased the level of p-Akt greatly in the first 40 min after which 
the level of p-Akt came down to a level comparable to that of the HRG alone 
treatment. The increasing effect of pertuzumab was reversed by trastuzumab since 
the level of p-Akt in the combination of trastuzumab and pertuzumab treatment 
group went back to a similar level to that of the HRG alone treatment group in the 
first 40 min and then to a lower level thereafter.  
 
The phosphorylation of HER-2 at Y877 in MCF-7/HER2-18 cells was slightly 
induced by HRG (Figure 45). Addition of trastuzumab or pertuzumab drastically 
increased the phosphorylation.  The combination of trastuzumab and pertuzumab had 





























































Figure 44 Effects of trastuzumab (tras, 100nM), pertuzumab (pert, 100nM) and their 
combination on the time course profiles of p-ERK1/2 and p-Akt expression in MCF-7/HER2-18 
stimulated by 1nM HRG.  ‘M’ denotes protein ladder. Results are indicated as the ratio of the OD of 
































Figure 45 Effects of trastuzumab (tras, 100nM), pertuzumab (pert, 100nM) and their 
combination on the time course profile of p-HER-2 (Y877) in MCF-7/HER2-18 cells stimulated 
by 1nM HRG. The targets were detected with LI-COR infrared imaging system.  Results are 
indicated as the ratio of the OD of p-HER-2 to that of total HER-2. The ratio at 80min in 
HRG+pertuzumab+trastuzumab group was not plotted on the graph since the ratio was decreased 
sharply at 80min to the basal level in 10 min. This was considered as artefact. 
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The levels of p-Akt and p-ERK1/2 expression in BT474 cells stimulated by HRG 
were not affected by trastuzumab (Figure 46) within the 90-min time course, 
consistent with trastuzumab not affecting the growth stimulated by HRG in BT474 



























































Figure 46 Time-course profiles of p-Akt (S473) and p-ERK1/2(T202/Y204) in BT474 cells 
stimulated by 1nM HRG either with or without 100nM trastuzumab (tras). ‘M’ denotes protein 
ladder. Results were indicated as the ratio of the OD of phospho-targets to α-tubulin. 
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 As previously described in this section, after stimulation of MCF-7 cells with HRG 
the level of p-ERK1/2 was enhanced by trastuzumab, while, the phosphorylation of 
the upstream molecule MEK1/2 was reduced. This contrary result was not due to the 
regulation of the interaction between HER-2 and HER-3 as mentioned above.  It is 
possible that the transcriptional feedback plays a role in the regulation of the level of 
p-MEK1/2 and p-ERK1/2. If so, signalling alteration triggered by trastuzumab would 
be blocked by CHX, which blocks de novo protein synthesis. However, the reversal 
of the down-regulation of p-MEK1/2 was not observed (Figure 47). The regulation of 
p-ERK1/2 by trastuzumab was not mediated by transcriptional feedback either since 
the early enhancement of the level of p-ERK1/2 was still present in the presence of 
CHX (Figure 48). Another possibility is that crosstalk with another pathway 
regulates the Raf/MEK/ERK pathway at the node of MEK1/2. It was reported that 
p38 MAPK inhibited MEK1/2 through the activation of protein phosphatases (298). 
However, p-p38 MAPK was activated under the treatment of HRG plus trastuzumab 
at a very late time point (90 min) (Figure 49). It is inconsistent that this late 
activation of p38 MAPK would affect the early decrease of p-MEK1/2. Additionally, 
it was reported that ERK1/2 could exert negative feedback on MEK1 through the 
inhibitory phosphorylation of MEK1 at T292/386, thereby facilitating the 
dephosphorylation of the activating residues of S217/221 (240, 299). It is feasible that 
trastuzumab may cause the dissociation of MEK1 from the MEK1-MEK2 complex 
or enhance the inhibitory phosphorylation of MEK1 at T292. A recently published 
study (300) showed that the knockout or dissociation of MEK1 from MEK1-MEK2 
heterodimer could enhance the phosphorylation of MEK2 at S222/226 and ERK1/2 at 
T202/Y204 under the stimulation of growth factors. Compared to the wild type MEK1, 
mutant MEK1 with non-phosphorylatable T292A increased the level and duration of 































Figure 47 Time course profile of p-MEK1/2 (S217/221) in MCF-7 cells treated with HRG plus 
trastuzumab or CHX or their combination. HRG, trastuzumab and CHX were used at 1nM, 100nM 
and 10µM respectively. ‘M’ denotes protein ladder. The results are presented as the ratio of OD of p-



































Figure 48 Time course profile of p-ERK1/2 (T202/Y204) in MCF-7 cells treated with HRG plus 
trastuzumab or CHX or their combination. HRG, Trastuzumab and CHX were used at 1nM, 
100nM and 10µM respectively. ‘M’ denotes protein ladder. The results are presented as the ratio of 





Figure 49 The activation of p38 MAPK in MCF-7 treated with HRG or HRG plus trastuzumab.  
p38 MAPK was activated when cells were treated with HRG plus trastuzumab for 90 min. HRG was 
used at 1nM. Trastuzumab was used at 100nM. 
4.2.4 Discussion 
 
Although several mechanisms of action of trastuzumab on breast cancers have been 
proposed (Introduction section 1.7.1), it has not been clearly elucidated why 
trastuzumab is only effective in HER-2 over-expressing metastatic breast cancers 
rather than in HER-2 low expressing breast cancers. Badache et al (301) in their 
review explained that trastuzumab could block the signalling mediated by HER-2 
homodimers in HER-2 over-expressing cells but could not block the signalling 
mediated by heterodimers. In HER-2 over-expressing cells, the HER-2 homodimer 
could form spontaneously but could not in HER-2 low expressing cells. HER-2 over-
expression is insufficient for the selection criteria of trastuzumab responding patients 
since only 30% of patients with HER-2 over-expression respond to trastuzumab 
monotherapy (302) and patients who were initially responsive to trastuzumab may 
develop resistance within one year (142). Yuste et al (303) and de Alava et al (304) 
demonstrated that trastuzumab inhibited the proliferation of HER-2 normally 
expressing MCF-7 cells which were transfected with membrane bound neuregulin in 
vitro and inhibited the growth of xenografts in vivo. In their studies, however, 
trastuzumab didn’t affect the proliferation of wild type MCF-7 cells and HER-2 
over-expressing MCF-7 cells, which was in line with my findings. In their studies, 
transmembrane neuregulin conferred sensitivity of MCF-7 cells to trastuzumab. In 
my study, trastuzumab only slowed down the proliferation rate of MCF-7 and MCF-
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7/HER2-18 cells stimulated by 1nM of HRG, but trastuzumab had no effect on final 
cell numbers. However, trastuzumab inhibited the proliferation of both cell lines as 
well as BT474 cell line driven by 1nM EGF. It is therefore possible that trastuzumab 
inhibits tumour growth driven by EGF. These observations have clinical implications 
for where trastuzumab might be effective.  
 
Since EGF binds HER-1 and HRG binds HER-3, trastuzumab’s differential effects 
on growth could be explained by observations reported by Wehrman et al (115). 
They suggested that trastuzumab effectively inhibited the interaction of HER-2 and 
HER-1 but did not interfere with the interaction of HER-2 and HER-3. Treatment of 
cells expressing HER-1 and HER-2 with trastuzumab will induce more HER-1 
homo-dimerisation and subsequently more internalization of HER-1. Diermeier et al 
(305) also showed that the growth inhibitory effect of trastuzumab was considerably 
modulated by HER-1 co-expression and subsequently the dimerisation of HER-1-
HER-2 in HER-2 over-expressing cell lines. However, their study did not explain 
why trastuzumab just slowed down the growth rate under the stimulation of HRG.  
 
Trastuzumab reduced the growth rate of both MCF-7 and MCF-7/HER2-18 cells 
stimulated by 1nM HRG, but the signalling induced by the intervention was different. 
The activation of ERK1/2 in MCF-7 cells was altered from the sustained to the 
transient by trastuzumab, while in MCF-7/HER2-18 cells trastuzumab did not change 
the duration but reduced the magnitude. Activation of Akt was reduced by 
trastuzumab in MCF-7 cells as well as in MCF-7/HER2-18 cells after treatment for 
90 min. When comparing the time course profiles of p-ERK1/2 and p-Akt expression 
in MCF-7 cells induced by HRG+LY294002 (Figure 29) and HRG+trastuzumab 
(Figure 40 & 41), I observed a marked similarity of profiles caused by 5 µM 
LY294002 and 100 nM trastuzumab. Both drugs resulted in downstream inhibition 
of the activity of Akt over the whole time course and enhanced the activity of 
ERK1/2. LY294002 acts through inhibiting the kinase activity of PI3K, thereby 
inhibiting activation of Akt which inhibits the Raf/MEK1&2/ERK1&2 through 
phosphorylating Raf-1 at S259 as shown in Figure 50. It means that the inhibition of 
p-Akt by LY294002 can enhance the level of p-ERK1/2. Here, it is speculated that 
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trastuzumab may act on the signalling in MCF-7 cells in the same way as LY294002 
does, suggesting that trastuzumab and LY294002 may have similar effects on cell 
growth. This hypothesis can be supported by the observation in the study of Zheng et 
al (306) that Akt inhibition by LY294002 could decrease cell growth rate of MCF-7 
cells. These observations strongly argue that the inhibition of Akt plays a key role in 
trastuzumab’s anti-proliferation effects. It is feasible that in MCF-7 cells, inhibition 
of EGF-triggering proliferation by trastuzumab is due to the inhibition of Akt and 
decreased HRG-triggering growth rate of MCF-7 and MCF-7/HER2-18 cells is also 
due to the inhibition of Akt. It was reported by other investigators (117) that the 
inhibition of Akt at least partly resulted in the changes of cell cycle and apoptosis 
regulatory molecules and the deactivation of PI3K and Akt was required for the anti-
tumour effect of trastuzumab.  
 
Figure 50 Schematic presentation of the crosstalk between PI3K/Akt and Raf/MEK/ERK 
pathways. 
 
Studies presented in this thesis demonstrated that HER-2 phosphorylation alone is 
insufficient to drive cell growth. The slight phosphorylation induction of HER-2 by 
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HRG in MCF-7/HER2-18 cells was not due to the refractoriness of HER-2 to be 
phosphorylated, as was indicated by the dramatic induction by trastuzumab, 
pertuzumab and their combination. It demonstrated the high resting phosphorylation 
since over-expressed HER-2 was constitutively phosphorylated in breast cancer cells 
and tumours (307, 308), which may be induced by HER-2 homodimerisation. This 
observation supported the previous investigation reported by Yuste et al (303). In 
their study, the level of resting phospho-tyrosine at HER-2 in HER-2 over-expressing 
MCF-7 cells was very high and was not altered by the stimulation of neuregulin 
either. Although phosphorylation of HER-2 was slightly induced by HRG, the 
propagation of MCF-7/HER2-18 cells was increased 3.5 fold by the stimulation of 
1nM HRG for 4 days. Moreover, the phosphorylation of HER-2 in MCF-7/HER2-18 
cells was significantly up-regulated by trastuzumab (which was also observed by 
Yuste et al (303)), pertuzumab and their combination while cell growth was slowed 
down by trastuzumab and blocked by pertuzumab and their combination. Gijsen et al 
(309) demonstrated that the up-regulation of HER-2 phosphorylation by trastuzumab 
resulted from a feedback production of HER ligands which activated HER-1, HER-3 
and HER-4 which in turn dimerised with HER-2. These observations suggested that 
the phosphorylation of HER-2 was not sufficient to drive cell growth. Since HRG is 
the specific ligand for HER-3, upon the stimulation of HRG, HER-3 would be 
phosphorylated and HER-2 required HER-3 to drive breast cancer cells to proliferate 
(310). Although the phosphorylation of HER-2 was not induced by HRG in HER-2 
over-expressing MCF-7 cells, the phosphorylation of HER-3 was induced to a very 
high extent (303). The phosphorylation of HER-3 was inhibited by trastuzumab 
while the phosphorylation of HER-2 was increased (303). Activated HER-3 has six 
potential docking sites for SH2 domain of p85 subunit (the regulatory domain of 
PI3K) (89) and one proline-rich sequence forming consensus binding sites for the 
SH3 domain (311) and has potent activity mediating the PI3K/Akt pathway (312). In 
my study, although phosphorylation of HER-3 was not assayed, the activity of Akt in 
MCF-7/HER2-18 cells stimulated by HRG was slightly affected by trastuzumab 
before the 90-min point and then was reduced during the rest of the 2h time course.  
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Trastuzumab did not affect the level of p-Akt and p-ERK1/2 in BT474 cells 
stimulated by HRG, supporting the observation that trastuzumab does not affect the 
growth driven by HRG. Controversially, another reported study (305) demonstrated 
significant proliferation inhibition by trastuzumab in BT474 stimulated by HRG. 
However, consistent with the observation in MCF-7 cells, cell growth of BT474 cells 
driven by EGF was inhibited to the level comparable to that of control.  It suggested 
again that trastuzumab may be more potent on the tumours driven by HER-1-binding 
ligands.   
 
Since pertuzumab can block dimerisation with HER-2 and consequently inhibit 
signalling, the phosphorylation of Akt and/or ERK1/2 in MCF-7 was inhibited. 
Under the stimulation of HRG, both p-Akt and p-ERK1/2 in MCF-7 were reduced by 
pertuzumab to the basal line, suggesting that the association of HER-2 with HER-3 
was vital for the induction for Akt and ERK1/2 pathways. Under the stimulation of 
EGF, only p-Akt was inhibited and p-ERK1/2 was not affected. Since HER-3 is 
deficient in kinase activity, pertuzumab is more potent in inhibiting HRG-mediated 
HER-3-HER-2 signalling than EGF-mediated HER-1-HER-2 signalling. The 
homodimerisation of HER-1 would increase when the HER-1-HER-2 complex was 
blocked by pertuzumab. These may explain why the levels of p-Akt and p-ERK1/2 
stimulated by HRG in MCF-7 were inhibited to background level while the level of 
p-Akt was slightly reduced by pertuzumab and the level of p-ERK1/2 was not altered. 
Distinct from that in MCF-7 cells, the level of p-ERK1/2 was slightly reduced by 
pertuzumab for the first 50 min within the 2 h time course and then reduced to the 
background level over the duration of the time course in MCF-7/HER2-18 cells 
stimulated by HRG. It suggested that the signalling in MCF-7/HER2-18 cells was not 
blocked as effectively as in MCF-7 cells, which may be due to the over-expression of 
HER-2 and 100nM of pertuzumab was not sufficient to inhibit the signalling to the 
basal level. On the contrary, the level of p-Akt in MCF-7/HER2-18 cells stimulated 
by HRG was increased by pertuzumab for the first 50 min within the 2h time course 
and then went down to the similar level as that in HRG alone treatment group during 
the rest of the time course, suggesting that the interaction of HER-3-HER-2 was 
enhanced by pertuzumab since HER-3 was a potent mediator of PI3K/Akt pathway 
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as mentioned above. The enhancement of HER-3-HER-2 interaction was possibly 
due to the blockade of spontaneous homodimerisation of HER-2, which increased the 
chance of HER-3 to associate with free HER-2. The enhancement of HER-3-HER-2 
interaction can also explain p-ERK1/2 profile.  
 
When trastuzumab and pertuzumab were used in combination, trastuzumab and 
pertuzumab bind to the different epitopes at HER-2 and do not interfere with each 
other for binding when used together (157).  The combination reduced the number of 
EGF-stimulated BT474 cells to fewer than the untreated group (control group). The 
combination led to continuous reduction of cell numbers during the 7-day time 
course, implying cell death. Nahta et al (288) demonstrated apoptosis induced by the 
combination in BT474 cells. They also observed that the inhibition of proliferation of 
BT474 cells either by trastuzumab or pertuzumab was mediated by cell arrest rather 
than by apoptosis. It was very interesting that the combined use of two cytostatic 
drugs had synergistic cytotoxic effects. However, the synergy was not observed in 
HRG-stimulated BT474 cells, suggesting the HERx-HER-2 complex dependent 
manner of the synergy in BT474 cells. The combined use of trastuzumab and 
pertuzumab conferred a promising example of effective multiplex targeted therapies. 
However, the molecular mechanism of synergy has not been elucidated.  Although 
there are some preclinical and clinical studies about the anti-tumour activity of 
pertuzumab and the combined use with trastuzumab, there are very few published 
papers about the effects of pertuzumab and the combination on signalling in breast 
cancer cell lines. Further investigations of effects on signalling would uncover the 
biochemical mechanisms of action which in turn help researchers to develop 
therapeutic regimes to overcome drug resistance or effectively combine their use 
with other drugs or therapies.  
 
In this study, variation was observed between two independent experiments 
measuring the same response of p-ERK1/2 and p-MEK1/2 to HRG stimulation in the 
presence or absence of trastuzumab. Variations may come from the technical 
replicates since in my study Western blotting on a different day measuring the same 
samples resulted in some degree of variation.  Variations can be reduced if technical 
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replicates of one sample can be assigned on one blot and the results are shown as 
mean value with SD. Variation may also come from the biological replicates. Cells 
for the different experiments may have variations in viability so that the responses to 
HRG stimulation are different. Variation in cell viability can be due to over-digestion 
with trypsin/EDTA, over-confluence before sub-culturing and variable confluence at 
the time of HRG treatment. Although there are variations in terms of signalling 
response to trastuzumab between Figure 40 and 48, Figure 41 and 47, consistent 
early increase of p-ERK1/2 and some degree of inhibition of p-MEK1/2 by 
trastuzumab are observed in all individual experiments.  
 
Generally, conclusions have been drawn from this study together with others’ 
previous work. 
1)  Growth inhibitory effects of trastuzumab are ligand dependent, which 
means trastuzumab differentially interferes with differing HERx-HER-2 
interactions. 
2) Over-expression of HER-2 might be insufficient to be an indicator of the 
application of trastuzumab. The clinical use of trastuzumab might be 
expanded for example to EGF-driven low HER-2 expressing tumours. 
3) Pertuzumab works effectively on low or high HER-2 expression cells line 
regardless of the types of ligands. 
4) Trastuzumab and pertuzumab have synergistic anti-growth activity which 
is due to apoptosis in BT474 cells.  
5) HER-3 and PI3K/Akt pathway plays a critical role in mediating cell 
growth and trastuzumab’s anti-proliferation activity. 
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4.3  Tumour suppressor PTPN13 in breast cancer  
4.3.1 PTPN13 as a candidate transcriptional regulator of the 
oscillation 
 
PTPN13 (protein tyrosine phosphatase, non-receptor type 13) has been proposed as a 
tumour suppressor in breast cancers through the observation of epigenetic regulation 
by promoter hyper-methylation (313, 314). Expression levels of the protein are lower 
in breast cancers than in benign breast tumours (315) and this protein is a pro-
apoptotic tyrosine phosphatase in breast cancers (316). PTPN13 inhibition drastically 
increased tumour growth in athymic mice and cell proliferation as well as cell 
invasion. It regulated breast cancer aggressiveness through being up-regulated by 
tamoxifen treatment and apoptosis was triggered by PTPN13 in breast cancer cells 
through inhibition of the PI3K/Akt pathway after treatment with tamoxifen (317). 
Tamoxifen-induced apoptosis was abrogated in stable antisense PTPN13 
transfectants. The time-dependent expression of PTPN13 in MCF-7 cells specifically 
dephosphorylated IRS-1 (Insulin Receptor Substrate-1) and abolished the survival 
action of insulin-like growth factor through reducing the activity of the IRS-
1/PI3K/Akt pathway (317, 318).  
 
 Initially, before screening candidate proteins which may transcriptionally modulate 
the oscillation in a gene expression assay, I found that PTPN13 was possibly 
involved in the modulation from a search of the literature. Zhu et al (319) 
demonstrated negative regulation of HER-2-mediated signalling pathways by 
PTPN13. They screened the phosphatases which may affect the phosphorylation of 
HER-2 with a phosphatase siRNA library. Among 193 phosphatases in the library, 
the knockdown of only 7 phosphatases increased dramatically the phosphorylation of 
HER-2 after growth factor stimulation. By over-expressing these 7 phosphatases in 
cells, they observed that over-expression of only PTPN13 and PTPN14 decreased the 
phosphorylation of HER-2. The phosphatase activity could only be detected in 
PTPN13. Moreover, increase of the phosphorylation of ERK1/2 and Akt by the 
knockdown of PTPN13 started immediately after stimulation for 5 min with EGF in 
HeLa cells. This observation was similar to the effect of HRG/EGF+CHX treatment 
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in MCF-7 cells in my study. The increase of phosphorylation of ERK1/2 and Akt by 
treatment of CHX started approximately 10 min after HRG or EGF stimulation. This 
similarity made me consider that PTPN13 might be a transcriptional feedback 
regulator of oscillation. Therefore, I knocked down PTPN13 with siRNA in MCF-7 
cells within a time course experiment. The knockdown resulted in the death of a 
great number of cells with control siRNA. The number of cells adherent to the plate 
in the control siRNA group was much less than that in the PTPN13 siRNA group. 
The cell number in the PTPN13 siRNA group was less than in the non-transfection 
group. This suggested that the transfection reagent was toxic to MCF-7 cells. So, I 
incubated MCF-7 cells with transfection reagent with the RNAi tranfection protocol. 
No major difference in cell numbers adherent to the plate compared with the non-
transfection group was observed. Since the confluence of the cells was dramatically 
different between PTPN13 siRNA group and control siRNA group, I did not carry on 
the time course experiment. However, an alternative way to find out whether 
PTPN13 was the transcriptional regulator of the oscillation was to seek whether this 
gene was modulated in the gene expression assay. PTPN13 mRNA expression was 
not induced by 1nM of HRG (p>0.05, 40’HRG vs control, student’s t-test), 
suggesting PTPN13 was not a transcriptional feedback regulator of the oscillation 


















Figure 51 mRNA expression level of PTPN13 in MCF-7 stimulated by 1nM of HRG for 5, 10, 20 
and 40 min. The grey line denotes the control and the blue line denotes the HRG stimulation group.  
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4.3.2 The expression level of PTPN13 was correlated with PIK3CA 
mutation 
 
Bompard et al (317) demonstrated that PTPN13 was a tumour suppressor in breast 
cancer and could trigger apoptosis of breast cancer cells. In my study I observed that 
HER-2 over-expressing MCF-7 cells had a much lower expression of PTPN13 than 
parental MCF-7 (Figure 52). The expression level of PTPN13 was dramatically 
reduced by treatment with 0.01nM HRG, 100nM trastuzumab and 
HRG+trastuzumab for 3 days in MCF-7 cells. In contrast, the expression level in 
MCF-7/HER2-18 was not altered by HRG, but increased by trastuzumab and 
HRG+trastuzumab (Figure 52). The differential changes of the expression level of 
PTPN13 by the treatment of trastuzumab between MCF-7/HER2-18 were associated 
with differential growth. Trastuzumab slowed down the growth rate of MCF-7 
stimulated by 0.01nM HRG and blocked the growth of MCF-7/HER2-18 stimulated 
by 0.01nM HRG (Figure 53). Additionally, in MCF-7/HER2-18 cells trastuzumab 
alone inhibited the growth compared to control, but in MCF-7 cells trastuzumab 
alone did not cause significant difference of the growth. These observations 
suggested that the increased level of PTPN13 was associated with the stronger 
growth inhibition. I hypothesized that the high level of PTPN13 in breast tumours 
was an indicator of favourable outcomes for breast cancer patients.  
 
 
Figure 52 Differential expression level of PTPN13 in MCF-7 and MCF-7/HER2-18. Cells were 
treated with 0.01nM HRG, 100nM trastuzumab and their combination for 3 days before being 
subjected to Western Blot analysis. ‘Tras’ is a short form for trastuzumab.  ‘H+T’ denotes the 
combination of 0.01nM HRG and 100nM trastuzumab. ‘Positive control’ was the whole HEK293 cell 











































Figure 53 Time course growth assay of MCF-7 and MCF-7/HER2-18 cells.  Cells were grown in 
96-well plates and treated with 0.01nM HRG, 100nM trastuzumab and their combination for 1, 2, 3, 4, 
5, 6 and 7 days respectively. SRB assay was applied to measure the relative cell numbers. The results 
are shown as the average of OD540 from 6 wells ±SD. 
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To test this possibility, I analyzed the expression level of PTPN13 by 
immunofluorescence in a cohort of 120 trastuzumab-treated tumours from metastatic 
breast cancer patients. Levels of PTPN13 expression did not associate directly with 
overall survival, HER-2 expression level or histological grade (Table 6). However I 
observed a correlation between the expression levels of PTPN13 and PIK3CA 
mutation (Spearman correlation coefficient -0.254, p value 0.005). The tumours 
harbouring oncogenic PIK3CA mutation had lower PTPN13 expression level 
compared to those without mutations (p<0.01, Mann-Whitney U test, Figure 54). 
Although the correlation of the protein level of PTPN13 with overall survival was 
not observed in this study, Revillion et al (320) suggested by analysing the mRNA 
levels from breast tumours that the expression of PTPN13 was an independent 
prognostic marker for overall survival in breast cancers. This controversy may result 
from the restricted subgroup of the tumours (trastuzumab-treated, metastatic, HER-2 
over-expressing) in my study. 
 
Table 6 Correlation analysis between PTPN13 expression level and other clinical parameters. 
  
PIK3CA Mutation 












-0.254** -0.012 0.007 0.057
PTPN13 
Expression 
p value 0.005 0.899 0.936 0.539
2-tailed Spearman correlation test was used. The significant correlation is defined as p value less than 
0.05. ** Correlation is significant. 
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Figure 54 The correlation of PTPN13 expression level with PIK3CA mutation status in 
Trastuzumab-treated tumours from 120 metastatic breast cancer patients. Three sections from 
each tumour were analysed for the expression level of PTPN13 by immunofluorescence with AQUA 
imaging system.  The y-axis value is the mean of the three AQUA scores from each tumour.  The 
Black bars represent the individual medians from the two groups. Statistical significance was analyzed 
with Mann-Whitney U-test (p=0.006).  
4.3.3 Discussion 
 
The protein tyrosine phosphatase (PTP) super family functions co-ordinately with 
protein tyrosine kinases to regulate the amplification and duration of signalling 
pathways which are the basis for a wide range of fundamental physiological 
processes (313). In tumours this coordination is disrupted through for example the 
oncogenic mutation of kinases or suppression of phosphatases. Phosphatases often 
act as components of feedback loops in signalling pathways. For example, as 
mentioned previously DUSP family members were induced by growth factors and 
dephosphorylated p-ERK1/2 as part of a transcriptional negative feedback loop. 
Although PTPN13 was not observed to be involved in the transcriptional regulation 
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of the oscillation, it is possible that the existing PTPN13 protein in MCF-7 cells 
modulates the oscillation of p-ERK1/2 and p-Akt by dephosphorylating p-HER-2 
and reducing the activity of PI3K/Akt pathway.   
 
I observed in this study that the expression level of PTPN13 in trastuzumab-treated 
breast tumours was correlated with PIK3CA mutation status. The tumours 
harbouring the oncogenic mutation had lower PTPN13 expression, suggesting the 
high level of PTPN13 can protect cells from oncogenic PIK3CA mutation. The 
oncogenic PIK3CA mutations which caused the constitutive activation of PI3k/Akt 
pathway occurred in 18%-40% breast tumours (321). The study of Miron et al (322) 
suggested that the somatic PIK3CA mutation was an early event in breast cancer and 
played roles in cancer initiation rather than progression. Kataoka et al (145) 
demonstrated the association of the gain-of-function mutation of PIK3CA and the 
resistance to trastuzumab. Therefore, high level of PTPN13 may protect tissues from 




In this study, I have described the oscillation of both p-ERK1/2 and p-Akt expression 
after EGF and HRG activation in breast cancer cells. While oscillatory activation of 
p-ERK1/2 had been predicted by Kholodenko et al (235, 250-252), it required 
experimental validation, and I was able to demonstrate that not only could HRG as 
well as EGF produce p-ERK1/2 oscillation but another (Akt) pathway could also 
demonstrate this phenomenon.  The presence of oscillation indicates the involvement 
of feedback signalling in ERK1/2 and Akt pathways (Figures 55 and 56). Based on 
the findings within this thesis, a scheme which demonstrates the oscillation-
regulating transcriptional feedback loops, pathway interaction and impact of 
pertuzumab and trastuzumab on signalling is presented in Figure 55. Candidate 
feedback loops modulate dynamics of HER-mediated signalling primarily from three 
layers: enhancement of receptor activation by autocrine growth factors, positive or 




Figure 55 Scheme of HER-mediated signalling including crosstalk and transcriptional feedback 
loops based on the findings in this thesis. Ligand-bound HER receptors dimerise with HER-2 and 
activate the autophosphorylation of receptors. The phosphorylated residues on receptors provide 
docking sites for signalling molecules. Activated receptors mediate Ras/Raf/MEK/ERK and PI3K/Akt 
pathways. Effector molecules of the two pathways activate transcription factors (TF) that promote 
gene expression including genes functioning as feedback loops of the two pathways. Among the 
feedback loops, autocrine growth factors enhance the activation of HER receptors. DUSPs inhibit the 
phosphorylation of ERK1/2. Early positive and late negative feedback loops to MEK1/2 from 
unknown genes may be present. SPRED2 inhibits phosphorylation of Raf and inactivates Raf activity. 
PP1 can dephosphorylate Akt. AKAP9, PPP1R3C and PPP1R15A regulate the activity of PP1, so 
these three genes indirectly regulate Akt as negative transcriptional feedback loops. Gene expression 
of AKAP9 and PPP1R3C is down-regulated by HRG, but that of PPP11R15A is up-regulated.  
Ras/Raf/MEK/ERK and PI3K/Akt pathways interact through the inhibitory phosphorylation of Raf-1 
at S259 from Akt. PI3K inhibitor LY294002 blocks (red cross) activation of Akt, therefore blocks (red 
cross) downstream gene expression and crosstalk with ERK1/2 pathway. The effects of LY294002 on 
signalling might be mimicked by trastuzumab. Pertuzumab binds the dimerisation arm of HER-2 and 
therefore blocks downstream signalling while trastuzumab binds the extracellular juxtamembrane 
domain of HER-2. 
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Referring to the experimental data presented in this thesis and published studies, an 
Ordinary Differential Equation (ODE)-based mathematical model established by Dr. 
Alexey Goltsov from SIMBIOS Centre, University of Abertay, Dundee in Scotland 
predicted that the negative feedback loop from p-ERK1/2 to SOS, negative feedback 
loops from DUSPs to p-ERK1/2, crosstalk with Akt pathway as well as the over-
expression of HER-2 as a feedforward could modulate oscillations of p-ERK1/2. 
Simulations with HER-2 over-expression and DUSP expression generated by Dr. 
Goltsov fit the experimental data well (Figures 56 and 57). Negative feedback loops 
from Akt to casein kinase 2 (CK2)/glycogen synthase kinase 3 (GSK3) were also 




Figure 56 Scheme of mathematical model. Negative feedback loops from p-ERK1/2 to SOS, from 
DUSPs to p-ERK1/2 and crosstalk with Akt pathway as well HER-2 over-expression as feedforward 
were predicted to modulate oscillations of p-ERK1/2. Negative feedback loops from Akt to 




Figure 57 Simulations of the model. In the upper simulation figure, red curve is p-ERK1/2 time 
course profile with high HER-2 expression and blue curve is that with low HER-2 expression. In the 
lower simulation figure, red curve is p-ERK1/2 time course profile with no DUSP expression and blue 
curve is that with DUSP expression. Green curve is DUSP mRNA expression time course profile and 
orange curve is DUSP protein expression time course profile. Simulations of the model with/without 
HER-2 over-expression fitted well the experimental data that HER-2 over-expression could enhance 
oscillations. Simulations with/without DUSP gene expression also fitted well the experimental data, 
showing the modulation of p-ERK1/2 oscillations by DUSPs (kindly provided by Dr. Goltsov).  
 
Significance of signalling oscillations 
 
Oscillation is a particular form of dynamics and is a common biological phenomenon 
which has been shown to be significant in somite segmentation, cell cycle, and 
circadian control. Oscillations of p-ERK1/2 and p-Akt were observed in this study. 
The oscillation of p-Akt is a novel finding. In this study, oscillations were 
demonstrated as the outcome of the interaction of positive feedback/feedforward and 
negative feedback loops. Oscillations may reflect the defect of negative feedback 
loops in timing, strength and duration. In turn, this may indicate a defect in signalling 
control within breast cancer cells.  
High HER2
Low HER2
p-ERK, no gene feedback


















Components of the model / testing the model 
 
The oscillation model established in collaboration with Dr. Alexey Goltsov is based 
on the previously published kinetic model of Raf/MEK/ERK and PI3K/PTEN/Akt 
signalling described by Faratian, Goltsov et al (323) which described the response 
kinetics of the signalling network to HRG-induced HER receptor activation and to 
pertuzumab on ERK1/2 and Akt activation in human carcinoma cell lines. Faratian 
and Goltsov’s model took into account the following feedback loops and cross-talk 
in HER signalling: negative feedback through inhibition of Raf -1 activation by p-
ERK1/2 phosphorylating SOS and cross-talk due to inhibition of Raf -1 activity by 
its phosphorylation by p-Akt at S259. In addition to the above feedback loops and 
crosstalk, we also considered in the model gene regulation feedback due to p-
ERK1/2-induced expression of DUSPs which in turn dephosphorylate p-ERK1/2. 
The model described phosphorylation of transcription factors (TF) by p-ERK1/2, 
binding of TF with DNA, transcription of DUSPs mRNA, and translation of DUSPs. 
The results of the modelling showed that modulation of these feedback loops by 
CHX, pertuzumab, and HER-2 expression levels significantly influenced the 
induction of p-ERK1/2 oscillation. Apart from DUSPs, possible genes that might 
regulate the oscillations such as regulatory subunits of PP1, SPRED2 and related 
transcription factors have been identified based on expression analysis and other 
published studies. Further work is needed to knockdown or over-expresses each gene 
and their combination to find out which genes modulate oscillations. Once 
oscillation-regulated genes are confirmed, it may be feasible to modulate oscillations 
transcriptionally through controlling gene product expression levels, timing or 
duration. The model-predicted feedback loops would also need further confirmation. 
For example, in order to test the existence of negative feedback loop from p-ERK1/2 
to SOS, the four ERK1/2 phosphorylating sites in SOS (233) can be replaced with 
alanine residues. It will also be important to elucidate how oscillations are regulated 
spatially since timing together with location dynamics plays critical roles in 
determining cellular outcomes. Here, the developed RPPA method is an option to 
screen the feedback loops or molecules regulating oscillations in a high throughput 
manner. Large volumes of data on signalling molecule time course profiles can be 
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produced using this technique. Comparing the time course profiles under different 
treatments and through development of the mathematical model, it should be feasible 
to more completely define the pathways and mechanisms involved in the oscillation.  
 
Impact of inhibitors and differential effects 
 
Trastuzumab, pertuzumab and their combination altered the dynamics of either or 
both of the pathways and subsequently the cell growth in different cell lines. The 
oscillation pattern of p-ERK1/2 elicited by HRG in MCF-7 cells was altered from the 
sustained to the transient, but the amplitude was increased.  Further experiments are 
required to elucidate how trastuzumab changed the oscillation pattern although I 
have suggested it is not through a transcriptional manner and trastuzumab may 
mimic the mechanism of action of LY294002. Pertuzumab inhibited signalling 
effectively in MCF-7 cells and pertuzumab and trastuzumab synergistically inhibited 
cellular growth driven by HRG. In the future the effectiveness of combined use of 
trastuzumab and pertuzumab can be tested in HRG-driven HER-2 ‘normally’ 
expressing xenografts in mice. This work might expand the clinical use of 
trastuzumab not only in HER-2 over-expressing metastatic breast cancers but also in 
HER-2 ‘normally’ expressing breast cancers and support the concept of multiplex 
therapy. As well, pertuzumab is a good option to bypass trastuzumab resistance. 
Further experiments are required to work out what resulted in the differential effects 
of pertuzumab on Akt signalling between MCF-7 cells and MCF-7/HER2-18 cells. 
As expected, pertuzumab inhibited ERK1/2 signalling in both cell lines stimulated by 
HRG. However, pertuzumab augmented Akt signalling in MCF-7/HER2-18 cells but 
inhibited signalling in MCF-7 cells. It is possible that this difference is caused by 
difference of HER-2/HER-3 molecule number ratio in the two cell lines and the 
concentration of pertuzumab used in this thesis primarily interferes with HER-2 
homodimerization, so increases the chance of HER-3 interacting with HER-2 in 
MCF-7/HER2-18 cells but this concentration is high enough to block HER-2/HER-3 
interaction in MCF-7 cells. In the future, increased concentrations of pertuzumab will 
be used in MCF-7/HER2-18 cells stimulated by HRG in order to block both HER-2 
homodimerisation and HER-2/HER-3 interaction. HER-2 homo- and hetero-
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interaction with HER-3 will be analysed. In addition, the expression levels of p-Akt 
will be analyzed under different concentrations of pertuzumab. It is expected that the 
higher concentrations would interfere with HER-2/HER-3 interaction and inhibit Akt 
signalling. The significance of this is that an optimal dose of pertuzumab might differ 
in breast cancers with varying HER-2/HER-3 ratio. RPPA and ICW both can be used 
to assay how the different concentrations of pertuzumab affect Akt signalling. 
 
Ongoing and future modelling 
 
The current model has considered a few factors that might modulate p-ERK1/2 
oscillation. More work is needed to model p-Akt oscillation. As mentioned in Figure 
55, besides the regulation of ERK1/2 by transcriptional feedback loops from DUSPs, 
MEK1/2 and Raf can also be regulated transcriptionally. Activation of HER 
receptors by growth factors can be enhanced by autocrine growth factors as positive 
feedback loops. Early transcription factors regulate the production of feedback loops 
that modulate HER-mediated signalling. Apart from the crosstalk with 
Raf/MEK/ERK pathway, PP1 might also regulate oscillation of p-Akt, so it is 
reasonable to consider in the model the gene expression of AKAP9, PPP1R3C and 
PPP1R15A which are the regulatory subunits of PP1. These factors should be taken 
into account in future modelling.  
In summary, signalling oscillations demonstrate an interruption of tight feedback 
controls that are vital for cell growth. Oscillations may indicate the importance of 
feedback loops in controlling outgrowth of cancer cells. The impact of trastuzumab, 
pertuzumab and the combination on signalling and cell growth shows the promise of 
multiplex therapies and supports their value in more effective tumour control. 
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Gene selection criteria: the whole gene list of the array was sorted by fold change (highest to lowest, 20’HRG vs control). The top 100 genes with p value less than 
0.05 were selected. 
 
After putting these 100 genes into DAVID Bioinformatics Resources 6.7 for functional annotation clustering, 9 genes were found to be involved in MAPK signalling 
pathway within KEGG_PATHWAY database. 
Gene Name Description  
DDIT3  DNA-damage-inducible transcript 3   
DUSP1  dual specificity phosphatase 1   
DUSP2  dual specificity phosphatase 2  
DUSP4  dual specificity phosphatase 4  
DUSP5  dual specificity phosphatase 5   
JUN  jun oncogene  
SRF  serum response factor (c-fos serum response element-binding transcription factor)   
FOS  v-fos FBJ murine osteosarcoma viral oncogene homolog   
MYC  v-myc myelocytomatosis viral oncogene homolog (avian) 
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Table S2 Genes proposed by Takeshi Nagashima et al (91) which might regulate HER signalling 
dynamics through positive and negative feedback loops. 
genes description 
AKAP9 A kinase (PRKA) anchor protein (yotiao) 9 
AREG amphiregulin 
ATF3 activating transcription factor 3 
BHLHB2 basic helix-loop-helix domain containing, class B, 2 
DUSP1 dual specificity phosphatase 1 
DUSP10 dual specificity phosphatase 10 
DUSP2 dual specificity phosphatase 2 
DUSP4 dual specificity phosphatase 4 
DUSP5 dual specificity phosphatase 5 
DUSP8 dual specificity phosphatase 8 
EGR 
family 
Early growth response 
FOS v-fos FBJ murine osteosarcoma viral oncogene homolog 
FOXA1 forkhead box A1 
HBEGF heparin-binding EGF-like growth factor 
JUN jun oncogene 
KLF family Kruppel-like factor 
MAP2K3 mitogen-activated protein kinase kinase 3 
MAP3K14 mitogen-activated protein kinase kinase kinase 14 
MAP3K3 mitogen-activated protein kinase kinase kinase 3 
MYC v-myc myelocytomatosis viral oncogene homolog 
(avian) 
NFIL3 nuclear factor, interleukin 3 regulated 
NR4A 
family 
nuclear receptor subfamily 4, group A 
PIP5K1A phosphatidylinositol-4-phosphate 5-kinase, type I, alpha 
PPP1R15A protein phosphatase 1, regulatory  subunit 15A 
PPP1R3C protein phosphatase 1, regulatory  subunit 3C 
PPP1R3D protein phosphatase 1, regulatory subunit 3D 
SOX2 SRY (sex determining region Y)-box 2 
SPRED2 sprouty-related, EVH1 domain containing 2 
TGFB2 transforming growth factor, beta 2 
TOB2 transducer of ERBB2, 2 
VEGF vascular endothelial growth factor 
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Table S1 is overlapped with table S2 in Genes marked in blue ink. 19 out of 100 genes in table S1 are 
found in table S2, which means at least 19% of the genes in this gene candidate pool are involved in 
positive or negative feedback regulation of HER signalling dynamics. 
 
Table S3 In addition to the overlapped genes, 6 other genes in table S2 which were induced 
significantly (p<0.05, 20’HRG vs control, Student’s t-test) are observed. The remaining genes are not 
induced significantly by HRG.  











Figure S1 Time course profiles of individual candidate genes. MCF-7 cells were stimulated by 1 
nM HRG for 5, 10, 20 and 40 min respectively. Controls for 0 and 40 min were included. Grey lines 
















































































































































































































































































































































































































































































































Table S4 300 most induced genes by HRG in MCF-7 cells (p<0.05, 40’HRG vs control, Student’s t-test fold change ranging from 1.218 to 75.956). 
Gene Change fold Gene Change fold Gene Change fold Gene Change fold 
ACTB 1.62669 C14orf4 1.38474 CNN2 1.73161 EIF1 1.72906 
ACTG1 1.83804 C14orf43 1.49651 CNTD2 1.27937 EIF5 1.39554 
ACTG2 4.58910 C17orf91 1.82824 COL1A1 1.24696 ELF3 1.21981 
ADM 2.19308 C19orf6 1.54798 COQ10B 1.69496 EPC1 1.31558 
AMY1A 1.38484 C1orf107 1.25691 CPEB3 1.23285 ERRFI1 2.37348 
AMY1B 1.26357 C1orf108 1.48440 CTGF 49.31077 ETS2 2.07049 
AMY1C 1.22017 C20orf111 1.69037 CXCR4 1.52925 FAM100A 1.98022 
ANKRD37 1.82197 C20orf175 1.99327 CYCS 1.34182 FAM46B 2.27772 
ANKRD57 1.95991 C5orf41 1.32870 CYCSL1 1.31683 FBXL12 1.34082 
ARC 2.51931 C6orf66 1.21888 CYP26B1 1.58559 FBXO46 1.22011 
ARF4 1.50702 C6orf85 1.22814 CYR61 33.65828 FERMT2 1.36869 
ARG2 1.22830 C8orf4 1.32153 DCP1A 1.33534 FHL2 7.26980 
ARL5B 1.43873 C9orf32 1.29058 DCUN1D3 2.60225 FILIP1L 1.21921 
ATF3 14.73896 CACYBP 1.23473 DDIT3 3.46021 FLJ13236 1.23439 
ATP2A2 1.35532 CBX4 2.79774 DDX43 1.22351 FOS 36.30673 
AVPI1 1.52369 CCBL2 1.29739 DDX5 1.42818 FOSB 75.95573 
AXUD1 5.62476 CCNL1 2.29506 DKK1 1.71896 FOSL1 2.56544 
B3GNT2 1.48183 CD68 1.43461 DNAJB1 2.34937 FOXC1 3.31256 
BARD1 1.35344 CDKN1A 1.68130 DUSP1 7.58109 FOXD4 1.31789 
BCL10 1.60090 CDR2 1.42224 DUSP10 1.27175 FOXD4L1 1.29117 
BCL2L12 1.21938 CEBPB 1.39998 DUSP2 5.32710 FOXQ1 1.35223 
BCL7B 1.33776 CENTG3 1.22234 DUSP4 2.50582 FST 1.35207 
BHLHB2 1.46824 CGGBP1 1.29393 DUSP5 6.25464 FVT1 1.29863 
BIK 1.39729 CHIC2 1.25315 DUSP8 2.07186 FZD9 1.41816 
C11orf56 1.22690 CISH 1.22228 EDN1 11.47651 GADD45A 1.49496 
C12orf44 1.43087 CITED2 1.53932 EGR1 8.92255 GADD45B 1.27265 
C12orf5 1.25434 CKS2 2.72874 EGR2 51.61896 GDF15 2.32124 
C14orf138 1.24802 CLIC5 1.36216 EGR3 9.58592 GEM 1.55664 
C14orf28 3.52274 CLK1 1.57975 EGR4 18.60352 HBEGF 1.56410 
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Table S4 (continued) 
Gene Change fold Gene Change fold Gene Change fold Gene Change fold 
HERPUD1 1.67755 KCNF1 1.38426 LOC730820 1.23360 NT5DC3 1.23918 
HIC2 1.31756 KCTD5 1.28848 LRRC8A 1.43109 OBFC2A 1.32572 
HMGCR 1.36520 KIAA1754 3.50186 MAD2L1BP 1.42764 ODC1 1.31895 
HNRNPAB 1.25618 KLF10 3.79783 MAFF 3.33847 OSGIN2 1.54713 
HNRPDL 1.39168 KLF2 15.33393 MAFG 1.48002 P704P 1.33514 
HSPC111 1.36865 KLF6 7.77205 MAP3K14 1.39146 PCF11 1.29996 
ID3 1.51982 KLHL21 1.27807 MAT2A 1.75027 PDRG1 1.22870 
IER2 3.13299 KLHL28 1.54178 MBD1 1.30854 PER2 1.43654 
IER3 2.56416 KLK7 1.24449 MCL1 4.17160 PFKFB3 1.60087 
IER5 1.67329 KRT17 2.28012 MED9 1.85101 PHC2 1.36963 
IHPK2 1.32288 LAG3 1.88359 MEF2D 1.69797 PHF15 1.23802 
IL8 4.92193 LDLR 2.46017 MESDC1 1.27075 PHF20L1 1.22219 
ING1 1.36383 LMCD1 1.23056 METRNL 1.29323 PHLDA1 3.54013 
ING3 1.41933 LOC199800 1.34867 MIDN 1.51456 PHLDA2 2.47347 
INSIG1 1.23925 LOC201164 1.21848 MOAP1 1.81683 PIM3 1.47061 
IRS2 2.64607 LOC387763 1.49174 MOBKL2C 1.80007 PLEKHO1 1.38972 
IRX3 1.37716 LOC401238 1.45751 MRCL3 1.63551 PLEKHO2 1.47745 
ISG20 1.33939 LOC402221 1.54847 MSX1 2.91829 PPP1R10 1.37753 
ISG20L1 1.63042 LOC402617 1.50607 MYADM 4.65128 PPP1R15A 4.01235 
ISG20L2 1.41785 LOC554206 1.38243 MYC 1.92173 PPRC1 1.42616 
ISL1 1.51809 LOC642361 1.38485 NAB2 1.51991 PRO0628 1.88473 
JMJD1A 1.43153 LOC646509 1.25847 NCOA7 5.35993 PTP4A1 1.37735 
JMJD6 1.85434 LOC648526 2.47018 NEDD9 1.44814 PTRH2 1.59164 
JUN 15.34621 LOC650369 1.22347 NFKBIZ 1.50377 RAB32 1.63393 
JUNB 6.88658 LOC651621 1.31392 NOLA1 1.22817 RARA 1.32852 
JUND 1.60029 LOC651816 1.40127 NR4A1 10.14752 RASD1 52.85122 
KBTBD2 1.28119 LOC653158 1.84395 NR4A2 2.40912 RASSF1 1.33229 
KBTBD8 1.27128 LOC654244 1.24214 NR4A3 5.31811 RBM15 1.85520 
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Table S4 (continued) 
Gene Change fold Gene Change fold Gene Change fold Gene Change fold 
RCAN1 1.75154 SLC20A1 1.54543 TMEM55B 1.28005 UBC 1.72300 
RCSD1 1.26873 SLC25A25 2.81230 TMEM88 1.49274 UBXD5 1.92992 
REXO1 1.22645 SLC25A4 1.33224 TMEM93 1.25143 USP36 1.69171 
RIPK1 1.23869 SLC3A2 1.62554 TNFAIP3 1.64358 VGF 1.40074 
RND1 2.21130 SNF1LK 7.82245 TNFRSF12A 1.37110 WDR1 1.31833 
RND3 1.47305 SNX16 1.26458 TOB1 1.51893 WDR47 1.29401 
RNF103 1.22640 SOCS1 1.24618 TP53INP2 1.56635 WEE1 1.48444 
RNF39 1.76369 SOS1 1.34167 TP53RK 1.24861 YRDC 2.00047 
RPPH1 1.64545 SPRY4 1.26314 TPM1 4.63607 ZC3H12A 2.75004 
RPS4Y2 2.20756 SRF 4.68190 TPM2 1.43071 ZFAND5 1.39870 
RRM2 1.28802 STX12 1.30342 TRAFD1 1.40629 ZFP36 10.04192 
SBDSP 1.56707 TAGLN 16.91685 TRIB1 5.25405 ZNF24 1.28397 
SC5DL 1.30951 TFAP2C 1.26339 TRIM26 1.23237 ZNF274 1.32121 
SEDLP 1.23294 THBS1 3.06056 TRK1 1.47276 ZNF446 1.26296 
SERTAD1 5.70524 TIMP3 1.75374 TSC22D2 1.48793 ZNF593 1.28615 
SLC10A3 1.30147 TIPARP 2.24564 TSKU 1.37215 ZNF787 1.26129 
SLC16A6 1.30692 TMEM185B 1.30963 TSPYL2 1.61898 ZNF828 1.22182 
SLC18A1 1.24372 TMEM49 1.60705 TUFT1 3.32892 ZYX 3.65502 
Gene selection criteria: the whole gene list of the array was sorted by change fold (highest to lowest, 40’HRG vs control). The top 300 genes with p value less than 
0.05 were selected. 
